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Abbreviations  
 
 
AAL  Aleuria aurantia lectin 
Alum  aluminium 
APC  antigen presenting cell 
ASGP-R asialoglycoprotein receptor 
BSA  bovine serum albumin 
BSSL  Bile salt stimulated lipase 
CD  cluster of differentiation 
CD4bs CD4 binding site 
CD4i  CD4 induced 
cDNA  complementary DNA 
CEA  carcinoembryonic antigen 
CEACAM1 CEA related cell adhesion molecule 1
  
CHO  Chinese hamster ovary cells 
CLR  C-type lectin receptor 
CMV  cytomegalo virus 
CRD  carbohydrate recognition domain 
DC  dendritic cell 
DC-SIGN  DC-specific ICAM3-grabbing non-
integrin 
EEA-1 early endosome antigen 1 
ELISA Enzyme-Linked Immuno Sorbent 
Assay 
FasL  Fas-ligand 
FCS  foetal calf serum 
FITC  fluorescein isothiocyanate 
FMLP  formyl-methionylleucylphenylalanine 
Fut  fucosyltransferase 
GalNAc N-acetylgalactosamine 
GM-CSF Granulocyte-macrophage colony-
stimulating factor 
GNA  Galanthus nivalis lectin 
gp  glycoprotein 
GT  glycosyltransferase 
HCV  hepatitis C virus 
HIV-1  human immunodeficiency virus 1 
HLA  human leukocyte antigen 
HRP  horseradish peroxidase 
IC  immune complex 
ICAM  intercellular adhesion molecule 
iDC  immature DC;  
IFN  interferon 
IL  interleukin 
ITIM immunoreceptor tyrosine-based 
inhibitory motif 
KC  Kupffer cell 
LAMP lysosome-associated membrane 
protein 
LDL-R low density lipoprotein receptor 
Le  Lewis 
LFA  leukocyte functional antigen-1 
LNFP  lacto-N-fucopentaose 
LPS  lipopolysaccharide 
LSEC  liver sinusoidal endothelial cell 
LSECtin liver and lymph node sinusoidal endothelial 
cell C-type lectin 
L-SIGN  liver and lymph node-specific ICAM3-
grabbing non-integrin 
LSP-1 leukocyte-specific protein-1 
LTA  Lotus tetragonolobus lectin 
LV  lentviral 
MAA  Maackia amurensis agglutinin 
ManLAM Mannosylated lipoarabinomannan 
mDC   mature DC 
MGL macrophage galactose type C-type lectin 
MHC  major histocompability complex 
MIP  macrophage inflammatory protein 
MR  mannose receptor 
mRNA messenger RNA 
MTCT  mother-to-child transmission 
NPA  Narcissus Pseudonarcissus Lectin 
PAA   polyacrylamide 
PAMP pathogen associated molecular pattern 
PBMC peripheral blood mononuclear cell 
PBS  phosphate-buffered saline 
PE  phycoerythrin 
PMN  polymorphonuclear  
PPR  pattern recognition receptors 
R5   CCR5 coreceptor using HIV-1 isolate  
RNA  ribonuclease acid 
RT-PCR real time PCR 
sCD4  soluble CD4 
siRNA small interfering RNA 
SIV  simian immunodeficiency virus 
SLPI  secretory leukocyte protease inhibitor 
SNA  Sambucus nigra agglutinin 
SR-B1 scavenger receptor class B type I 
ST  sialyl transferase 
TCID   tissue culture infectious dose;  
Th  helper T  
TLR  Toll-like receptor 
TNF  tumour necrosis factor 
UEA-1 Ulex europaeus agglutinin 1 
VLP  virus like particle 
wt  wild type 
X4   CXCR4 coreceptor using HIV-1 isolate.
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Introduction 
 
Antigen presenting cells (APCs) are specialized cells that capture antigens and process them 
for antigen presentation on MHC class II molecules to T and B lymphocytes. Macrophages, 
dendritic cells (DCs) and B cells are the main APCs for antigen presentation to T cells and 
follicular DCs for presentation to B cells. In this way an antigen specific response is generated, 
modulated by expression of costimulatory molecules and production of cytokines. Endothelial 
cells can also present antigens to T cells, although endothelial cells need to be activated to 
express MHC class II. In contrast, in the liver a specialized endothelial cell population is 
localized, liver sinusoidal endothelial cells (LSECs) that constitutively express MHC II and 
possess a great endocytic capacity and lysosomal activity [1]. Therefore these LSECs can act 
as professional APC. 
 
 
 
Dendritic cells 
 
DCs function as a bridge between innate and adaptive immunity. Immature DCs are positioned 
at strategic positions in the body, where they act as sentinels of the immune system constantly 
screening the environment. DCs function in pathogen recognition, however unlike innate 
immune cells, they do not function primarily in the destruction of pathogens, but moreover they 
present pathogen-derived antigens to T cells and induce antigen-specific immune responses 
[2]. DCs not only present antigens to T cells but also direct the differentiation of CD8+ T cells to 
cytotoxic T cells and CD4+ T cells to T helper type 1, type 2, or regulatory T cells [3-5].  
Pathogens possess pathogen associated molecular patterns (PAMPs) that are recognized by 
pattern recognition receptors (PPR). These PAMPs are highly conserved and pathogen 
specific. DCs express several PPRs like Fcγ receptors, complement receptors, scavenger 
receptors, C-type lectin receptors (CLRs) and several members of the Toll-like receptor (TLR) 
family [6-11]. The TLR family consists, up to now, of 11 different TLRs, with each a specific 
recognition pattern. TLR4 for example binds lipopolysaccharide (LPS), a cell-wall component 
of gram-negative bacteria [12]. TLRs act upon interaction with microbial ligands by a cascade 
of inflammatory signals resulting in DC activation and migration to lymph nodes.  
Besides TLRs, DCs also express a wide variety of CLRs that recognize pathogens through 
specific carbohydrate moieties. CLRs are composed of one or more carbohydrate recognition 
domains (CRDs) and calcium is involved in the interaction with ligands [13;14]. In contrast to 
TLRs that respond by activation of DCs, CLRs internalize pathogens for antigen processing 
and presentation (Fig. 1.1). Among the CLRs expressed on DCs are the mannose receptor 
(MR), DEC-205, Dectin-1 and -2, DCIR, DLEC, CLEC, langerin, MGL and DC-SIGN [11]. They 
are expressed on specific DC subsets, langerin for example is only expressed on Langerhans 
cells [15], and their expression is tightly regulated and dependent on the activation state of the 
DC. DC-SIGN for example is highly expressed on monocyte-derived DCs, but expression is 
down-regulated upon maturation [16]. Besides pathogens, CLRs recognize also endogenous 
ligands, mediating cell-cell interactions and soluble ligand binding, resulting in tolerance as 
was shown for DEC-205 [17]. The combined stimulation of CLR and TLR results in fine tuning 
and modulation of the TLR mediated response. The simultaneously activation of Dectin-1 and 
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TLR2 by Saccharomyces cerevisiae derived zymosan results in the synergistic production of 
pro-inflammatory mediators by DCs [18]. On the other hand, the combined binding of the 
Mycobacterium tuberculosis component ManLAM by TLR4 and DC-SIGN results in interleukin-
10 (IL-10) production and inhibition of DC activation [19]. 
The CLR family can be divided in type I and type II CLRs, depending on the number of CRDs 
present in the extracellular domain. Type I CLRs, like MR and DEC205 have multiple CRDs, 
whereas type I CLRs, like DC-SIGN and MGL have just one CRD. Furthermore, CLRs can be 
divided on basis of the amino acid sequence of the CRD; CLRs with EPN based CRD 
recognizing mainly mannose structures and CLRs with QPD based CRD recognizing galactose 
structures [20].  
 
 
 
DC-SIGN receptor family 
 
In human three members of the DC-SIGN family have been identified: dendritic cell-specific 
ICAM-grabbing non-integrin (DC-SIGN, CD209), liver and lymph node specific SIGN (L-SIGN, 
CD209R, CD299), and liver and lymph node sinusoidal endothelial cell C-type lectin (LSECtin). 
They are located on chromosome 19p13.3 in close proximity to the CD23 gene [21;22].  
DC-SIGN is expressed on DCs [16;23], and L- SIGN and LSECtin are expressed on liver 
sinusoidal endothelial cells and on lymph node sinusoidal endothelial cells [22;24;25].  
L-SIGN shares 77% amino acids with DC-SIGN, with the highest homology in the CRD. 
However, although DC-SIGN has 7 complete and one incomplete neck repeats, there are 7 
alleles for L-SIGN identified, resulting in 3 to 9 neck repeats [25]. The neck repeats function in 
multimerisation of the receptors. Indeed it has been shown that DC-SIGN is forming tetramers 
when expressed on the cell surface [26;27]. In the cytoplasmic tail of DC-SIGN there are three 
internalisation motifs: a tyrosine based motif, a di-leucine motif and a triacidic cluster. L-SIGN 
shares the di-leucine motif and the triacidic cluster but is lacking the tyrosine motif. These 
motifs are associated with internalisation and targeting to late endosomes/lysosomes and 
indeed it has been demonstrated that DC-SIGN can take up ligands and target these to  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interactions of pathogens with TLRs or CLRs on DCs 
have different outcomes.  
Upon binding of a pathogen to a TLR, a signalling cascade 
is started resulting in NF-κB translocation with subsequent 
DC maturation. Upon interaction of a pathogen with a CLR, 
the complex is internalized into the lysosomal pathway, 
degraded and presented on MHC II to CD4+ T cells. 
N=nucleus, EE=early endosome, L=lysosome. 
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lysosomes for antigen presentation [28;29].  
DC-SIGN recognizes mannose structures as expected by the presence of an EPN based 
CRD. However, DC-SIGN binding is not only based on primary mannose groups but also 
depends on the protein backbone, which organizes carbohydrate structures in a distinct three-
dimensional structure [30]. Besides the specificity for mannose structures, DC-SIGN also binds 
fucose-containing carbohydrates such Lewisa (Lea), Leb, Lex, and Ley [26;31-33].  
L-SIGN has the highest degree of homology in the CRD compared to DC-SIGN, and therefore 
the binding characteristics are very similar. L-SIGN binds mannose structures and the fucose 
containing sugars Lea, Leb, and Ley [34]. However, whereas DC-SIGN recognizes Lex antigen, 
L-SIGN lacks the capacity to bind this particular fucose containing carbohydrate structure. This 
is based on the difference in one amino acid in the CRD: DC-SIGN has a valine on position 
351 (Val351), whereas L-SIGN has on this position a serine molecule (Ser363) [30;35]. Lex 
binding capacity is restored by replacing Ser363 in L-SIGN with a valine residue, which results 
in the formation of a hydrophobic pocket [35]. 
 
 
Murine DC-SIGN homologues. 
In mice several DC-SIGN homologues are described, but only mDC-SIGN and mSIGNR1 are 
expressed on APCs. mDC-SIGN is expressed on CD8a- and CD8a+ DCs [36] and on 
plasmacytoid pre-DCs that differentiate into CD8+ CD205- DCs [37], but this C-type lectin is 
non-functional [38]. mSIGNR1 is expressed on a macrophage population in lymph nodes, in 
spleen on marginal zone macrophages [39;40], in liver on sinusoidal endothelial cells [39], and 
on peritoneal macrophages [41]. That mSIGNR1 is expressed on LSECs similar as human L-
SIGN makes it a suitable candidate for investigating the in vivo role of L-SIGN. 
 
 
 
Cellular ligands for DC-SIGN 
 
Immature DCs migrate from the blood to peripheral tissue across the endothelial cell layer. 
Before diapedesis through the endothelial cell layer, DCs should tether and role over the 
endothelial cells. DC-SIGN is mediating DC adherence and rolling over endothelial cells by 
binding to intercellular adhesion molecule-2 (ICAM-2) expressed on endothelial cells [42]. The 
DC-SIGN-ICAM-2 interaction is strong enough to resist the shear stress of the blood flow [42]. 
Besides in the process of migration of immature DCs to peripheral tissues, DC-SIGN-ICAM-2 
mediated rolling could also be involved in the homing of DCs to secondary lymphoid organs. 
Binding of DC-SIGN to ICAM-2 is endothelial cell specific, as for instance ICAM-2 on platelets 
is not recognized due to different glycosylation [43]. Moreover, glycosylation of ICAM-2 can 
differ between endothelial cells, dependent on activation state or localization, thereby defining 
specific sites for DC migration. 
After antigen uptake, DCs interact with T cells to present antigen on MHC class II. This 
interaction is initiated by DC-SIGN-ICAM-3 interactions, followed by ICAM-1-leukocyte 
functional antigen-1 (LFA-1) interactions [16]. Moreover, the interaction of DC-SIGN on DCs 
with ICAM-3 on T cells promotes the recruitment of LFA-1 to the immunological synapse at the 
DC-T cell interface [44]. Eventually this is strengthening the interaction between DC and T cell 
and thereby facilitating T-cell receptor interactions with MHC II-peptide complexes. 
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Neutrophils (PMNs) and DCs reside in different compartments during homeostasis. However, 
during inflammation neutrophils and DCs accumulate both at the site of infection. Neutrophils 
can transfer antigens to DCs [45] and therefore should interact with DCs. DCs facilitate this 
interaction by DC-SIGN mediated binding to Mac-1 and CEACAM1 on the neutrophil 
membrane [46;47] (Fig. 1.2). 
 
 
 
DC-SIGN/L-SIGN-pathogen interactions 
 
DC-SIGN was originally identified as a human immunodeficiency virus 1 (HIV-1) gp120 binding 
receptor [48]. DC-SIGN plays a key-role in the dissemination of HIV-1 by DCs through HIV-1 
gp120 binding [49]. Other studies have demonstrated that DC-SIGN also functions as a 
receptor for other viruses, such as cytomegalovirus (CMV) [50], and Ebola virus [51], bacteria,  
including Mycobacterium tuberculosis [19], and helminths such as Schistosoma mansoni egg 
antigens [32]. Most pathogens use DC-SIGN for their own benefit; viruses, such as HIV-1 [49] 
and hepatitis C virus (HCV) [52], use the interaction with DC-SIGN for viral dissemination by 
circumventing lysosomal degradation and transmission to other cells, and bacteria, such as 
Mycobacterium tuberculosis [19] and Helicobacter pylori [53] modulate DC mediated immune 
responses by binding to DC-SIGN (Fig. 1.2). 
 
 
DC(-SIGN) and HIV-1. 
T cells are the main targets of HIV-1, and the virus enters these cells via interaction of gp120 
envelope glycoprotein on HIV-1 and CD4 and a chemokine coreceptor (CCR5 or CXCR4) on 
the T cell, which results in membrane fusion. However, DCs are thought to be the first cells to 
encounter the virus upon infection [54]. Adults are mainly infected as a result of sexual  
transmission; whereas mother-to-child transmission is the main cause of infection among  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Examples of cellular and 
pathogen ligands for DC-SIGN. 
DCs interact via DC-SIGN with 
ICAM-2 on endothelial cells, ICAM-3 
on T cells and CEACAM1 and Mac-
1 expressed on PMNs (left side). 
DC-SIGN on DCs mediates 
interaction with particular bacteria 
via binding of Lex structures on LPS, 
and with viruses via binding of highly 
glycosylated envelope proteins.  
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children. DC-SIGN+ DCs are present in both genital and intestinal mucosa [23]. In cervix and  
vagina, DC-SIGN expressing cells are located in the subepithelial lamina propria underneath 
the squamous epithelial layer [23;49], the rectal mucosa is rich in DC-SIGN+ DCs [23], and in 
the intestines, DC-SIGN expressing cells are located in the Peyer’s patches [23]. Thus DC-
SIGN+ DCs are present at all sites susceptible of HIV-1 infection. 
DCs themselves are poorly infected by HIV-1, but the presence of DCs greatly enhances 
infection of T cells [55;56]. DC-SIGN on DCs recognizes gp120 via high mannose residues on 
the glycoprotein [57-59]. Upon binding of DC-SIGN and HIV-1, DCs internalise the virus into 
CD81+ vesicles [60], where it can be retained for several days [49]. DCs then travel to lymph 
nodes and upon CD4+ T cell encounter, HIV-1 is re-localised in a so-called ‘infectious synapse’ 
at the DC-T cell interface [61]. In the infectious synapse, which resembles the immunological 
synapse, CD4 is present at high concentrations and hereby T cell-infection is enhanced. In the 
immunological synapse, DC-SIGN binding to ICAM-3 enhances LFA-1 redistribution to the 
synapse, strengthening the interaction between DC and T cell [16]. A similar process might be 
involved in the interaction of DC and T cell upon viral transmission in the infectious synapse. 
The presence of DC-SIGN is necessary for enhancement of T-cell infection, since knockdown 
of DC-SIGN expression with siRNA abolishes the T-cell infection in trans [62].  
However, upon internalisation in DCs, HIV-1 can also partially be degraded [49] and presented 
to T cells. Cross presentation of HIV-1 antigens to CD8+ T cells on MHC class I requires 
membrane fusion [63;64], whereas MHC class II restricted presentation to CD4+ T cells occurs 
without membrane fusion in acidic endosomal vesicles [65]. Both mechanisms of presentation 
are DC-SIGN dependent.  
 
L-SIGN can, similar to DC-SIGN, mediate uptake and transmission of HIV-1 [24;25]. L-SIGN 
positive cells are located in liver and lymph node in close proximity to CD4+/CCR5+ cells, 
Kupffer cells (KCs) and CD4+ T cells respectively, to which virus can be transmitted. 
Homozygosity for 7 neck repeats in L-SIGN has shown to result in an increased susceptibility 
for HIV-1 [66] demonstrating that L-SIGN is indeed involved in HIV-1 infections. 
 
 
 
DC-SIGN/L-SIGN and HCV. 
HCV is an enveloped plus stranded RNA virus [67] that is mainly infecting hepatocytes, but in 
the recent years more and more evidence for infection of other cells arises. In the liver, positive 
signals of replicative intermediate RNA were detected in different subsets of sinusoidal cells 
(LSECs, KCs, and Stellate cells), suggesting that HCV replication may also occur in these cell 
types [68;69]. An indication for an extrahepatic virus reservoir is the rapid reinfection of the 
liver in chronic HCV patients after liver transplantation, and indeed, HCV can replicate in 
monocytes and B cells [70]. Infection with HCV results in chronic and persistent infection in 
70% of the patients [71]. The virus can persist because of immunomodulation by directly 
affecting immune cell function and by a high mutation rate.  
Several HCV receptors have been described: CD81 [72], and the CD36 family member SR-B1 
[73] are both binding HCV envelope glycoprotein E2. In addition, the hepatocyte specific 
asialoglycoprotein receptor (ASGP-R) [74] and LDL-R [75] have shown to interact with HCV.  
Both DC-SIGN and L-SIGN bind HCV envelope glycoproteins [76-78]. Therefore, HCV might 
directly target DCs to modulate immune responses. Indeed it has been shown that the DC 
number is lower in chronic HCV infected patients than in healthy donors [79]. Although DCs 
present HCV antigens to T cells [80], the T cells might be not properly stimulated, because DC 
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maturation and their immune stimulatory functions are impaired in HCV positive patients 
[81;82].  
HCV might not only target DC-SIGN and L-SIGN for dissemination by immunomodulation 
through DCs, but also by transmission to adjacent hepatocytes upon binding by L-SIGN on 
LSECs [52].  
 
 
 
 
The Liver 
 
The liver functions in digestion, detoxification of blood born substances, and in production of 
plasma proteins. It receives oxygen rich blood from the hepatic artery and 75% of the blood supply 
comes from the hepatic portal vein. This blood is coming from the gastro-intestinal tract and is rich 
in food antigens, environmental toxins and bacterial products like LPS. Although most of these 
antigens are non-self, an immune response to food-borne antigens is rarely induced, and clearance 
of e.g. LPS takes place without signs of inflammation [87;88]. 
 
The liver is composed of parenchymal and non-parenchymal cells. The parenchymal cells, the 
hepatocytes, are the main participants in the metabolic function of the liver. The liver sinusoid 
contains the most of the non-parenchymal cells. Among these non-parenchymal cells are the liver 
resident macrophages (Kupffer cells), the stellate or Ito cells that function in fat and vitamin A 
storage and production of extracellular matrix components, pitt cells, a liver natural killer cell like 
population, and sinusoidal endothelial cells. Between the endothelial cell layer and the hepatocytes 
the space of Disse is situated. Lymph is collected in the space of Disse to subsequently flow into 
lymph vessels (Fig. 1.3). 
 
Endothelial cells of the liver sinusoids are different from endothelial cells residing in other tissues. 
These liver sinusoidal endothelial cells (LSECs) are fenestrated and lack a basement membrane 
[89]. With the fenestrae, dynamic structures clustered in sieve plates, LSECs regulate by varying 
the size and amount of their pores the flow of substances from the bloodstream into the space of 
Disse, and thus subsequently to the hepatocytes [90;91]. Furthermore LSECs regulate uptake by 
hepatocytes of material by transcytosis from the luminal to the abluminal side of the endothelial cell 
layer [92], and LSECs can change the glycosylation of substances and thereby further facilitating 
uptake by hepatocytes [93]). 
 
Because the small size of only 5 to 7 µm and the low and intermittent blood flow in the sinusoids, 
passing blood cells might interact with LSECs independent of selectin-adressin interaction [94]. 
Normally adhesion of leukocytes to the endothelial cell layer is a two-step process starting with P 
and E selectin mediated tethering and rolling of leukocytes over endothelial cells and then ICAM1-
LFA1 mediated adhesion. In liver sinusoids blood flow is low and therefore adhesion of leukocytes 
to LSECs takes place without prior rolling [94]. 
 
 
Tolerance induction. 
The liver is capable of promoting tolerance, as was demonstrated already in 1967 by the possibility 
to induce antigen-specific tolerance by administration of the antigen via the portal vein [95;96]. 
Furthermore, allogenic liver transplants can be accepted without immunosuppression [97], and the 
acceptance of other transplants is increased when simultaneously a liver from the same donor is 
transplanted [98]. Several cell populations have been implicated in liver specific tolerance induction. 
For example, removal of KCs from the liver abrogates tolerance induction [99;100]. Also LSECs are 
capable of promoting tolerance. Adoptive transfer of antigen challenged LSECs results in tolerance 
to the antigen in the recipient [101]. Both murine and human LSECs constitutively express MHC 
class II on their surface [102;103], and mouse LSECs also express the costimulatory molecules 
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CD40, CD80 and CD86 [104;105]. Strikingly, human LSECs express CD40 but lack expression of 
CD80 and CD86 [106]. LSEC presentation on MHC II to CD4+ leads to IL-10/IL-4 expressing T cells 
with regulatory function [107]. Overall, the CD4+ Th1/Th2 balance in the liver seems to be 
preferentially resulting in Th2 responses; the Th1 cytokine interferon (IFN) γ is suppressed [108] 
and CD4+ Th1 cells become non-functional in the liver [109]. LSECs also cross-present antigens to 
CD8+ T cells, however the CD8+ T cell are not cytotoxic but tolerant for the antigen [101]. 
Furthermore there are indications for liver specific selective retention of activated CD8+ T cells 
[110], where they undergo apoptosis and are cleared from the blood [111]. However this tolerogenic 
milieu in the liver could also promote the survival of hepatotropic pathogens, such as hepatitis B 
and C virus. 
 
 
Clearance of redundant cells.  
Beside a role in processing food metabolites, the liver also functions in the clearance of redundant 
cells. T cells are cleared from the blood when they pass the liver, where both KCs and LSECs are 
able to bind apoptotic cells [112]. KCs recognize apoptotic T cells through phosphatidyl serine that 
is normally located in the inner membrane, but upon apoptosis is translocated to the outer 
membrane. LSECs express Galactin-1 that can induce apoptosis of T cells and facilitates binding of 
apoptotic T cells [113]. Furthermore, activated CD8+ T cells have an increased expression of LFA-1 
and in combination with the constitutive expression of ICAM-1 on LSECs this could result in an 
increased trapping of especially activated CD8+ T cell in the liver. LSECs can phagocytose 
subsequently the apoptotic cells [112;114]. The liver is also implicated in the clearance of 
redundant PMNs. Although PMNs are also cleared at other sites, matured and activated PMNs are 
predominantly cleared in the liver where KCs participate in the phagocytosis of apoptotic PMNs 
[115;116].  
 
 
Liver architecture.  
(A) The liver parenchyma is divided by connective tissue into liver lobules. These hexagonal structures of 
plates of hepatocytes radiating from the central vein (CV). At the corners of the lobulus, the portal triads (PT), 
composed of a bile duct, hepatic artery and portal vein branches are situated. (B) The hepatocytes are 
adjoined at two or more sides to the sinusoids. These sinusoids are lined with fenestrated endothelial cells 
(LSEC). In between the hepatocytes and the endothelial cell layer, the space of Disse is situated. Kupffer cells 
(KC) penetrate the endothelial cell layer to reach the hepatocytes through the space of Disse.  
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Thesis Outline 
 
In the research described in this thesis the functional role of L-SIGN and DC-SIGN in the 
immune system is investigated. L-SIGN and DC-SIGN have comparable binding 
characteristics, with specificity for fucose and high mannose containing carbohydrates. 
However, there are also differences in binding characteristics; whereas DC-SIGN is binding 
Lex containing ligands, L-SIGN is not. In chapter 2 a novel L-SIGN specific carbohydrate 
ligand, highly expressed on the well-differentiated hepatoma cell line HUH7, is described. This 
ligand contains sialic acids, of which the expression is lost in metastatic hepatocellular 
carcinoma cells. Therefore these hepatocellular carcinoma cells could loosen the interaction 
with surrounding cells and metastasise to remote sites. On the other hand expression of L-
SIGN binding carbohydrates is increased upon malignant transformation of colon epithelial 
cells (chapter 2). This could be involved in the frequent metastasis of colon carcinomas to the 
liver. 
DC-SIGN and L-SIGN bind several pathogens such as HIV-1 and HCV virus. HCV envelope 
glycoproteins E1 and E2 are both recognized by DC-SIGN and L-SIGN, and upon 
internalisation HCV virus like particles are retained in early endosomes in antigen-presenting 
cells (chapter 3 [83]), promoting viral dissemination. Additionally, after DC-SIGN or L-SIGN 
mediated uptake of HCV immune complexes, antigens were presented to CD4+ T cells. 
Furthermore degradation of HCV is enhanced in the presence of HCV specific antibodies 
(chapter 4). 
DC-SIGN and L-SIGN also interact with the HIV-1 envelope glycoprotein gp120. DC-SIGN 
positive DCs are located at sites of infection and capture of HIV-1 by DC-SIGN on DCs 
enhances viral transmission of HIV-1 to CD4+ T cells. In addition, DC-SIGN binding to gp120 
induces conformational changes that enhance gp120 binding to CD4 (chapter 5 [84]). 
Therefore blocking HIV-1-DC-SIGN interactions could decrease transmission of virus. We 
investigated blocking with a panel of anti-gp120 antibodies and demonstrate that although the 
V3 loop is not essential for DC-SIGN binding, antibodies against the V3 loop of gp120 reduce 
DC-SIGN binding, suggesting that these antibodies sterically hinder DC-SIGN binding to 
gp120 (chapter 5 [84]).  
Furthermore DC-SIGN-gp120 interactions can be blocked by a component present in human 
milk. The blocking milk component contains Lex that binds to DC-SIGN and thereby blocks 
HIV-1 gp120 binding (chapter 6 [85]). The milk component doe not block L-SIGN-gp120 
interactions as Lex can not be bound by L-SIGN.  
 
Besides the recognition of pathogens, DC-SIGN and L-SIGN also mediate interactions with 
immune cells. In addition to interactions with T cells via ICAM-3 binding [16], DC-SIGN and L-
SIGN are mediating interactions with neutrophils. DC-SIGN is recognizing both neutrophil Mac-
1 and CEACAM1. This interaction modulates both DC and neutrophil responses (chapter 7 
[46;86]). L-SIGN recognizes only Mac-1 on neutrophils, and by binding to L-SIGN, neutrophils 
facilitate rolling over L-SIGN expressing endothelium (chapter 7 addendum). 
Additionally, L-SIGN can mediate binding to monocytes (chapter 8). Monocytes are 
macrophage precursor cells and in mouse the interaction with mSIGNR1 is involved in 
homeostasis of the resident liver macrophages, the Kupffer cells. mSIGNR1 deficient mice 
have less KCs than wild type mice (chapter 8). 
General Introduction 
21 
 
 
 
References 
 
 1.  Smedsrod B, Pertoft H, Gustafson S, Laurent TC: Scavenger functions of the liver endothelial cell. 
Biochem.J. 1990, 266:313-327. 
 2.  Steinman R, Inaba K: Immunogenicity: role of dendritic cells. Bioessays 1989, 10:145-152. 
 3.  Dhodapkar MV, Steinman RM: Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) 
regulatory T cells in vivo in humans. Blood 2002, 100:174-177. 
 4.  Moser M, Murphy KM: Dendritic cell regulation of TH1-TH2 development. Nat.Immunol. 2000, 1:199-205. 
 5.  Yamazaki S, Iyoda T, Tarbell K, Olson K, Velinzon K, Inaba K, Steinman RM: Direct expansion of 
functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J.Exp.Med. 2003, 
198:235-247. 
 6.  Bajtay Z, Csomor E, Sandor N, Erdei A: Expression and role of Fc- and complement-receptors on human 
dendritic cells. Immunol.Lett. 2006, 104:46-52. 
 7.  Gordon S: Pattern recognition receptors. Doubling up for the innate immune response. Cell 2002, 111:927-
930. 
 8.  Garcia-Garcia E, Rosales C: Signal transduction during Fc receptor-mediated phagocytosis. J.Leukoc.Biol. 
2002, 72:1092-1108. 
 9.  Medzhitov R: Toll-like receptors and innate immunity. Nat.Rev.Immunol. 2001, 1:135-145. 
 10.  Peiser L, Mukhopadhyay S, Gordon S: Scavenger receptors in innate immunity. Curr.Opin.Immunol. 2002, 
14:123-128. 
 11.  Cambi A, Figdor CG: Dual function of C-type lectin-like receptors in the immune system. Curr.Opin.Cell 
Biol. 2003, 15:539-546. 
 12.  Beutler B: Tlr4: central component of the sole mammalian LPS sensor. Curr.Opin.Immunol. 2000, 12:20-
26. 
 13.  Drickamer K: Ca(2+)-dependent sugar recognition by animal lectins. Biochem.Soc.Trans. 1996, 24:146-
150. 
 14.  Drickamer K: C-type lectin-like domains. Curr.Opin.Struct.Biol. 1999, 9:585-590. 
 15.  Valladeau J, Ravel O, Dezutter-Dambuyant C, Moore K, Kleijmeer M, Liu Y, Duvert-Frances V, Vincent C, 
Schmitt D, Davoust J, Caux C, Lebecque S, Saeland S: Langerin, a novel C-type lectin specific to 
Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity. 2000, 
12:71-81. 
 16.  Geijtenbeek TB, Torensma R, van Vliet SJ, van Duijnhoven GC, Adema GJ, van Kooyk Y, Figdor CG: 
Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune 
responses. Cell 2000, 100:575-585. 
 17.  Steinman RM, Hawiger D, Nussenzweig MC: Tolerogenic dendritic cells. Annu.Rev.Immunol. 2003, 
21:685-711. 
 18.  Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM: Collaborative induction of inflammatory 
responses by dectin-1 and Toll-like receptor 2. J.Exp.Med. 2003, 197:1107-1117. 
 19.  Geijtenbeek TB, van Vliet SJ, Koppel EA, Sanchez-Hernandez M, Vandenbroucke-Grauls CM, Appelmelk 
B, van Kooyk Y: Mycobacteria Target DC-SIGN to Suppress Dendritic Cell Function. J.Exp.Med. 2003, 
197:7-17. 
 20.  Drickamer K: Engineering galactose-binding activity into a C-type mannose-binding protein. Nature 1992, 
360:183-186. 
 21.  Soilleux EJ, Barten R, Trowsdale J: DC-SIGN; a related gene, DC-SIGNR; and CD23 form a cluster on 
19p13. J.Immunol. 2000, 165:2937-2942. 
 22.  Liu W, Tang L, Zhang G, Wei H, Cui Y, Guo L, Gou Z, Chen X, Jiang D, Zhu Y, Kang G, He F: 
Characterization of a novel C-type lectin-like gene, LSECtin: demonstration of carbohydrate binding and 
expression in sinusoidal endothelial cells of liver and lymph node. J.Biol.Chem. 2004, 279:18748-18758. 
 23.  Jameson B, Baribaud F, Pohlmann S, Ghavimi D, Mortari F, Doms RW, Iwasaki A: Expression of DC-SIGN 
by dendritic cells of intestinal and genital mucosae in humans and rhesus macaques. J.Virol. 2002, 
76:1866-1875. 
Chapter 1 
22 
 24.  Pohlmann S, Soilleux EJ, Baribaud F, Leslie GJ, Morris LS, Trowsdale J, Lee B, Coleman N, Doms RW: 
DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian 
immunodeficiency viruses and activates infection in trans. Proc.Natl.Acad.Sci.U.S.A 2001, 98:2670-2675. 
 25.  Bashirova AA, Geijtenbeek TB, van Duijnhoven GC, van Vliet SJ, Eilering JB, Martin MP, Wu L, Martin TD, 
Viebig N, Knolle PA, KewalRamani VN, van Kooyk Y, Carrington M: A dendritic cell-specific intercellular 
adhesion molecule 3-grabbing nonintegrin (DC-SIGN)-related protein is highly expressed on human liver 
sinusoidal endothelial cells and promotes HIV-1 infection. J.Exp.Med. 2001, 193:671-678. 
 26.  Mitchell DA, Fadden AJ, Drickamer K: A novel mechanism of carbohydrate recognition by the C-type 
lectins DC- SIGN and DC-SIGNR. Subunit organization and binding to multivalent ligands. J.Biol.Chem. 
2001, 276:28939-28945. 
 27.  Bernhard OK, Lai J, Wilkinson J, Sheil MM, Cunningham AL: Proteomic analysis of DC-SIGN on dendritic 
cells detects tetramers required for ligand binding but no association with CD4. J.Biol.Chem. 2004, 
279:51828-51835. 
 28.  Engering A, Geijtenbeek TB, van Vliet SJ, Wijers M, van Liempt E, Demaurex N, Lanzavecchia A, Fransen 
J, Figdor CG, Piguet V, van Kooyk Y: The dendritic cell-specific adhesion receptor DC-SIGN internalizes 
antigen for presentation to T cells. J.Immunol. 2002, 168:2118-2126. 
 29.  Tacken PJ, de Vries I, Gijzen K, Joosten B, Wu D, Rother RP, Faas SJ, Punt CJ, Torensma R, Adema GJ, 
Figdor CG: Effective induction of naive and recall T cell responses by targeting antigen to human dendritic 
cells via a humanized anti-DC-SIGN antibody. Blood 2005. 
 30.  Guo Y, Feinberg H, Conroy E, Mitchell DA, Alvarez R, Blixt O, Taylor ME, Weis WI, Drickamer K: 
Structural basis for distinct ligand-binding and targeting properties of the receptors DC-SIGN and DC-
SIGNR. Nat.Struct.Mol.Biol. 2004, 11:591-598. 
 31.  Feinberg H, Mitchell DA, Drickamer K, Weis WI: Structural basis for selective recognition of 
oligosaccharides by DC- SIGN and DC-SIGNR. Science 2001, 294:2163-2166. 
 32.  Appelmelk BJ, van Die I, van Vliet SJ, Vandenbroucke-Grauls CM, Geijtenbeek TB, van Kooyk Y: Cutting 
edge: carbohydrate profiling identifies new pathogens that interact with dendritic cell-specific ICAM-3-
grabbing nonintegrin on dendritic cells. J.Immunol. 2003, 170:1635-1639. 
 33.  van Die I, van Vliet SJ, Nyame AK, Cummings RD, Bank CM, Appelmelk B, Geijtenbeek TB, van Kooyk Y: 
The dendritic cell-specific C-type lectin DC-SIGN is a receptor for Schistosoma mansoni egg antigens and 
recognizes the glycan antigen Lewis x. Glycobiology 2003, 13:471-478. 
 34.  Koppel EA, Ludwig IS, Appelmelk BJ, van Kooyk Y, Geijtenbeek TB: Carbohydrate specificities of the 
murine DC-SIGN homologue mSIGNR1. Immunobiology 2005, 210:195-201. 
 35.  van Liempt E, Imberty A, Bank CM, van Vliet SJ, van Kooyk Y, Geijtenbeek TB, van Die I: Molecular basis 
of the differences in binding properties of the highly related C-type lectins DC-SIGN and L-SIGN to Lewis X 
trisaccharide and schistosoma mansoni egg antigens. J.Biol.Chem. 2004. 
 36.  Caminschi I, Lucas KM, O'Keeffe MA, Hochrein H, Laabi Y, Brodnicki TC, Lew AM, Shortman K, Wright 
MD: Molecular cloning of a C-type lectin superfamily protein differentially expressed by CD8alpha(-) 
splenic dendritic cells. Mol.Immunol. 2001, 38:365-373. 
 37.  O'Keeffe M, Hochrein H, Vremec D, Caminschi I, Miller JL, Anders EM, Wu L, Lahoud MH, Henri S, Scott 
B, Hertzog P, Tatarczuch L, Shortman K: Mouse plasmacytoid cells: long-lived cells, heterogeneous in 
surface phenotype and function, that differentiate into CD8(+) dendritic cells only after microbial stimulus. 
J.Exp.Med. 2002, 196:1307-1319. 
 38.  Gramberg T, Caminschi I, Wegele A, Hofmann H, Pohlmann S: Evidence that multiple defects in murine 
DC-SIGN inhibit a functional interaction with pathogens. Virology 2006, 345:482-491. 
 39.  Geijtenbeek TB, Groot PC, Nolte MA, van Vliet SJ, Gangaram-Panday ST, van Duijnhoven GC, Kraal G, 
van Oosterhout AJ, van Kooyk Y: Marginal zone macrophages express a murine homologue of DC-SIGN 
that captures blood-borne antigens in vivo. Blood 2002, 100:2908-2916. 
 40.  Kang YS, Yamazaki S, Iyoda T, Pack M, Bruening SA, Kim JY, Takahara K, Inaba K, Steinman RM, Park 
CG: SIGN-R1, a novel C-type lectin expressed by marginal zone macrophages in spleen, mediates uptake 
of the polysaccharide dextran. Int.Immunol. 2003, 15:177-186. 
 41.  Taylor PR, Brown GD, Herre J, Williams DL, Willment JA, Gordon S: The role of SIGNR1 and the beta-
glucan receptor (dectin-1) in the nonopsonic recognition of yeast by specific macrophages. J.Immunol. 
2004, 172:1157-1162. 
 42.  Geijtenbeek TB, Krooshoop DJ, Bleijs DA, van Vliet SJ, van Duijnhoven GC, Grabovsky V, Alon R, Figdor 
CG, van Kooyk Y: DC-SIGN-ICAM-2 interaction mediates dendritic cell trafficking. Nat.Immunol. 2000, 
1:353-357. 
General Introduction 
23 
 43.  Weber KS, Alon R, Klickstein LB: Sialylation of ICAM-2 on platelets impairs adhesion of leukocytes via 
LFA-1 and DC-SIGN. Inflammation 2004, 28:177-188. 
 44.  van Gisbergen KP, Paessens LC, Geijtenbeek TB, van Kooyk Y: Molecular mechanisms that set the stage 
for DC-T cell engagement. Immunol.Lett. 2005, 97:199-208. 
 45.  Megiovanni AM, Sanchez F, Robledo-Sarmiento M, Morel C, Gluckman JC, Boudaly S: 
Polymorphonuclear neutrophils deliver activation signals and antigenic molecules to dendritic cells: a new 
link between leukocytes upstream of T lymphocytes. J.Leukoc.Biol. 2006, 79:977-988. 
 46.  van Gisbergen KP, Sanchez-Hernandez M, Geijtenbeek TB, van Kooyk Y: Neutrophils mediate immune 
modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN. 
J.Exp.Med. 2005, 201:1281-1292. 
 47.  Bogoevska V, Horst A, Klampe B, Lucka L, Wagener C, Nollau P: CEACAM1, an adhesion molecule of 
human granulocytes, is fucosylated by fucosyltransferase IX and interacts with DC-SIGN of dendritic cells 
via Lewis x residues. Glycobiology 2006, 16:197-209. 
 48.  Curtis BM, Scharnowski S, Watson AJ: Sequence and Expression of a Membrane-Associated C-Type 
Lectin that Exhibits CD4-Independent Binding of Human Immunodeficiency Virus Envelope Glycoprotein 
gp120. PNAS 1992, 89:8356-8360. 
 49.  Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, Cornelissen IL, Nottet 
HS, KewalRamani VN, Littman DR, Figdor CG, van Kooyk Y: DC-SIGN, a dendritic cell-specific HIV-1-
binding protein that enhances trans-infection of T cells. Cell 2000, 100:587-597. 
 50.  Halary F, Amara A, Lortat-Jacob H, Messerle M, Delaunay T, Houles C, Fieschi F, Arenzana-Seisdedos F, 
Moreau JF, Dechanet-Merville J: Human Cytomegalovirus Binding to DC-SIGN Is Required for Dendritic 
Cell Infection and Target Cell trans-Infection. Immunity. 2002, 17:653-664. 
 51.  Alvarez CP, Lasala F, Carrillo J, Muniz O, Corbi AL, Delgado R: C-Type Lectins DC-SIGN and L-SIGN 
Mediate Cellular Entry by Ebola Virus in cis and in trans. J.Virol. 2002, 76:6841-6844. 
 52.  Cormier EG, Durso RJ, Tsamis F, Boussemart L, Manix C, Olson WC, Gardner JP, Dragic T: L-SIGN 
(CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. 
Proc.Natl.Acad.Sci.U.S.A 2004, 101:14067-14072. 
 53.  Bergman MP, Engering A, Smits HH, van Vliet SJ, van Bodegraven AA, Wirth HP, Kapsenberg ML, 
Vandenbroucke-Grauls CM, van Kooyk Y, Appelmelk BJ: Helicobacter pylori Modulates the T Helper Cell 
1/T Helper Cell 2 Balance through Phase-variable Interaction between Lipopolysaccharide and DC-SIGN. 
J.Exp.Med. 2004, 200:979-990. 
 54.  Belyakov IM, Berzofsky JA: Immunobiology of mucosal HIV infection and the basis for development of a 
new generation of mucosal AIDS vaccines. Immunity. 2004, 20:247-253. 
 55.  Cameron PU, Freudenthal PS, Barker JM, Gezelter S, Inaba K, Steinman RM: Dendritic cells exposed to 
human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. Science 
1992, 257:383-387. 
 56.  Pope M, Betjes MG, Romani N, Hirmand H, Cameron PU, Hoffman L, Gezelter S, Schuler G, Steinman 
RM: Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with 
HIV-1. Cell 1994, 78:389-398. 
 57.  Lue J, Hsu M, Yang D, Marx P, Chen Z, Cheng-Mayer C: Addition of a Single gp120 Glycan Confers 
Increased Binding to Dendritic Cell-Specific ICAM-3-Grabbing Nonintegrin and Neutralization Escape to 
Human Immunodeficiency Virus Type 1. J.Virol. 2002, 76:10299-10306. 
 58.  Lin G, Simmons G, Pohlmann S, Baribaud F, Ni H, Leslie GJ, Haggarty BS, Bates P, Weissman D, Hoxie 
JA, Doms RW: Differential N-linked glycosylation of human immunodeficiency virus and Ebola virus 
envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J.Virol. 2003, 77:1337-
1346. 
 59.  Hong PW, Flummerfelt KB, de Parseval A, Gurney K, Elder JH, Lee B: Human immunodeficiency virus 
envelope (gp120) binding to DC-SIGN and primary dendritic cells is carbohydrate dependent but does not 
involve 2G12 or cyanovirin binding sites: implications for structural analyses of gp120-DC-SIGN binding. 
J.Virol. 2002, 76:12855-12865. 
 60.  Garcia E, Pion M, Pelchen-Matthews A, Collinson L, Arrighi JF, Blot G, Leuba F, Escola JM, Demaurex N, 
Marsh M, Piguet V: HIV-1 trafficking to the dendritic cell-T-cell infectious synapse uses a pathway of 
tetraspanin sorting to the immunological synapse. Traffic. 2005, 6:488-501. 
 61.  McDonald D, Wu L, Bohks SM, KewalRamani VN, Unutmaz D, Hope TJ: Recruitment of HIV and its 
receptors to dendritic cell-T cell junctions. Science 2003, 300:1295-1297. 
Chapter 1 
24 
 62.  Arrighi JF, Pion M, Garcia E, Escola JM, van Kooyk Y, Geijtenbeek TB, Piguet V: DC-SIGN-mediated 
infectious synapse formation enhances X4 HIV-1 transmission from dendritic cells to T cells. J.Exp.Med. 
2004, 200:1279-1288. 
 63.  Moris A, Nobile C, Buseyne F, Porrot F, Abastado JP, Schwartz O: DC-SIGN promotes exogenous MHC-I-
restricted HIV-1 antigen presentation. Blood 2004, 103:2648-2654. 
 64.  Buseyne F, Le Gall S, Boccaccio C, Abastado JP, Lifson JD, Arthur LO, Riviere Y, Heard JM, Schwartz O: 
MHC-I-restricted presentation of HIV-1 virion antigens without viral replication. Nat.Med. 2001, 7:344-349. 
 65.  Moris A, Pajot A, Blanchet F, Guivel-Benhassine F, Salcedo M, Schwartz O: Dendritic cells and HIV-
specific CD4+ T cells: HIV antigen presentation, T-cell activation, and viral transfer. Blood 2006, 108:1643-
1651. 
 66.  Liu H, Carrington M, Wang C, Holte S, Lee J, Greene B, Hladik F, Koelle DM, Wald A, Kurosawa K, 
Rinaldo CR, Celum C, Detels R, Corey L, McElrath MJ, Zhu T: Repeat-region polymorphisms in the gene 
for the dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin-related molecule: 
effects on HIV-1 susceptibility. J.Infect.Dis. 2006, 193:698-702. 
 67.  Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M: Isolation of a cDNA clone derived 
from a blood-borne non-A, non-B viral hepatitis genome. Science 1989, 244:359-362. 
 68.  Chang M, Williams O, Mittler J, Quintanilla A, Carithers RL, Jr., Perkins J, Corey L, Gretch DR: Dynamics 
of hepatitis C virus replication in human liver. Am.J.Pathol. 2003, 163:433-444. 
 69.  Yan FM, Chen AS, Hao F, Zhao XP, Gu CH, Zhao LB, Yang DL, Hao LJ: Hepatitis C virus may infect 
extrahepatic tissues in patients with hepatitis C. World J.Gastroenterol. 2000, 6:805-811. 
 70.  Bare P, Massud I, Parodi C, Belmonte L, Garcia G, Nebel MC, Corti M, Pinto MT, Bianco RP, Bracco MM, 
Campos R, Ares BR: Continuous release of hepatitis C virus (HCV) by peripheral blood mononuclear cells 
and B-lymphoblastoid cell-line cultures derived from HCV-infected patients. J.Gen.Virol. 2005, 86:1717-
1727. 
 71.  Chisari FV: Unscrambling hepatitis C virus-host interactions. Nature 2005, 436:930-932. 
 72.  Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, 
Grandi G, Abrignani S: Binding of hepatitis C virus to CD81. Science 1998, 282:938-941. 
 73.  Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, 
Vitelli A: The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C 
virus. EMBO J. 2002, 21:5017-5025. 
 74.  Saunier B, Triyatni M, Ulianich L, Maruvada P, Yen P, Kohn LD: Role of the asialoglycoprotein receptor in 
binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes. J.Virol. 2003, 
77:546-559. 
 75.  Monazahian M, Bohme I, Bonk S, Koch A, Scholz C, Grethe S, Thomssen R: Low density lipoprotein 
receptor as a candidate receptor for hepatitis C virus. J.Med.Virol. 1999, 57:223-229. 
 76.  Gardner JP, Durso RJ, Arrigale RR, Donovan GP, Maddon PJ, Dragic T, Olson WC: L-SIGN (CD 209L) is 
a liver-specific capture receptor for hepatitis C virus. Proc.Natl.Acad.Sci.U.S.A 2003, 100:4498-4503. 
 77.  Lozach PY, Lortat-Jacob H, de Lacroix de Lavalette A, Staropoli I, Foung S, Amara A, Houles C, Fieschi F, 
Schwartz O, Virelizier JL, Arenzana-Seisdedos F, Altmeyer R: DC-SIGN and L-SIGN are high affinity 
binding receptors for hepatitis C virus glycoprotein E2. J.Biol.Chem. 2003, 278:20358-20366. 
 78.  Pohlmann S, Zhang J, Baribaud F, Chen Z, Leslie GJ, Lin G, Granelli-Piperno A, Doms RW, Rice CM, 
McKeating JA: Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J.Virol. 2003, 
77:4070-4080. 
 79.  Wertheimer AM, Miner C, Lewinsohn DM, Sasaki AW, Kaufman E, Rosen HR: Novel CD4+ and CD8+ T-
cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. 
Hepatology 2003, 37:577-589. 
 80.  Barth H, Ulsenheimer A, Pape GR, Diepolder HM, Hoffmann M, Neumann-Haefelin C, Thimme R, 
Henneke P, Klein R, Paranhos-Baccala G, Depla E, Liang TJ, Blum HE, Baumert TF: Uptake and 
presentation of hepatitis C virus-like particles by human dendritic cells. Blood 2005. 
 81.  Auffermann-Gretzinger S, Keeffe EB, Levy S: Impaired dendritic cell maturation in patients with chronic, 
but not resolved, hepatitis C virus infection. Blood 2001, 97:3171-3176. 
 82.  Bain C, Fatmi A, Zoulim F, Zarski JP, Trepo C, Inchauspe G: Impaired allostimulatory function of dendritic 
cells in chronic hepatitis C infection. Gastroenterology 2001, 120:512-524. 
 83.  Ludwig IS, Lekkerkerker AN, Depla E, Bosman F, Musters RJ, Depraetere S, van Kooyk Y, Geijtenbeek 
TB: Hepatitis C virus targets DC-SIGN and L-SIGN to escape lysosomal degradation. J.Virol. 2004, 
78:8322-8332. 
General Introduction 
25 
 84.  Lekkerkerker AN, Ludwig IS, van Vliet SJ, van Kooyk Y, Geijtenbeek TB: Potency of HIV-1 envelope 
glycoprotein gp120 antibodies to inhibit the interaction of DC-SIGN with HIV-1 gp120. Virology 2004, 
329:465-476. 
 85.  Naarding MA, Ludwig IS, Groot F, Berkhout B, Geijtenbeek TB, Pollakis G, Paxton WA: Lewis X 
component in human milk binds DC-SIGN and inhibits HIV-1 transfer to CD4+ T lymphocytes. J.Clin.Invest 
2005, 115:3256-3264. 
 86.  van Gisbergen KP, Ludwig IS, Geijtenbeek TB, van Kooyk Y: Interactions of DC-SIGN with Mac-1 and 
CEACAM1 regulate contact between dendritic cells and neutrophils. FEBS Lett. 2005, 579:6159-6168. 
 87.  Catala M, Anton A, Portoles MT: Characterization of the simultaneous binding of Escherichia coli endotoxin 
to Kupffer and endothelial liver cells by flow cytometry. Cytometry 1999, 36:123-130. 
 88.  van Oosten M., van de Bilt E., van Berkel TJ, Kuiper J: New scavenger receptor-like receptors for the 
binding of lipopolysaccharide to liver endothelial and Kupffer cells. Infect.Immun. 1998, 66:5107-5112. 
 89.  Wisse E: An electron microscopic study of the fenestrated endothelial lining of rat liver sinusoids. 
J.Ultrastruct.Res. 1970, 31:125-150. 
 90.  Wisse E, de Zanger RB, Charels K, van der Smissen P, McCuskey RS: The liver sieve: considerations 
concerning the structure and function of endothelial fenestrae, the sinusoidal wall and the space of Disse. 
Hepatology 1985, 5:683-692. 
 91.  Wisse E, Braet F, Luo D, de Zanger R, Jans D, Crabbe E, Vermoesen A: Structure and function of 
sinusoidal lining cells in the liver. Toxicol.Pathol. 1996, 24:100-111. 
 92.  Kataoka M, Tavassoli M: The role of liver endothelium in the binding and uptake of ceruloplasmin: studies 
with colloidal gold probe. J.Ultrastruct.Res. 1985, 90:194-202. 
 93.  Tavassoli M, Kishimoto T, Kataoka M: Liver endothelium mediates the hepatocyte's uptake of 
ceruloplasmin. J.Cell Biol. 1986, 102:1298-1303. 
 94.  Wong J, Johnston B, Lee SS, Bullard DC, Smith CW, Beaudet AL, Kubes P: A minimal role for selectins in 
the recruitment of leukocytes into the inflamed liver microvasculature. J.Clin.Invest 1997, 99:2782-2790. 
 95.  Battisto JR, Miller J: Immunological unresponsiveness produced in adult guinea pigs by parenteral 
introduction of minute quantities of hapten or protein antigen. Proc.Soc.Exp.Biol.Med. 1962, 111:111-115. 
 96.  Cantor HM, Dumont AE: Hepatic suppression of sensitization to antigen absorbed into the portal system. 
Nature 1967, 215:744-745. 
 97.  Calne RY, Sells RA, Pena JR, Davis DR, Millard PR, Herbertson BM, Binns RM, Davies DA: Induction of 
immunological tolerance by porcine liver allografts. Nature 1969, 223:472-476. 
 98.  Kamada N, Davies HS, Roser B: Reversal of transplantation immunity by liver grafting. Nature 1981, 
292:840-842. 
 99.  Roland CR, Mangino MJ, Duffy BF, Flye MW: Lymphocyte suppression by Kupffer cells prevents portal 
venous tolerance induction: a study of macrophage function after intravenous gadolinium. Transplantation 
1993, 55:1151-1158. 
 100.  Yu S, Nakafusa Y, Flye MW: In vitro analysis of gadolinium chloride abrogation of the systemic tolerance 
induced by portal venous administration of ultraviolet B-irradiated donor cells. Transplantation 1997, 
64:1684-1688. 
 101.  Limmer A, Ohl J, Kurts C, Ljunggren HG, Reiss Y, Groettrup M, Momburg F, Arnold B, Knolle PA: Efficient 
presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-
cell tolerance. Nat.Med. 2000, 6:1348-1354. 
 102.  Lautenschlager I, Taskinen E, Inkinen K, Lehto VP, Virtanen I, Hayry P: Distribution of the major 
histocompatibility complex antigens on different cellular components of human liver. Cell Immunol. 1984, 
85:191-200. 
 103.  Rubinstein D, Roska AK, Lipsky PE: Liver sinusoidal lining cells express class II major histocompatibility 
antigens but are poor stimulators of fresh allogeneic T lymphocytes. J.Immunol. 1986, 137:1803-1810. 
 104.  Knolle PA, Germann T, Treichel U, Uhrig A, Schmitt E, Hegenbarth S, Lohse AW, Gerken G: Endotoxin 
down-regulates T cell activation by antigen-presenting liver sinusoidal endothelial cells. J.Immunol. 1999, 
162:1401-1407. 
 105.  Lohse AW, Knolle PA, Bilo K, Uhrig A, Waldmann C, Ibe M, Schmitt E, Gerken G, Meyer Zum 
Buschenfelde KH: Antigen-presenting function and B7 expression of murine sinusoidal endothelial cells 
and Kupffer cells. Gastroenterology 1996, 110:1175-1181. 
 106.  Leifeld L, Trautwein C, Dumoulin FL, Manns MP, Sauerbruch T, Spengler U: Enhanced expression of 
CD80 (B7-1), CD86 (B7-2), and CD40 and their ligands CD28 and CD154 in fulminant hepatic failure. 
Am.J.Pathol. 1999, 154:1711-1720. 
Chapter 1 
26 
 107.  Knolle PA, Schmitt E, Jin S, Germann T, Duchmann R, Hegenbarth S, Gerken G, Lohse AW: Induction of 
cytokine production in naive CD4(+) T cells by antigen- presenting murine liver sinusoidal endothelial cells 
but failure to induce differentiation toward Th1 cells. Gastroenterology 1999, 116:1428-1440. 
 108.  Gorczynski RM, Hozumi N, Wolf S, Chen Z: Interleukin 12 in combination with anti-interleukin 10 reverses 
graft prolongation after portal venous immunization. Transplantation 1995, 60:1337-1341. 
 109.  Yu S, Nakafusa Y, Flye MW: Portal vein administration of donor cells promotes peripheral allospecific 
hyporesponsiveness and graft tolerance. Surgery 1994, 116:229-234. 
 110.  Huang L, Soldevila G, Leeker M, Flavell R, Crispe IN: The liver eliminates T cells undergoing antigen-
triggered apoptosis in vivo. Immunity. 1994, 1:741-749. 
 111.  Crispe IN, Mehal WZ: Strange brew: T cells in the liver. Immunol.Today 1996, 17:522-525. 
 112.  Dini L, Pagliara P, Carla EC: Phagocytosis of apoptotic cells by liver: a morphological study. 
Microsc.Res.Tech. 2002, 57:530-540. 
 113.  Perillo NL, Pace KE, Seilhamer JJ, Baum LG: Apoptosis of T cells mediated by galectin-1. Nature 1995, 
378:736-739. 
 114.  Berg M, Wingender G, Djandji D, Hegenbarth S, Momburg F, Hammerling G, Limmer A, Knolle P: Cross-
presentation of antigens from apoptotic tumor cells by liver sinusoidal endothelial cells leads to tumor-
specific CD8(+) T cell tolerance. Eur.J.Immunol. 2006, 36:2960-2970. 
 115.  Suratt BT, Young SK, Lieber J, Nick JA, Henson PM, Worthen GS: Neutrophil maturation and activation 
determine anatomic site of clearance from circulation. Am.J.Physiol Lung Cell Mol.Physiol 2001, 281:L913-
L921. 
 116.  Shi J, Gilbert GE, Kokubo Y, Ohashi T: Role of the liver in regulating numbers of circulating neutrophils. 
Blood 2001, 98:1226-1230. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
L-SIGN participation in tumour metastasis in the liver 
 
A novel carbohydrate ligand for L-SIGN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Irene S. Ludwig 
 Juan J. García Vallejo 
Teunis B.H. Geijtenbeek 
Yvette van Kooyk 
 
 
Manuscript in preparation 
Chapter 2 
28 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
 
The C-type lectin receptors (CLRs) DC-SIGN and L-SIGN recognize pathogens and self-
ligands through recognition of specific carbohydrate moieties on glycoconjugates. DC-SIGN 
has been shown to function in both pattern recognition and immune regulation. Due to a high 
degree of homology between the carbohydrate recognition domains of DC-SIGN and L-SIGN, 
both CLRs have affinity for high mannose structures and the fucose containing Lewisa, Lewisb, 
and Lewisy antigens, with the exception of Lewisx, which is only bound by DC-SIGN. 
DC-SIGN, expressed on dendritic cells, mediates interactions with colon carcinoma cells, 
which express high levels of Lewisy-and Lewisx-decorated CEA and CEACAM1. Here we show 
that, similar to DC-SIGN, L-SIGN found on liver sinusoidal endothelial cells (LSECs) 
recognizes tumour derived CEA, probably because of the presence of Lewisy on CEA, and 
therefore could participate in colon cancer liver metastasis.  
We furthermore demonstrate that L-SIGN recognizes a novel L-SIGN specific carbohydrate 
ligand on hepatoma cells. Notably, the ligand is neuraminidase-sensitive suggesting that L-
SIGN recognizes a sialic acid containing glycan structure that is not recognized by DC-SIGN. 
Hepatocytes express high amounts of sialylated glycans, which are abrogated in metastasizing 
hepatocellular carcinoma cells. We therefore think that L-SIGN may have a dual function 
implicated both in the maintenance of normal liver structure by binding sialic acid structures 
expressed on healthy hepatocytes as well as the formation of liver metastasis by recognizing 
Lewisy expressing tumour associated CEA.  
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Introduction 
 
C-type lectin receptors (CLRs) mediate important interactions in homeostasis and pathogen 
recognition. CLRs contain one or more carbohydrate recognition domains (CRDs) that are able 
to interact with carbohydrate moieties expressed on pathogens and self-antigens. CLRs with 
an EPN motif in the binding domain mainly recognize mannose and fucose structures, 
whereas CLRs with a QPD motif recognize galactose containing glycan structures [1]. 
Mutagenesis of the EPN motif of MBP-A into QPD changes the mannose specificity into 
galactose specificity [1], confirming the importance of these motifs in defining the carbohydrate 
specificity. 
The dendritic cell specific ICAM-3 grabbing non-integrin (DC-SIGN) binds several pathogens 
and self-antigens [2;3]. DC-SIGN is a CLR that has one CRD containing an EPN motif, and 
therefore recognizes high-mannose glycans. The DC-SIGN carbohydrate specificity is well 
documented and DC-SIGN has been demonstrated to recognize, besides high mannose 
structures, also non-sialylated fucose-containing Lewis-type antigens, such as Lewisa (Lea), 
Lewisb (Leb), Lewisx (Lex), and Lewisy (Ley) [4-7] when present both on pathogens and self-
antigens. 
L-SIGN, the DC-SIGN homologue, is not expressed on DCs but on liver sinusoidal endothelial 
cells (LSECs) [8;9], which are specialized endothelial cells with scavenger and antigen 
presenting functions [10;11]. L-SIGN shares 77% amino acid sequence identity with DC-SIGN, 
with the highest degree of homology in the CRD. The high degree of homology between the 
CRDs of DC-SIGN and L-SIGN is reflected in their ligand specificity. L-SIGN, similar to DC-
SIGN, recognizes high-mannose glycans [4;12], and binds high-mannose-containing ligands 
such as HIV-1 and HCV envelope proteins [9;13]. Furthermore, L-SIGN also recognizes Ley, 
Lea, and Leb antigens [12]. In contrast to DC-SIGN, L-SIGN does not bind Lex. The lack of Lex 
binding by L-SIGN is due to one amino acid replacement in the CRD of L-SIGN. Whereas DC-
SIGN has a valine at position 351 (Val351), L-SIGN has at this same position a serine 
molecule (Ser363) [14;15]. Lex binding capacity is restored by replacing Ser363 in L-SIGN with 
a valine residue, thereby creating a hydrophobic pocket [15]. Thus, although L-SIGN and DC-
SIGN are quite similar, there are differences in expression and binding specificity pattern, and 
no ligand unique for L-SIGN only has been described so far. 
Both DC-SIGN and L-SIGN function as pathogen recognition receptors. DC-SIGN was first 
identified as a receptor for the highly glycosylated HIV-1 gp120 envelope protein [16]. By now 
a plethora of pathogenic, self and altered self-ligands that are bound by both DC-SIGN and L-
SIGN have been identified. Specificity of DC-SIGN and L-SIGN for these ligands is based on 
the glycan profile of these ligands. Often when the ligands express mannose-rich structures or 
Ley, Lea, or Leb antigens, both DC-SIGN and L-SIGN recognize the ligand. When only Lex is 
expressed, the ligand is exclusively recognized by DC-SIGN, and not by L-SIGN.  
Glycosylation is a highly dynamic and heterogeneous phenomenon, varying not only within 
tissues or even cell subsets, but also in different (patho)physiological conditions within the 
same cell type. Oncogenic transformation often results in a perturbation of the glycosylation 
machinery [17], which has severe effects on the metastatic properties of the tumour. In the 
case of colon epithelial cells, malignant transformation results in an increased expression of 
Lex and Ley epitopes [18]. As a consequence DC-SIGN discriminates between healthy colon 
tissue and colon carcinoma tissue. DC-SIGN specifically binds to carcinoembryonic antigen 
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(CEA) and CEA related cell adhesion molecule 1 (CEACAM1) from primary colon carcinoma 
and from colon carcinoma cell lines [19].  
Colon carcinomas often metastasize in the liver where L-SIGN is strategically expressed on 
LSECs. We therefore investigated whether L-SIGN is involved in binding of colon carcinoma 
derived CEA. We demonstrate that L-SIGN, similar to DC-SIGN, recognizes colon carcinoma 
derived CEA and therefore could function in colon carcinoma metastasis to the liver. 
Furthermore, we investigated the interaction of DC-SIGN and L-SIGN with a hepatocyte 
derived tumour, often metastasising in remote sites in the liver. Surprisingly, the hepatoma cell 
line expresses a ligand containing sialic acid residues exclusively recognized by L-SIGN. 
Sialylated glycans are abundantly expressed on normal hepatocytes, and loss of sialic acid 
structures on the cell surface during oncogenesis is associated with bad prognosis. Therefore, 
L-SIGN could participate in maintenance of normal liver structure. 
 
 
 
Materials and methods 
 
Antibodies. 
The following antibodies were used: col-1 (anti-CEA (Becton Dickinson, San Jose, CA), DC-SIGN- and 
L-SIGN-specific antibody AZN-D2 [16], anti-stalk 4 (anti-L-SIGN/DC-SIGN), avidin-Alexa Fluor 488 
(Molecular Probes, Eugene, OR), anti-mouse-biotin (Jackson Immunoresearch, Cambridgeshire, UK), 
and anti-human Fc-FITC (Jackson Immunoresearch, Cambridgeshire, UK). 
 
Cells. 
Raji-1 and K562 transfectants expressing wild-type DC-SIGN or L-SIGN were generated by transfection 
with 10 µg pRc/CMV-DC-SIGN or pRc/CMV-L-SIGN plasmid by electroporation as previously described 
[9;16]. HUH7 (human hepatoma cell line [20]) and SW948 (human colorectal adenocarcinoma cell line, 
ATCC number CCL-237) were cultured in DMEM and RPMI respectively supplemented with 
penicillin/streptomycin and 10% FCS. Cells were subcultured regularly. 
 
Cell-cell adhesion assay.  
To examine cellular interactions of DC-SIGN and L-SIGN with colon carcinoma SW948 and hepatoma 
HUH7 cells, SW948 and HUH7 cells were grown to confluent cultures in flat-bottom 96 well plates. Raji-
1 cells transfected with DC-SIGN or L-SIGN were labelled with the green fluorescent dye Calcein-AM (1 
µM, Molecular Probes, Eugene, OR) for 15 minutes at 37°C and incubated with SW948 and HUH7 cells 
in TSM (20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM CaCl2, 2 mM MgCl2) 0.5% BSA for 2 hours at 
37°C. To determine specific adhesion the Raji transfectants were preincubated with anti-DC-SIGN and 
anti-L-SIGN antibodies or isotype control antibodies (20 µg/ml) for 30 minutes at 37°C. Unbound cells 
were washed away, and remaining cells were lysed in lysis buffer (50 mM Tris-HCl pH 8.0, 0.1% SDS). 
Cell-cell adhesion was measured by fluorimetry of cell lysates at 488 nm (Fluostar Galaxy, BMG 
Labtechnologies Inc., Durham, NC). Maximal adhesion (100%) was calculated by subtraction of 
background fluorescence from the fluorescence without washing. Binding of cells in the samples was 
calculated by subtraction of the background fluorescence from the measured fluorescence divided by 
the 100% adhesion value.  
 
Soluble DC-SIGN and L-SIGN binding assay.  
The DC-SIGN-Fc chimera [21] contained the extracellular portion of DC-SIGN (amino acid residues 64-
404) fused at the C-terminus to a human IgG1-Fc fragment. The L-SIGN-Fc chimera was composed of 
the extracellular portion of L-SIGN fused to human IgG1-Fc fragment with a triple glutamine linker. DC-
SIGN-Fc and L-SIGN-Fc were produced in Chinese hamster ovary K1 (CHO) cells and purified with a 
protA column. To determine DC-SIGN and L-SIGN binding to SW948 and HUH7 cells, cells were 
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harvested and incubated with 10 µg/ml DC-SIGN or L-SIGN-Fc in TSM/BSA for 45 minutes at 37°C.  
Cells were subsequently stained with FITC labelled anti-human-Fc antibodies and binding was analysed  
by flow cytometry (FACScan, Becton Dickinson, Oxnard, CA). Binding was expressed as mean 
fluorescence intensity of the cells. Specificity of binding was determined by preincubating DC-SIGN-Fc 
and L-SIGN-Fc with EGTA (10 mM). 
 
Fluorescent bead adhesion assay. 
Carboxylated TransFluorSpheres (488/645 nm, 1.0 µm; Molecular Probes, Eugene, OR) were coated 
with normal colon tissue or colon carcinoma derived CEA or DC-SIGN- or L-SIGN-Fc [16]. In short, 
streptavidin was covalently coupled onto TransFluoSpheres as described by manufacturer. Streptavidin-
coated beads were incubated with biotinylated goat anti-mouse or goat anti-human Fc F(ab’)2 fragments 
(10 µg/ml, Jackson ImmunoResearch) in PBS 0.5% BSA for 2 hours at 37°C, and washed. 
Subsequently, the beads were incubated overnight at 4°C with mouse anti-CEA antibodies, washed, 
and incubated with lysates from colon material or DC-SIGN- or L-SIGN-Fc (2 µg/ml) respectively for 48 
hours.  
The fluorescent bead adhesion assay was performed as previously described [22]. In the experiments 
investigating DC-SIGN and L-SIGN binding to CEA, mock transfected K562 cells or K652 cells 
transfected with DC-SIGN or L-SIGN were preincubated for 30 min at 37°C with inhibitors (mannan (1 
mg/ml), or EGTA (10 mM)). Next, CEA-coated fluorescent beads (20 beads/cell) were added to the cells 
for 45 min at 37°C, washed and analyzed by flow cyt ometry (FACScan, Becton Dickinson, Oxnard, CA), 
by measuring the percentage of cells that had bound fluorescent beads. 
In the experiments investigating DC-SIGN- and L-SIGN-Fc coated beads adhesion to SW948 and HUH7 
cells the beads were preincubated with inhibitors (anti-DC-SIGN/L-SIGN antibodies (20 µg/ml), or EDTA 
(10 mM)) for 30 min at 37°C. Subsequently the cells  were added to the beads and incubated for 45 min 
at 37°C, washed and analyzed by flow cytometry (FAC Scan, Becton Dickinson, Oxnard, CA), by 
measuring the percentage of cells that had bound fluorescent beads.  
 
Real time-PCR. 
RT-PCR was performed as previously described [23]. In short, SW948 and HUH7 cells were lysed, and 
mRNA was isolated using an mRNA capture kit (Roche, Switzerland/Boehringer Mannheim GmbH, 
Germany). Subsequently cDNA was generated with a Reverse Transcription System kit (Promega, 
USA) according to the manufacturer’s instructions. Briefly, cell lysates were incubated with biotin-
labelled oligo(dT)20 for 5 minutes at 37°C and 50 µl was incubated in streptavidin coated tubes for 5 
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minutes at 37°C. After washing, 30 µl of reverse transcription mixture (5mM MgCl2, 1x reverse 
transcripture buffer, 1 mM dNTP, 0.4 U recombinant RNasin ribonuclease inhibitor, 0.4 U AMV reverse 
transcriptase, 0.5 µg random hexamers) was added and incubated for 10 minutes at room temperature 
and 45 minutes at 42°C. Samples were heated for 5 minutes at 99°C to inactivate AMV reverse 
transcriptase and to isolate cDNA. Samples were stored at -20°C until analysis.  
Gene expression of the selected genes was quantified by real time PCR with the SYBR Green method 
using an ABI 7900 HT sequence detection system (Applied Biosystems, USA). Primers were 
synthesized by Invitrogen (Invitrogen, Belgium) and have been previously described [23]. In short, 
reactions were set on a 96 well plate by mixing 4 µl of SYBR Green Master Mix (Applied Biosystems, 
USA) with 2 µl of an oligonucleotide solution containing 5 nmol/µl of both oligonucleotides and 2 µl of a 
cDNA solution corresponding to 1/100 of the cDNA synthesis product. The thermal profile for all the 
reactions was 2 min at 50°C, followed by 10 min at 95°C and then 40 cycles of 15 sec at 95°C and 1 min 
at 60°C. The housekeeping gene GAPDH was used as endogenous reference [24]. The relative 
abundance was calculated according to the ∆Ct method [25]: 100x2(Ct GAPDH-Ct glycosyltransferase). 
 
Lectin staining. 
To evaluate the expression of carbohydrate structures on SW948 and HUH7 cells, cells were harvested 
and incubated with a panel of biotinylated lectins (10 µg/ml in TSM/BSA, Vector laboratories, 
Peterborough, UK). The lectins used are Ulex europaeus agglutinin 1 (UEA-1), recognizing α-1,2-linked 
fucose residues, Lotus tetragonolobus lectin (LTA), recognizing α-1,3/4-fucosylated oligosaccharides, 
Aleuria aurantia lectin (AAL), binding preferentially to Fucα1,6GlcNAc (core fucose) or to 
Fucα1,3/4Galβ1,4/3GlcNAc (Lewis-type) structures, Narcissus Pseudonarcissus Lectin (NPA), 
recognizing α-linked mannose, preferentially α-1,6 linked polymannose structures, Galanthus nivalis 
lectin (GNA), which preferentially binds α-1,3 linked mannose structures, Sambucus nigra lectin (SNA), 
which preferentially binds to α-2,6 linked sialic acid to terminal galactose or GalNAc, and Maackia 
amurensis agglutinin (MAA), recognizing α-2,3-sialylated structures. 
Lectin binding was detected by staining with avidin-Alexa Fluor 488 and measured by flow cytometry 
analysis (FACScan, Becton Dickinson, Oxnard, CA). Binding was expressed as mean fluorescence 
intensity of the cells. 
 
Neuraminidase treatment 
Sialic acids were removed from cell surface glycans by incubating intact cells prior to flow cytometry in 
100 µl solution in 50 mM sodium acetate, 154 mM sodium chloride, 9 mM calcium chloride, 25 mg/l 
human serum albumin (pH 5.5) containing 10 mU of Vibrio cholerae neuraminidase (Roche, 
Switzerland) for 60 minutes at 37°C. After washing, efficiency of neuraminidase treatment was 
determined by staining the cells with SNA and MAA as described above. 
 
 
 
Results  
 
L-SIGN and DC-SIGN bind to the colon carcinoma cell line SW948. 
DC-SIGN has been demonstrated to bind the colon carcinoma cell line SW948 [19]. In order to 
study whether L-SIGN can play a role in interactions with colon carcinoma cells, and thereby 
function in liver metastasis formation, we investigated whether L-SIGN interacts with SW948 
cells. For this a cell-cell based adhesion assay was developed in which both Raji cells 
transfected with DC-SIGN or L-SIGN were investigated for their potency to bind a monolayer of 
SW948 cells. Both DC-SIGN and L-SIGN transfected cells strongly bound to SW948 cells 
(40% binding, Fig. 2.1A). This binding was specific since mock-transfected cells did not 
interact with SW948 and anti-DC-SIGN/L-SIGN antibodies could block the interaction to 
background levels (Fig. 2.1A).  
To further confirm L-SIGN binding to SW948, fluorescent beads were coated with DC-SIGN-Fc 
or L-SIGN-Fc chimeras, incubated with SW948 cells, and binding was measured by flow 
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cytometry. Both DC-SIGN-Fc and L-SIGN-Fc coated beads interacted strongly with SW984 
cells (Fig. 2.1B). This binding was specific since specific antibodies against DC-SIGN and L-
SIGN as well as EDTA blocked the interaction (Fig. 2.1B).  
 
L-SIGN binds primary colon carcinoma CEA more strongly than normal colon CEA. 
DCs interact with colon carcinoma cells through DC-SIGN binding of tumour CEA(CAM1). 
Tumour CEA(CAM1) carries higher levels of the carbohydrates Lex/y than normal colon tissue, 
resulting in DC-SIGN recognition [19]. Since colon carcinomas frequently metastasize in liver 
sinusoids and the colon carcinoma cell line SW948 binds L-SIGN (Fig. 2.1), we investigated 
whether L-SIGN, a C-type lectin highly related to DC-SIGN and expressed on LSECs, interacts 
with tumour CEA. Therefore, normal colon tissues and tumour tissues were lysed and CEA 
was captured from the lysate with a CEA specific antibody coated on fluorescent beads. K562 
cells transfected with DC-SIGN or L-SIGN and mock-transfected K562 cells were incubated 
with CEA coated beads and adhesion was measured by flow cytometry. Clearly both K562-
DC-SIGN and K562-L-SIGN cells were able to bind more strongly to beads coated with 
tumour-derived CEA than to beads coated with CEA from healthy colon tissue (Table 2.1). This 
binding could be blocked by preincubating the cells with EGTA or mannan (Fig. 2.2). Mock-
transfected K562 cells did not bind to CEA from either normal or tumour material (Fig. 2.2). 
This indicates that L-SIGN, similar to DC-SIGN, binds more strongly to tumour derived CEA 
than to CEA derived from healthy colon tissue. This interaction is probably due to the 
increased Ley expression on tumour-derived CEA since L-SIGN does not bind Lex residues 
[15;19]. This demonstrates that L-SIGN binds to primary colon carcinoma cells and colon 
carcinoma cell lines. Therefore, L-SIGN could be involved in liver metastasis of colon 
carcinomas. 
 
 
 
 
Binding of DC-SIGN and L-SIGN to the colon carcinoma cell line SW948.  
(A) Cellular binding of DC-SIGN and L-SIGN transfected cells to colon carcimoma SW948 cells. SW948 cells were 
cultured in 96 well plates and fluorescently labelled Raji cells transfected with DC-SIGN or L-SIGN were incubated 
on the cells. Binding after several washes was measured using fluorimetry. Binding specificity was confirmed using 
DC-SIGN/L-SIGN specific antibodies (20 µg/ml, grey bars), or isotype controls (white bars). Error bars represent 
standard deviations (n=4). One representative experiment out of three is shown. (B) Binding of DC-SIGN- and L-
SIGN-Fc coated beads to SW948 cells. DC-SIGN- and L-SIGN-Fc were coupled to fluorescent beads and incubated 
with SW948 cells. Adhesion was measured by flow cytometry. Specificity was determined by blocking with EDTA 
(10 mM, white bars) or DC-SIGN/L-SIGN specific antibodies (20 µg/ml, grey bars). One representative experiment 
out of three is shown. 
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DC-SIGN and L-SIGN bind more 
strongly to colon carcinoma derived 
CEA than to normal colon CEA.  
CEA isolated from colon carcinoma or 
non-neoplastic lysates was captured on 
fluorescent beads. The CEA coated 
beads were incubated with DC-SIGN, L-
SIGN or mock transfected K562 cells. 
Adhesion was measured by flow 
cytometry. Specificity was determined by 
blocking with mannan (1 mg/ml, black 
bars) or EGTA (10 mM, grey bars). Error 
bars represent standard deviations (n=3). 
One representative patient out of six is 
shown. 
 
 
 
 
L-SIGN exclusively binds hepatoma cell line HUH7. 
Besides metastasis of colon carcinoma in the liver, also tumours from hepatic origin frequently 
form intrahepatic metastasis. Therefore, we investigated the binding of L-SIGN and DC-SIGN 
to the hepatoma cell line HUH7. A cell-cell adhesion assay was performed similar as with 
SW948 cells. Fluorescently labelled Raji cells transfected with DC-SIGN or L-SIGN were 
added on a monolayer of HUH7 cells and binding was measured using fluorimetry. Strikingly, 
only Raji-L-SIGN cells were binding to HUH7 cells. No binding of Raji-DC-SIGN or mock-
transfected Raji cells was observed (Fig. 2.3A). The binding of Raji-L-SIGN cells could be 
specifically blocked by an L-SIGN specific antibody (Fig. 2.3A). Next, we further investigated 
adhesion of DC-SIGN-Fc and L-SIGN-Fc coated beads to HUH7. In this assay, L-SIGN-Fc 
coated beads bound strongly to HUH7 cells and DC-SIGN-Fc coated beads did not bind the 
cells (Fig. 2.3B), supporting the data from the cell-cell adhesion assay. This indicates that L-
SIGN recognizes a ligand expressed on the hepatocyte cell line that is not recognized by DC-
SIGN, demonstrating that this ligand is exclusive for L-SIGN.  
 
HUH7 cells express high levels of sialic acid. 
These data suggest that there is a difference in glycosylation between the colon carcinoma cell 
line SW948 and the hepatoma cell line HUH7 resulting in the differential binding of DC-SIGN 
and L-SIGN, with both DC-SIGN and L-SIGN binding to SW948 but only L-SIGN binding to 
HUH7. This is of special interest since no carbohydrate ligand is yet identified that is 
exclusively bound by L-SIGN and not by DC-SIGN. In order to identify which L-SIGN specific 
glycan structure is expressed on HUH7 cells, we compared the expression of glycosylation-
related genes in SW948 cells and HUH7 cells. The expression levels of a set of 
glycosyltransferases (GTs) involved in the synthesis of Lewis-type, sialylated, and 
galactosylated structures in SW948 and HUH7 cells was assayed by quantitative real-time 
PCR. The most prominent difference in GT expression is reflected in the high expression of 
fucosyltransferases (Fut) 1, -2, -4 and -10 in SW948 cells, whereas HUH7 cells express only 
Fut10 (Fig. 2.4A). Fut1, -2, and -4 are necessary for the generation of fucosylated 
carbohydrates such as Lex and Ley, while Fut10 has been suggested to be involved in this 
process, although has not been demonstrated yet [26]. In contrast, HUH7 cells expressed high 
levels of sialyltransferases, especially of ST6Gal1 and ST3Gal6 that were not expressed by 
SW948 cells (Fig. 2.4A). ST3Gal4 is expressed in both SW948 and HUH7 at moderate levels. 
These data predict a higher expression of fucosylated glycans on SW948 cells while HUH7 
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L-SIGN binds specific to the hepatoma cell line HUH7.  
(A) Cellular interactions between L-SIGN transfected cells and hepatoma HUH7 cells occur but not between DC-
SIGN transfected cells and HUH7 cells. HUH7 cells were cultured in 96 wells plate to confluent monolayers and 
fluorescently labelled Raji cells transfected with DC-SIGN or L-SIGN were incubated on the cells. Binding after 
several washes was measured using fluorimetry. Binding specificity was confirmed using DC-SIGN/L-SIGN specific 
antibodies (20 µg/ml, grey bars), or isotype controls (white bars). Error bars represent standard deviations (n=4). 
One representative experiment out of three is shown. (B) L-SIGN-Fc coated beads, but not DC-SIGN-Fc coated 
beads bind to HUH7 hepatoma cells. DC-SIGN- and L-SIGN-Fc were coupled to fluorescent beads and incubated 
with HUH7 cells. Adhesion was measured by flow cytometry and represented as percentage cells positive for beads 
binding. Specificity was determined by blocking with EDTA (10 mM, white bars) or DC-SIGN/L-SIGN specific 
antibodies (20 µg/ml, grey bars). One representative experiment out of three is shown. 
 
 
glycans are expected to be highly sialylated. This modification is known to sterically inhibit DC-
SIGN binding [5;27].  
To confirm actual glycan expression on the cells, SW948 and HUH7 cells were stained with a 
panel of lectins with known glycan specificities (Fig. 2.4B). Indeed, SW948 cells were strongly 
bound by α-L-Fucose-specific lectins, Ulex europaeus agglutinin 1 (UEA-1), Lotus 
tetragonolobus lectin (LTA), and Aleuria aurantia lectin (AAL). SW948 cells were not stained 
by sambucus nigra lectin (SNA), which binds preferentially to sialic acid attached to terminal 
galactose in α-2,6 linkage (Fig. 2.4B, black bars). In contrast, the hepatoma cell line HUH7 was 
strongly bound by SNA, confirming a high expression of α-2,6 linked sialylated carbohydrates 
(Fig. 2.4B, grey bars). The α-L-Fucose binding lectins UEA-1, LTA, and AAL showed only low 
binding to HUH7 cells. Thus, SW948 are rich in fucosylated glycan structures whereas HUH7 
cells express only low levels of fucosylated carbohydrates and high levels of sialylated glycan 
structures. 
 
Neuraminidase abrogates L-SIGN-HUH7 interactions. 
Because sialic acids present on glycan structures may mask DC-SIGN binding sites [27], and 
our GTs and glycan profiles indicate that they may serve as L-SIGN ligands, we investigated 
the effect of neuraminidase treatment on DC-SIGN and L-SIGN binding. Neuraminidase 
cleaves terminal sialic acid residues from carbohydrate moieties on proteins, resulting in 
terminal galactose, GalNAc, or fucose. The panel of lectins (Fig. 2.4B) was used to identify 
which changes in carbohydrate structures were generated by neuraminidase treatment of 
HUH7 cells. As expected, SNA binding to neuraminidase treated cells was reduced indicating 
that the neuraminidase treatment was effective (Fig. 2.5A). The fucose recognizing lectins 
UEA-1, LTA, and AAL did not show increased binding to neuraminidase treated HUH7 cells 
compared to control HUH7 cells (Fig. 2.5A). 
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Glycosylation profile of HUH7 and SW948 cells.  
(A) Glycosyltransferases expressed in HUH7 and SW948. Total mRNA was isolated from SW948 (black bars) and 
HUH7 (grey bars) cell lysates. After reverse transcription to cDNA, relative expression compared to expression of 
the household gene GAPDH was determined by real time PCR. Expression levels of fucosyl transferases (FUT) 1 to 
7, Fut9 and Fut10, sialyl transferase (ST) 6Gal1, ST3Gal3, ST3Gal4 and ST3Gal6 were determined. (B) Glycan 
expression pattern of SW948 and HUH7 cells. SW984 (black bars) and HUH7 (grey bars) were stained with the 
biotinylated fucose specific UEA-1, LTA, and AAL, mannose specific NPA, and GNA, and sialic acid specific SNA, 
and MAA lectins. Lectin binding was determined by counterstaining with fluorescent-labelled avidin and represented 
as mean fluorescence intensity of the cells. One representative experiment out of three is shown. 
 
 
L-SIGN- and DC-SIGN-Fc binding to neuraminidase treated HUH7 was compared to the 
binding of untreated cells. L-SIGN-Fc binding to HUH7 cells after neuraminidase treatment 
was greatly decreased (Fig. 2.5B). In contrast, DC-SIGN binding to neuraminidase treated 
cells was increased compared to untreated cells (Fig. 2.5B). Thus removal of sialic acid 
residues from the glycan structures present on HUH7 eliminates the binding epitope of L-
SIGN, whereas the removal of sialic acid unmasks the DC-SIGN binding epitopes. 
These data suggest that the hepatoma cell line expresses a ligand which contains sialic acid 
residues that is exclusively recognized by L-SIGN and not by DC-SIGN. 
 
 
 
Discussion 
 
We demonstrate here that L-SIGN, similar to DC-SIGN, is involved in tumour antigen 
recognition and that L-SIGN also recognizes a novel glycan structure yet to be characterized 
and distinct from DC-SIGN on the well differentiated hepatoma cell line HUH7. Earlier studies 
have demonstrated that DC-SIGN on DCs recognizes colon carcinoma derived CEA and 
CEACAM1 [19]. Malignant transformation of colon epithelial cells may change the 
glycosylation machinery, resulting in higher expression of Lewis type antigens [18;28]. It has 
been demonstrated that binding of DC-SIGN to the colon carcinoma cell line SW948 is partially 
dependent on Lex and Ley expression, since α1,3/4-Fucosidase treatment, which disrupts 
Lewis antigen structures, reduces DC-SIGN binding to SW948 derived CEA and CEACAM1 
[19]. Here we demonstrate that L-SIGN, similar to DC-SIGN, binds to the colon carcinoma cell 
line SW948. Furthermore, we demonstrate that L-SIGN binds more strongly to tumour derived  
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L-SIGN binds to sialic acid containing glycan structures.  
(A) Glycan expression on HUH7 cells after neuraminidase treatment. HUH7 cells were incubated with buffer (black 
bars) or with neuraminidase (white bars) in order to remove sialic acid residues from carbohydrate structures on the 
cell surface, and binding of a selected panel of lectins was investigated similar as in Figure 4B. One representative 
experiment out of two is shown. (B) DC-SIGN- and L-SIGN-Fc binding to HUH7 cells after neuraminidase treatment. 
HUH7 cells were incubated with buffer or with neuraminidase and subsequently incubated with DC-SIGN- or L-
SIGN-Fc. Cells were counterstained with fluorescent labelled anti-human Fc antibodies and binding is represented 
as mean fluorescent intensity of the cells. Binding specificity was confirmed by blocking with EGTA (10 mM, black 
bars). One representative experiment out of two is shown. 
 
 
CEA than to CEA from healthy tissue. Colon carcinomas often form metastasis in the liver, and 
L-SIGN expressed on liver sinusoidal endothelial cells could be involved in binding and 
dissemination of tumour cells. Binding to L-SIGN may facilitate the arrest of metastasizing cells 
in the liver sinusoid which subsequently proliferate to secondary tumours. Furthermore, the 
intrinsic tolerogenic capacity of LSECs [10;29] may hamper the induction of adequate immune 
responses to the metastasizing tumour cells. It has been postulated that DC-SIGN binding of 
tumour antigens to DC-SIGN expressing cells without an additional activation stimulus might 
also result in tolerance induction [30]. Indeed it was demonstrated that in vivo DCs in close 
proximity to CEA expressing tumours have an immature phenotype [19] and therefore lack the 
capacity to induce a proper T-cell response to the tumour. Therefore the binding of colon 
carcinoma cells to both L-SIGN and DC-SIGN might be beneficial for the tumour, firstly by 
preventing an appropriate T-cell response by binding to both DC-SIGN and L-SIGN on APCs, 
and secondly facilitating the arrest and dissemination of tumour cells in the liver due to capture 
by L-SIGN on LSECs in the liver sinusoid. 
We observed that next to its interaction with colon carcinoma cell line SW948 and colon 
carcinoma tissue of patients, L-SIGN is also binding the hepatoma cell line HUH7. Strikingly, 
DC-SIGN does not interact with these cells, indicating the expression of an L-SIGN specific 
ligand on these cells. We observerd that HUH7 cells have different GTs and glycan expression 
levels compared to SW948 colon carcinoma cells. The most striking difference is the high 
expression of sialyltransferases ST6Gal1 and ST3Gal6 in HUH7, which are absent in SW948 
cells. Sialic acid residues can mask DC-SIGN ligands, and indeed DC-SIGN did not bind 
HUH7 cells. However, DC-SIGN binding could be restored by removal of sialic acids by 
neuraminidase treatment of the hepatoma cell line which is consistent with its capacity for non-
sialic acids. In contrast, L-SIGN binding to HUH7 was abrogated when sialic acid residues 
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were removed by neuraminidase treatment of the cells, suggesting that L-SIGN in contrast to 
DC-SIGN is recognizing sialic acid containing carbohydrates. 
Normal non-neoplastic hepatocytes express high levels of α-2,6-sialylated glycoconjugates, 
and binding of the plant lectin SNA, recognizing α-2,6 linked sialic acid, is mainly confined to 
the sinusoidal side of hepatocytes [31]. In hepatocellular carcinomas this SNA binding pattern 
to the membrane is disrupted, and instead SNA stains dense aggregates in the cytoplasm of 
neoplastic hepatocytes [31]. The HUH7 cell line used in this study is derived from a well-
differentiated hepatoma with similar characteristics as healthy hepatocytes [20]. Since L-SIGN 
binds this well-differentiated hepatoma cell line, it will be highly likely that L-SIGN also binds 
normal hepatocytes. L-SIGN binding to sialylated structures on hepatocytes could therefore be 
associated with maintenance of normal liver structure, and the loss of sialylated carbohydrate 
expression on the hepatocyte surface upon malignant transformation could therefore result in 
loss of normal hepatic organisation and spread of tumour cells. 
 
The carbohydrate recognition pattern of DC-SIGN has extensively been studied, and DC-SIGN 
has demonstrated to have specificity for high mannose and non-sialylated fucose-containing 
Lewis antigens such as Lex, Ley, Lea, and Leb. Sialylation of these Lewis type carbohydrates 
results in loss of DC-SIGN binding [5;12]. 
L-SIGN shares 77% amino acid sequence identity with DC-SIGN, with the highest similarity in 
the CRD and its binding characteristics have demonstrated to be very similar to DC-SIGN 
[4;12]. However, the difference in just one amino acid in the CRD of L-SIGN results in the 
inability to bind Lex [14;15]. L-SIGN has at position 363 a serine molecule (Ser363), whereas 
DC-SIGN has a valine at this position (Val351). Mutation of the serine into a valine restores the 
ability of L-SIGN to bind Lex [15]. 
Here we demonstrate that, in contrast to DC-SIGN, L-SIGN binds sialic acid residues 
expressed by hepatic cells. This is the first identification of an L-SIGN specific carbohydrate 
ligand. Davis et al. reported the differential binding of DC-SIGN and L-SIGN to West Nile virus, 
indicating an L-SIGN specific binding to West Nile virus produced in human cells which did not 
interact with DC-SIGN [32]. However, the glycan profile responsible for this difference was not 
investigated. Using a glycan array the specificity of soluble L-SIGN was demonstrated only to 
bind high-mannose oligosaccharides [14]. However, studies using beads coated with 
polyacrylamide (PAA)-linked carbohydrates and L-SIGN expressing cells, demonstrated that L-
SIGN also interacts with fucose containing ligands Ley, Lea, and Leb [12]. The different results 
found in these two assays could be due to the multimerisation of L-SIGN, but could also be 
due to multivalency of the carbohydrates and the protein backbone. The murine homologue of 
DC-SIGN and L-SIGN, mSIGNR1 has demonstrated to have also specificity for sialylated 
glycan structures since mSIGNR1 expressing cells bind sialylated Lewis antigens coupled to a 
PAA-backbone [12]. In this assay using cells expressing the C-type lectins and PAA-coupled 
carbohydrates on beads, L-SIGN did not bind sialylated Lewis antigens [12]. However it is 
possible that for binding, the carbohydrates should be expressed on an appropriate backbone. 
The fact that L-SIGN could bind to sialic acid structures expressed on hepatic cells, as 
demonstrated here, and not to sialic acid structures present on the glycan array or as PAA-
coupled beads remains to be defined in the near future.  
 
In conclusion this study demonstrates a dual role for L-SIGN on LSECs in the liver. Firstly, L-
SIGN may function in the dissemination of colon carcinoma metastases in the liver, through 
binding and arrest of colon carcinoma cells. On the other hand, L-SIGN may function in 
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homeostasis control through its interaction with specific sialic acid containing ligands on 
healthy hepatocytes. 
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Abstract 
 
Hepatitis C virus (HCV) is a major health problem. However, the mechanism of hepatocyte 
infection is largely unknown. We demonstrate that the DC-specific C-type lectin DC-SIGN and 
its liver-expressed homologue L-SIGN/DC-SIGNR are important receptors for the HCV 
envelope glycoproteins E1 and E2. Mutagenesis analyses demonstrates that both HCV E1 and 
E2 bind the same binding site on DC-SIGN as the pathogens HIV-1 and mycobacteria, which 
is distinct from the cellular ligand ICAM-3.  
HCV virus-like particles are efficiently captured and internalized by DCs through binding of DC-
SIGN. Antibodies against DC-SIGN specifically block the HCV capture by both immature and 
mature DCs, demonstrating that DC-SIGN is the major receptor on DCs. Interestingly, 
internalized HCV virus-like particles are targeted to non-lysosomal compartments within 
immature DCs, where they are protected from lysosomal degradation similarly as was 
demonstrated for HIV-1. Lewisx antigen, another ligand of DC-SIGN was internalized to 
lysosomes, demonstrating that the internalization pathway of DC-SIGN-captured ligands may 
depend on the structure of the ligand. Our results suggest that HCV may target DC-SIGN to 
‘hide’ within DCs and to facilitate viral dissemination. L-SIGN expressed by THP-1 cells 
internalizes HCV particles into similar non-lysosomal compartments, suggesting that L-SIGN 
on LSECs may capture HCV from blood and transmit it to hepatocytes, the primary target for 
HCV.  
We therefore conclude that both DCs and LSECs may act as reservoirs for HCV and that the 
C-type lectins DC-SIGN and L-SIGN, as important HCV receptors, may represent a molecular 
target for clinical intervention in HCV infection. 
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Introduction 
 
Hepatitis C virus (HCV) is the causal agent of hepatitis C, which is a major health problem 
affecting 170 million people worldwide [1]. Approximately 90% of patients develop chronic 
hepatitis [2], of which 20-30% progress to liver cirrhosis and end-stage liver disease [3;4]. HCV 
is an enveloped positive-stranded RNA virus [5] that belongs to the Flaviviridae family. The 
genome encodes for a single polyprotein [6;7] and a combination of host and viral peptidases 
processes the polyprotein into at least nine different structural and non-structural proteins [8-
10]. The HCV envelope is formed by two heavily N-glycosylated type I transmembrane 
envelope glycoproteins E1 (31 kD) and E2 (70 kD) [11-13], that are expressed as heterodimers 
on the virus membrane [13].  
A characteristic feature of HCV is the high incidence of persistent infection and chronic 
hepatitis with a strong risk for the development of hepatocellular carcinoma, although some 
patients exhibit acute self-limited infection [14]. This high incidence of chronicity suggests that 
the virus has developed efficient mechanisms to escape host immune responses. Indeed, 
cellular immune responses are weak in chronically infected patients [15-17], although the 
reason for this poor reaction remains unclear. 
HCV mainly infects hepatocytes but also peripheral blood mononuclear cells (PBMCs). 
However, the precise mechanisms of early HCV infection are largely unknown, especially how 
HCV infects hepatocytes in liver. Attempts to elucidate these early events have been 
hampered by the difficulties to obtain sufficient amounts of free virions from either plasma of 
infected individuals or in vitro systems for virus propagation. Nevertheless, it is generally 
accepted that HCV envelope glycoproteins E1 and E2, as with other enveloped viruses, may 
play a major role in virus binding and entry into target cells. Indeed, several putative HCV 
receptors have been identified that interact with the HCV envelope glycoproteins, such as 
CD81 [18], the scavenger receptor class B type I (SR-B1) [19], and the asialoglycoprotein 
receptor (ASGP-R) [20]. Recently, it was demonstrated that the C-type lectins DC-SIGN and L-
SIGN/DC-SIGNR may be involved in HCV binding through their interaction with the HCV 
envelope glycoprotein E2 [21-23]. 
DC-SIGN is specifically expressed on dendritic cells (DCs) [24;25], and plays a key-role in the 
dissemination of HIV-1 by DCs through HIV-1 gp120 binding [26]. Recent studies have 
demonstrated that DC-SIGN also functions as a receptor for other pathogens, including 
cytomegalovirus (CMV) [27], Ebola virus [28], and Mycobacterium tuberculosis [29]. It is 
becoming clear that other pathogens besides HIV-1 target DC-SIGN to promote their survival 
and, similarly, HCV binding to DC-SIGN may not only promote HCV dissemination but may 
also modulate DC function necessary for establishing chronic infections. Indeed, it has been 
shown that chronic HCV infection impairs DC maturation as well as their immune stimulatory 
function [30;31]. Thus, DCs may be a target for HCV to escape immune surveillance and 
knowledge about the interaction of DCs with HCV is essential to fully understand and combat 
HCV infections.  
The liver homologue of DC-SIGN, L-SIGN is specifically expressed by liver sinusoidal 
endothelial cells (LSECs) [32;33], a specialized endothelial cell type with antigen presenting 
cell (APC) function [34]. L-SIGN binds HIV-1 gp120 comparable to DC-SIGN, and may be 
involved in HIV-1 transmission to T cells [32]. Similarly, L-SIGN expressed by LSECs may 
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capture HCV from blood and mediate infection of adjacent hepatocytes, the main target cells 
for HCV. 
In order to unravel the interaction of HCV with both C-type lectins DC-SIGN and L-SIGN and 
their role in virus dissemination, we investigated the interaction of both C-type lectins with 
virus-like particles (VLPs) consisting of either the HCV glycoproteins E1 or E2 alone, or in a 
E1/E2 heterocomplex, as a suitable surrogate for native HCV particles. We demonstrate that 
the C-type lectins DC-SIGN and L-SIGN interact similarly with both glycoproteins E1 and E2 
and that the HCV glycoproteins occupy the same binding pocket in DC-SIGN as HIV-1 gp120 
and mycobacterial ManLAM. Both immature and mature DCs strongly bind the VLPs of E1 and 
E2 and this interaction is primarily mediated by DC-SIGN. Moreover, VLPs are rapidly 
internalized by DC-SIGN on immature DCs and targeted to EEA-1-positive early endosomes, 
where the VLPs are protected from degradation. In contrast, Lewisx (Lex)-antigens are 
internalized by DC-SIGN and targeted to the lysosomes for destruction. Furthermore, we 
demonstrate that LSECs efficiently capture HCV particles in situ through L-SIGN. L-SIGN 
rapidly internalizes HCV into early endosomes. Our data suggest that HCV may target DC-
SIGN and L-SIGN to hide within DCs and LSECs respectively. 
 
 
 
Materials and Methods 
 
Antibodies and proteins.  
The following antibodies were used: mouse anti-MR (Clone 19, BD Pharmingen, San Diego, CA, USA), 
DC-SIGN-specific mouse antibody AZN-D1 [24], DC-SIGN- and L-SIGN-specific antibody AZN-D2 [26], 
mouse anti-L-SIGN (R&D Systems, Minneapolis, MN, USA), mouse anti-LAMP-1 (H4A3, BD 
Pharmingen, San Diego, CA, USA), mouse anti-EEA-1 (BD Pharmingen, San Diego, CA, USA), human 
and mouse anti-HCV E1 (1C4 and 23C12 respectively, Innogenetics, Ghent, Belgium) and mouse anti-
E2 antibody (4H6B2, Innogenetics, Ghent, Belgium), goat anti-human IgG1 conjugated with FITC and 
PO (Jackson Immunoresearch, West Grove, PA, USA), goat anti-mouse conjugated with FITC (Zymed 
Laboratories Inc., South San Francisco, CA, USA) goat anti-mouse conjugated with Alexa Fluor 488 and 
594 and streptavidin Alexa Fluor 488 (Molecular Probes, Eugene, OR, USA). 
HIV-1 gp120 was obtained through the AIDS Research and Reference Reagent Program, Division of 
AIDS (NIAID, NIH, USA: HIV-1 IIIB gp120). 
 
HCV envelope glycoproteins.  
HCV envelope glycoproteins E1 and E2 were expressed separately either in Vero cells by infection with 
recombinant vaccinia virus or in the yeast Hansenula polymorpha. Both glycoproteins were derived from 
the structural region of a genotype 1b isolate and lacked the C-terminal membrane anchor (E1: aa 192-
326 and E2: aa 384-673). A C-terminal his-tag was added for purification purposes, with the exception of 
the E1 protein produced in Vero cells. 
Despite the truncation of the membrane anchor all proteins were retained intracellularly and were thus 
purified from cell lysates. In brief, the envelope proteins as expressed in Vero cells were extracted by 
means of Triton X-100 and purified using lentil affinity chromatography resulting in an E1 or E2 enriched 
protein fraction consisting mainly out of aggregated material. These aggregates were reduced to 
monomeric proteins by incubation with DTT and Empigen BB. After blocking of the free cysteines with 
iodoacetamide the monomeric E1 protein was recovered by means of size exclusion chromatography in 
the presence of Empigen BB. For the E2 protein both a size exclusion chromatography and a nickel 
metal affinity chromatography were required in order to obtain pure E2 monomers. In case of expression 
in yeast, the cells were lysed by means of GuHCl and sulfonation. The recovered proteins were purified 
by nickel metal affinity chromatography in the presence of Empigen BB. Finally, the proteins were 
reduced by incubation with DTT and free cysteines blocked with iodoacetamide.  
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Vero cell or yeast cell derived monomeric E1, E2 or equimolar mixtures of E1 and E2 were subjected to 
an additional size exclusion chromatography in the presence of betain. This step allowed to exchange 
the detergent Empigen resulting in formation of particles with a size ranging from 10-100 nm. 
 
Cells.  
Immature DCs were cultured as described before [35]. In short, human blood monocytes were isolated 
from buffy coats by a Ficoll and a 52% Percoll gradient, and subsequent an adherence step. Adhered 
monocytes were differentiated into immature DCs in the presence of IL-4 and GM-CSF (500 and 800 
U/ml, respectively; Schering-Plough, Brussels, Belgium). At day 6 the phenotype of the cultured DCs 
was confirmed by flow cytometric analysis. The DCs expressed high levels of MHC class I and II, CD11b, 
CD11c and ICAM-1, and low levels of CD80 and CD86. DCs were matured by adding 
lipopolysaccharide (LPS, 2 µg/ml, S. typhosa; Sigma Aldrich, St. Louis, MO) for 2 days. Maturation was 
verified by analysis of the expression of CD80, CD83 and CD86.  
Stable THP-1 and K562 transfectants expressing wild-type L-SIGN, DC-SIGN, or DC-SIGN mutants [36], 
were generated as previously described [26]. 
 
Soluble DC-SIGN-Fc binding ELISA.  
The DC-SIGN-Fc chimera [36] contained the extracellular portion of DC-SIGN (amino acid residues 64-
404) fused at the C-terminus to a human IgG1-Fc fragment. The soluble DC-SIGN-Fc binding assay was 
performed as previously described [36]. Soluble ligands were coated on ELISA plates (maxisorb plate 
NUNC, 0.25 µg/well unless indicated) overnight at 4°C, followed by blocking with 1% BSA for 30 
minutes at 37°C. Soluble DC-SIGN-Fc (5 µg/ml) was added for 2 hours at 37°C, and binding was 
determined by anti-IgG1 ELISA. Specificity was determined (unless indicated) in the presence of 50 
µg/ml blocking antibodies, 100 µg/ml mannan or 10 mM EGTA. 
 
Fluorescent bead adhesion assay.  
Binding of ligand-coated beads to cells was done as described by Geijtenbeek et al. [24]. In short, 
streptavidin was covalently coupled to the carboxylate-modified TransFluorSpheres (488/645 nm, 1.0 
µm; Molecular Probes, Eugene, OR, USA). The streptavidin-coated beads were incubated with 
biotinylated F(ab’)2 fragment goat anti-mouse IgG (6 µg/ml; Jackson Immunoresearch), followed by an 
overnight incubation with mouse-anti-HCV E1 or E2 antibody (23C12 or 4H6B2) at 4°C. The beads were 
washed and incubated with 250 ng/ml purified HCV envelope glycoproteins E1 or E2 overnight at 4°C. 
The fluorescent beads adhesion assay was performed as described before [37]. In short, 50,000 cells 
were incubated with beads for 45 minutes at 37°C. Mannan, EGTA and blocking antibodies against DC-
SIGN and L-SIGN were used to determine specificity of adhesion. Binding was measured by FACS 
analysis. 
 
DC activation.  
Immature DCs (120,000 cells/ml) were cultured in the presence of IL-4 (500 U/ml; Schering-Plough) and 
GM-CSF (800 U/ml; Schering-Plough). The effect of HCV on activation was determined by incubating 
immature DCs (day 6) with HCV-VLPs (12.5 µg/ml) in absence or presence of LPS (10 ng/ml) for 48 h at 
37°C. Activation was determined by cell-surface expression of the costimulatory molecules CD83, and 
CD86 using PE-conjugated antibodies. 
 
Immunofluorescence microscopy.  
Cells were incubated 4 hours or overnight at 37°C with HCV E1/E2 (30 µg/ml) or biotinylated Lex antigen 
(10 µg/ml). The transferrin receptor was detected by incubating the cells with Alexa Fluor 594-
conjugated transferrin (10 µg/ml, Molecular Probes, Eugene, OR, USA) for 15 minutes at 37°C prior to 
fixation. Labelled cells were fixed in 3% paraformaldehyde in PBS for 15 minutes and permeabilized in 
PBS/0.1% saponin prior to staining. Cells were stained in PBS/0.5% BSA with antibodies against HCV 
envelope glycoprotein E1 or E2, and against LAMP-1, EEA-1 or DC-SIGN, and subsequently with FITC- 
or Alexa Fluor 488/594-conjugated secondary antibodies, or with streptavidin-Alexa Fluor 488. Next, 
cells were allowed to adhere to poly-L-lysine coated glass slides and mounted in anti-bleach reagent. 
Fixed slides were either imaged with a ZEISS Axiovert 200 Marianas™ inverted microscope (Intelligent 
Imaging Innovations, Denver, CO, USA) equipped with a motorized stage (stepper-motor z-axis 
increments: 0.1 µm), multiple fluorescence as well as brightfield channels, and a cooled CCD camera 
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[Cooke Sensicam (Cooke, Tonawanda, NY), 1280 x 1024 pixels] with true 16-bit capability at 40X 
objective, or they were examined with a Nikon Eclipse E800 fluorescence microscope and pictures were 
captured with a digital NIKON DXM1200 camera at 40X objective. In both cases images were acquired 
in 3 independent series/sessions. Pictures were analyzed with SlideBook™ 4 digital microscopy 
software (Intelligent Imaging Innovations, Denver, CO) or Jasc Paint Shop Pro™ software. 
 
Liver section staining.  
Human liver tissue was obtained from biopsies of therapeutic surgeon and cryofrozen. 8 µm sections 
were placed on gelatin-coated slides and stored at -80°C. The sections were incubated with HCV-VLPs 
(10 µg/ml) for 2 hours and stained with the mouse anti-HCV antibody 23C12 and an Alexa Fluor 594-
conjugated secondary antibody or with the human anti-HCV antibody 1C4 and a FITC-conjugated 
secondary antibody. Binding of HCV envelope glycoprotein was blocked by incubation in the presence 
of 50 µg/ml AZN-D2. L-SIGN was detected by staining the liver sections with an anti-L-SIGN antibody 
and Alexa Fluor 594-conjugated secondary antibody. Sections were analyzed with a Nikon Eclipse E800 
fluorescence microscope and pictures were captured with a digital NIKON DXM1200 camera at 20X 
objective. 
 
 
DC-SIGN specifically binds HCV envelope glycoproteins E1 and E2.  
(A) DC-SIGN binds both yeast Hansenula- and mammalian cell-produced HCV envelope glycoproteins. DC-SIGN 
interaction with HCV envelope glycoproteins E1 and E2 (0.25 µg/well), produced by either yeast Hansenula or 
mammalian cells using recombinant vaccinia virus, was determined in an Fc-based ELISA. Specificity of the binding 
was confirmed using the DC-SIGN specific blocking antibody AZN-D1 (50 µg/ml), mannan (100 µg/ml) and the 
calcium chelator EGTA (5 mM). (B) DC-SIGN binds stronger to HCV envelope glycoprotein E2 than to E1. HCV 
glycoproteins E1 and E2 were titrated (0-16 or 0-14 µM resp.) and DC-SIGN-Fc binding was determined as 
described above. DC-SIGN-specific antibody AZN-D1 (50 µg/ml) was used to specifically block the interaction. (C) 
DC-SIGN has a higher affinity for envelope glycoprotein E2 than for envelope glycoproteins E1 and gp120. 
Mammalian produced glycoprotein E1 and E2 (10 nM) and gp120 (2 nM) were coated and DC-SIGN-Fc binding was 
determined as described above. Mannan was titrated (0-1000 µg/ml) to block the interaction. Binding is represented 
as percentage of the maximal binding. (D) DC-SIGN binding to HCV envelope glycoproteins E1 and E2, and HIV-1 
envelope gp120 is equally dependent on calcium. Viral envelope glycoproteins E1 and E2 (10 nM) and gp120 (2 
nM) were coated and DC-SIGN-Fc binding was measured as described above in the presence of a varying of 
calcium (0-5 mM). Binding is represented as percentage of maximal binding at 5 mM calcium. Standard deviations 
are < 2%. 
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Results 
 
DC-SIGN interacts with HCV envelope glycoproteins E1 and E2. 
The interaction of DC-SIGN with HCV envelope glycoproteins was investigated using the DC-
SIGN-Fc binding assay [36]. Purified HCV envelope glycoproteins E1 and E2 produced in 
either mammalian cells or in yeast Hansenula polymorpha are reconstituted into VLPs. 
Recombinant DC-SIGN-Fc specifically interacted with both mammalian- and yeast-produced 
HCV envelope glycoproteins E1, E2 and the mixed E1/E2 VLPs. This interaction could be 
blocked by the DC-SIGN-specific antibody AZN-D1, the calcium chelator EGTA, and the 
polycarbohydrate mannan (Fig. 3.1A). No difference in binding was observed between yeast 
and mammalian-produced envelope glycoproteins (Fig. 3.1A). Further experiments were 
performed with HCV envelope glycoproteins produced in mammalian cells. DC-SIGN bound 
stronger to glycoprotein E2 than to E1 (Fig. 3.1B), and the binding could be specifically 
blocked by anti-DC-SIGN antibodies (Fig. 3.1B). The interaction of DC-SIGN to HCV envelope 
glycoproteins E1 and E2 was further investigated by titration of mannan to block the 
interaction. Mannan could completely block the interaction of DC-SIGN with both E1 and E2 
(Fig. 3.1C), although higher concentrations of mannan were necessary to block HCV E2 
binding than to block HCV E1 and HIV-1 gp120 binding to DC-SIGN (Fig. 3.1C). This indicates 
that DC-SIGN has the same affinity for HCV glycoprotein E1 and HIV-1 gp120, and a higher 
affinity for HCV glycoprotein E2. 
The calcium dependency of the DC-SIGN interaction with the HCV envelope glycoproteins was 
investigated. The interaction of DC-SIGN with HCV envelope glycoproteins E1, E2 and HIV-1 
gp120 was equally dependent on calcium (Fig. 3.1D) with Ki50 values between 0.15 and 0.25 
mM. At calcium concentrations lower than 0.1 mM the binding of these three ligands was 
almost completely abolished. These data demonstrate that DC-SIGN binds both HCV 
glycoprotein E1 and E2 similarly as HIV-1 gp120. 
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Cellular DC-SIGN and L-SIGN bind to HCV envelope glycoproteins. 
K562 cells stably expressing DC-SIGN and L-SIGN were used to investigate the binding of 
cellular DC-SIGN and L-SIGN to HCV envelope glycoproteins. The transfectants expressed 
similar high levels of DC-SIGN and L-SIGN (Fig. 3.2A). K562 transfectants expressing either 
DC-SIGN or L-SIGN strongly bound to both HCV envelope glycoproteins E1 and E2 (Fig.3.2B), 
whereas the mock-transfected K562 cells did not bind the HCV glycoproteins (data not shown). 
The observed binding of both DC-SIGN and L-SIGN to the HCV glycoproteins was comparable 
and could be completely blocked by antibodies against DC-SIGN and L-SIGN (Fig. 3.2B).  
We used DC-SIGN mutants containing specific mutants in their ligand-binding site in order to 
investigate the binding site of DC-SIGN for HCV envelope glycoprotein E1 and E2 in more 
detail. The C-type lectin domain of DC-SIGN contains two calcium binding sites [24], site 1 
positioned at the auxiliary site of DC-SIGN and site 2 located near the primary ligand binding 
site. The Ca2+ ion at site 1 coordinates the correct positioning of the loops forming primary 
binding site [36;38]. To investigate the role of this calcium ion, four mutations were generated. 
Mutating Asp320 (D320A), Glu324 (E324A), Asn350 (N350A) or Asp355 (D355A) into alanine 
resulted in the loss of calcium binding at site 1 and subsequent loss of binding to HCV 
envelope glycoproteins (Table 3.1), as was also previously shown for both ICAM-3 and HIV-1  
gp120 [36]. Changing Asp366 that coordinates calcium binding at site 2 into an alanine residue 
(D366A), resulted in complete loss of binding to both HCV and HIV-1 glycoproteins (Table 3.1). 
The amino acid residues that are in close contact with the Ca2+ at site 2 (Glu347, Asn349, Glu354 
and Asn365) form the core of the ligand binding site [36]. Changing Glu347 (E347Q) into Gln, or 
Asn349 (N349D) and Asn365 (N365D) into Asp, also resulted in complete loss of binding to HCV  
 
 
 
 
 
 
 
 
 
 
 
 
HCV envelope glycoproteins are bound by cellular 
DC-SIGN and L-SIGN.  
(A) K562 transfectants express similar levels of DC-
SIGN and L-SIGN. K562 cells were transfected with 
DC-SIGN or L-SIGN as described in materials and 
methods. Expression was measured by FACS-staining 
with the DC-SIGN and L-SIGN specific antibody AZN-
D2. Dotted lines represent isotype control, black lines 
AZN-D2 staining. Mean fluorescence indices were 
>700. (B) Cellular DC-SIGN and L-SIGN bind to both 
envelope glycoproteins E1 and E2. HCV envelope 
glycoprotein binding by K562 cells expressing DC-
SIGN or L-SIGN was measured with a fluorescent-
coated bead adhesion assay. The L-SIGN and DC-
SIGN-specific blocking antibody AZN-D2 (50 µg/ml) 
was used to determine the specificity of the interaction. 
(C) The DC-SIGN Val351 mutant binds both HCV 
envelope glycoproteins E1 and E2. K562 transfected 
with DC-SIGN V351G binding to glycoproteins E1 and 
E2 coated beads was investigated in the presence or 
absence of the DC-SIGN specific antibody AZN-D2 
(50 µg/ml) and EGTA (10 µM). Standard deviations are 
< 5%. 
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envelope glycoproteins E1 and E2 and HIV-1 gp120 (Table 3.1). 
Recently, we demonstrated that the binding site of DC-SIGN for its cellular ligand ICAM-3 is 
distinct from that of its pathogen ligands HIV-1 gp120 [36] and mycobacterial ManLAM [29], 
since a specific mutation in DC-SIGN (V351G) abrogated ICAM-3, but not HIV-1 gp120 and 
ManLAM binding. Interestingly, the DC-SIGN V351G mutant also interacts with HCV E1 as 
well as E2 (Fig. 3.2C), demonstrating that both HIV-1 and HCV bind similarly to DC-SIGN at a 
distinct site from the cellular ligand ICAM-3.  
 
 
Internalization pathway of DC-SIGN and L-SIGN is dependent on cellular background.  
(A) DC-SIGN and L-SIGN expressed by K562 and THP-1 transfectants bind HCV-VLPs similarly. Binding of HCV-
E1/E2-VLPs to K562 and THP-1 transfectants with both DC-SIGN and L-SIGN was measured. Interaction was 
blocked by the DC-SIGN and L-SIGN specific antibody AZN-D2 (50 µg/ml). Standard deviations are <5%. (B-E) DC-
SIGN- or L-SIGN-bound HCV is targeted to the early endosomes (transferrin+) in THP-1 transfectants, in contrast to 
the lysosomal (LAMP-1+) targeting in K562 transfectants. K-562 (B, C) and THP-1 cells (D, E) expressing DC-SIGN 
or L-SIGN were incubated overnight with HCV-VLPs. HCV was detected using a human anti-HCV antibody and a 
FITC-labelled secondary antibody. Intracellular targeting was determined by staining the endosomal compartments 
with a mouse antibody against the lysosomal/late endosomal specific LAMP-1 and Alexa Fluor 594 labelled 
secondary antibody (B, D), or by co-incubating the cells for 15 minutes with Alexa Fluor 594 labelled transferrin 
which is specifically transported to the early endosomes (C, E). Cells were analyzed by fluorescence microscopy. 
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HCV virus-like particles are internalized by DC-SIGN and L-SIGN transfectants. 
DC-SIGN can function as an antigen receptor internalizing antigens [39]. Using a DC-SIGN 
specific antibody as an antigen, it was shown that DC-SIGN rapidly targets the antigen to 
lysosomal compartments for degradation and subsequent presentation on MHC class II [39]. In 
order to investigate the internalization and intracellular targeting of HCV-VLPs after capture by 
both DC-SIGN and L-SIGN, we used stable transfectants of the erythroleukemic cell line K562 
and the monocytic cell line THP-1. Both DC-SIGN- and L-SIGN-transfected K562 and THP-1 
cells efficiently bound HCV-E1/E2-VLPs (Fig. 3.3A).  
Transfectants were incubated overnight with E1/E2-VLPs. Intracellular compartments were 
subsequently stained with an antibody against LAMP-1, a marker for lysosomal/late 
endosomal vesicles, and with transferrin, which accumulates in the early endosomes through 
transferrin receptor uptake [40]. Cells were analyzed by immunofluorescence microscopy. In 
all transfectants, HCV-VLPs were rapidly internalized by DC-SIGN and L-SIGN and targeted to 
the endosomal pathway (Fig. 3.3B). Remarkably, our results demonstrate that the 
internalization pathway of both DC-SIGN and L-SIGN is dependent on the cell type. Both DC-
SIGN and L-SIGN expressed by K562 cells target HCV-E1/E2-VLPs to the LAMP-1-positive 
compartments (Fig. 3.3B), and not to the transferrin-positive early endosomes (Fig. 3.3C). In 
contrast, HCV-VLPs internalized by DC-SIGN and L-SIGN expressed by THP-1 cells are not 
targeted to the lysosomes. In these cells HCV-VLPs reside not within LAMP-1 positive  
compartments (Fig. 3.3D) but in transferrin-positive vesicles (Fig. 3.3E). 
The internalization was specific for both DC-SIGN and L-SIGN, since both mock-transfected 
K562 and THP-1 cells did not internalize HCV-VLPs (data not shown). Thus, both DC-SIGN 
and L-SIGN efficiently internalize HCV-VLPs, but the internalization pathway is dependent on 
the cell type, suggesting that cellular origin is important. Therefore we investigated antigen 
uptake with DC-SIGN on primary cells. 
 
DC-SIGN on dendritic cells targets HCV to early endosomes. 
DCs express high levels of various pathogen receptors such as DC-SIGN (Fig. 3.4A) and the 
mannose receptor (MR) [39]. We investigated the interaction of immature DCs with the 
different HCV envelope glycoproteins. The contribution of DC-SIGN on immature DCs in the 
binding to HCV envelope glycoproteins was investigated using specific blocking antibodies. 
Immature DCs showed a strong binding to HCV E1, E2 and E1/E2-VLPs. This binding could 
be blocked by a specific anti-DC-SIGN antibody, mannan, and EGTA, but not by an antibody 
against MR (Fig. 3.4B), demonstrating that DC-SIGN is the major receptor for HCV envelope 
glycoproteins on immature DCs. 
Moreover, mature DCs also captured the different HCV envelope glycoproteins, and this could 
be blocked by mannan, EGTA and an antibody against DC-SIGN but not by an MR-specific 
antibody (Fig. 3.4C). This indicates that also on mature DCs, DC-SIGN is the major receptor 
for HCV envelope glycoproteins. However, this binding was less strong than the binding by 
immature DCs, due to down regulation of DC-SIGN expression (Fig. 3.4A). 
Next, we investigated the effect of HCV on DC activation/maturation. Activation was 
determined by measuring the expression levels of the maturation markers CD83 and CD86. 
Immature DCs were incubated with HCV-VLPs for 48 hours. Both CD83 and CD86 expression 
did not change compared to DCs incubated without HCV (Fig. 3.4D), demonstrating that the 
HCV-VLPs do not induce maturation. We have demonstrated that mycobacterial 
lipoarabinomannan binding to DC-SIGN prevents DC activation [29]. In contrast, HCV had no 
effect on LPS-induced DC activation (Fig. 3.4D). This supports recent data showing that DCs 
function normally in chronic HCV infected patients [41], suggesting that HCV employs a 
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different way to evade DC immunity. Therefore, the fate of HCV-VLPs upon binding by 
immature DCs was investigated. Immature DCs were incubated with HCV-VLPs for 4h or 
overnight and co-localization with the lysosomal marker LAMP-1 or early endosomal markers 
EEA-1 [42] and transferrin was analyzed. After 4 hours, colocalization of the HCV-VLPs was 
observed with transferrin positive but not with LAMP-1 positive vesicles. Even after 24 hours, 
HCV was still primarily present in the EEA-1 positive vesicles (Fig. 3.5A), similar as was 
observed for THP-1 transfectants (Fig. 3.3D and E). HCV-VLP internalization was DC-SIGN 
dependent, since blocking of DC-SIGN with a DC-SIGN antibody completely abolished 
internalization of HCV-VLPs (data not shown). Subsequently, DC-SIGN co-localization with 
HCV-VLPs after incubation was investigated. After incubation 4°C, both HCV-VLPs and DC-
SIGN were localized at the cellsurface of the DCs (Fig. 3.5B). When incubated at 37°C for 4 
hours to allow internalization, internalized HCV-VLPs co-localized with DC-SIGN (Fig. 3.5B).  
 
 
Dendritic cells strongly bind to HCV glycoprotein E1 and E2 through DC-SIGN.  
(A) Immature DCs express high levels of DC-SIGN. LPS-matured DCs express lower levels of DC-SIGN. Monocyte-
derived dendritic cells were isolated as described in materials and methods. Expression of DC-SIGN was measured 
by FACS-staining with the DC-SIGN specific antibody AZN-D2. Open histograms represent isotype control, filled 
histograms AZN-D2 staining. (B, C) Immature DCs and mature DCs bind strongly to HCV envelope glycoproteins 
E1 and E2, and mixed HCV E1/E2-VLPs via DC-SIGN. Immature (B) and LPS-matured DCs (C) binding to HCV 
envelope glycoproteins was determined by a fluorescent bead adhesion assay. Specificity was determined by anti-
DC-SIGN antibody AZN-D2 (50 µg/ml), mannan (100 µg/ml), EGTA (10 µM), and anti-mannose receptor antibody 
(clone 19) (50 µg/ml). Standard deviations are < 5%. (D) HCV-VLPs do not affect DC activation/maturation. 
Immature DCs were incubated with HCV (12.5 µg/ml) alone, LPS (10 µg/ml) alone, or HCV and LPS together for 48 
h and activation was determined by measuring the expression of CD83 and CD86. Dotted lines represent isotype 
controls, filed histograms with thin lines represent incubations without HCV, open histograms with thick lines 
represent incubations without or with LPS in combination with HCV-VLPs. Upper panel are incubations without LPS, 
lower panel are incubations with LPS. One representative experiment out of three is shown. 
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DC-SIGN on immature DCs targets HCV-VLPs to 
early endosomes, but Lewisx antigen to 
lysosomes. (A) Immature DCs were incubated with 
HCV-VLPs (30 µg/ml) for 4 hours or overnight. HCV 
was detected with a human anti-HCV antibody and a 
FITC-labelled secondary antibody. Intracellular 
targeting was determined by staining the endosomal 
compartments with a mouse antibody against the 
lysosomal/late endosomal specific LAMP-1 or the 
early endosome specific marker EEA-1 and an 
Alexa Fluor 594 labelled secondary antibody, or by 
co-incubating the cells for 15 minutes with Alexa 
Fluor 594 labelled transferrin which is specifically 
transported to the early endosomes. (B) Immature 
DCs were incubated with HCV-VLPs (30 µg/ml) for 4 
hours or overnight at 37 or 4°C. HCV was detected 
as described for figure 3.5A. Localization of DC-
SIGN was determined with the DC-SIGN specific 
antibody AZN-D2 and an Alexa Fluor 594 labelled 
secondary antibody. Cells were analyzed on a 3i 
MarianasTM digital imaging microscopy workstation 
and SlideBookTM software. (C) DC-SIGN on 
immature DCs targets its ligand Lewisx antigen to 
late endosomes/lysosomes. Immature dendritic cells 
were incubated with Lewisx (10 µg/ml) for 4 hours. 
Intracellular targeting was determined by staining 
the endosomal compartments with a mouse 
antibody against the lysosomal/late endosomal 
specific LAMP-1 or by co-incubating the cells for 15 
minutes with Alexa Fluor 594 labelled transferrin 
which is specifically transported to the early 
endosomes. Cells were analyzed by fluorescence 
microscopy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Even after prolonged incubation (24 hours), DC-SIGN co-localized with HCV-VLPs, suggesting  
DC-SIGN has, besides a role in internalization, a role in intracellular routing of HCV-VLPs.  
Strikingly, the internalization pathway of DC-SIGN on immature DCs is dependent on the 
ligand, since the carbohydrate blood-group antigen Lewisx and mycobacterial ManLAM were 
efficiently captured and internalized by immature DCs through DC-SIGN, and targeted to 
transferrin negative, LAMP-1-positive lysosomes (Fig. 3.5C and [29]) but not on ligand-binding 
site as ManLAM is binding the same site as HCV E1 and E2 and gp120. Together, these data 
suggest that HCV targets DC-SIGN to enter DCs and escape degradation by preventing 
targeting to the lysosomes. 
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HCV interacts with L-SIGN expressing LSECs in situ.  
(A) L-SIGN is expressed by human liver sinusoidal endothelial cells, as was determined by staining of liver tissue 
with an L-SIGN specific antibody. (B) Binding of HCV-VLPs by liver tissue was determined by incubating liver 
sections with HCV-VLPs (10 µg/ml) for 2 hours at 37°C. HCV binding was detected using a human anti-HCV 
antibody and FITC labelled secondary antibody. (C) HCV-VLP binding to LSECs is specifically blocked by the L-
SIGN-specific antibody AZN-D2. Sections were pre-incubated with AZN-D2 (50 µg/ml) for 30 minutes at room 
temperature before adding HCV-VLPs as described in A. Sections were analyzed with fluorescence microscopy 
with a 20X objective. Bars are 50 µM. 
 
 
HCV interact with LSECs in situ. 
In the liver hepatocytes are the main target of HCV and although putative HCV receptors have 
been identified, it is unclear how HCV infects the hepatocytes. We have shown that cell lines 
transfected with L-SIGN can interact with HCV envelope glycoproteins (Fig. 3.2). L-SIGN is 
expressed on LSECs [32;33], the liver sinusoidal endothelial cells that are in close contact with 
the blood and could capture HCV from the blood and transmit it to the hepatocytes. However, 
these cells are difficult to isolate. Therefore we used an in situ binding assay to investigate 
which are the major HCV binding cells in the liver.  
L-SIGN was stained in liver tissue sections with an anti-L-SIGN antibody, and analyzed by 
immunofluorescence microscopy (Fig. 3.6A). HCV envelope glycoprotein binding in situ was 
investigated by incubating the liver sections with HCV-VLPs. VLPs were detected with anti-
HCV E1 antibody and fluorescent-labelled secondary antibody (Fig. 3.6B). The staining pattern 
of HCV-VLPs was similar to the L-SIGN staining in the sections, suggesting that the HCV 
binds to the L-SIGN expressing LSECs. Moreover, the HCV binding to LSEC was specifically 
blocked by a blocking antibody against L-SIGN (Fig. 3.6C), demonstrating that this binding was 
mediated by the C-type lectin L-SIGN. Strikingly, HCV-VLPs interacted only with the LSECs 
and not with hepatocytes that express the putative HCV receptor ASGP-R and are the main 
target cells for HCV. These data suggest that HCV is captured by L-SIGN that mediates 
internalization of HCV, and thus LSECs act as a HCV reservoir and may transmit the virus to 
hepatocytes. 
 
 
 
Discussion 
 
Our results demonstrate that HCV is efficiently captured by DCs through DC-SIGN and by 
LSECs through L-SIGN. The C-type lectins interact with both envelope glycoproteins E1 and 
E2. Strikingly, internalized HCV-VLPs are targeted by DC-SIGN on immature DCs to early 
endosomal compartments, where HCV is protected from degradation. Similarly, HCV captured 
by L-SIGN expressed on THP-1 is targeted to early endosomal compartments. In contrast, 
another ligand of DC-SIGN, Lewis X blood-group antigen, is targeted to the lysosomes. Thus, 
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HCV may target DC-SIGN and L-SIGN to use DCs and LSECs respectively as reservoirs to 
facilitate viral dissemination. 
Because of the lack of a suitable cell culture system for in vitro propagation of HCV and the 
unavailability of virions in sufficient quantities, truncated and secreted versions of the HCV 
envelope glycoproteins have been used as soluble surrogates for native virus particles. Here, 
we have used VLPs of the HCV envelope glycoproteins E1 and E2. The envelope 
glycoproteins E1 and E2 were produced in either yeast Hansenula or mammalian cells using a 
recombinant vaccinia virus, and were assembled into a VLP of noncovalently linked E1 or E2 
homomers or E1/E2 heteromers. We have used these purified HCV-VLPs to investigate their 
interaction with both DC-SIGN and L-SIGN.  
Both cellular DC-SIGN and L-SIGN bind strongly to the envelope glycoproteins E1 and E2 
alone as well as to the E1/E2 heterodimer particles (Fig. 3.2). The interactions were  
specifically inhibited by blocking antibodies against DC-SIGN and L-SIGN. Recently, it was 
shown that both DC-SIGN and L-SIGN interact with the HCV envelope glycoprotein E2 [21-23] 
and envelope glycoprotein E1 [23]. Here we demonstrate that DC-SIGN bound stronger to 
envelope glycoprotein E2 than to glycoprotein E1. Lozach et al. [22] demonstrated that the 
interaction of DC-SIGN with glycoprotein E2 is dependent on N-linked glycosylations. HCV 
envelope glycoprotein E2 has 11 potential N-linked glycosylation sites where envelope 
glycoprotein E1 has only 6 sites [13] what can explain the stronger binding of DC-SIGN to HCV 
envelope glycoprotein E2. Furthermore, we demonstrate that the interaction of DC-SIGN with 
HCV envelope glycoproteins E1 and E2 and HIV-1 envelope protein gp120 was equally 
dependent on calcium (Fig. 3.1E), suggesting that these viral envelope glycoproteins interact 
at the same binding site in DC-SIGN. Indeed site-directed mutagenesis demonstrates that both 
HCV glycoproteins E1 and E2 bind the primary ligand-binding site in DC-SIGN through 
coordination with the primary Ca2+-ion at site 2 (Table 3.1). Moreover, HCV envelope 
glycoproteins E1 and E2, like the pathogenic ligands HIV-1 gp120 and mycobacterial 
ManLAM, bind to the V351G DC-SIGN mutant, whereas the cellular ligand ICAM-3 does not 
bind this mutant [29;36]. These observations further suggest that DC-SIGN may distinguish 
between different types of ligand and may tailor its responses specifically to the ligand it 
recognizes. 
DC-SIGN functions as a more universal pathogen receptor [43] and the pathogens HIV-1 and 
M. tuberculosis target DC-SIGN to escape immune surveillance [26;29;44]. The interaction of 
the HCV envelope glycoproteins E1 and E2 with both DC-SIGN and L-SIGN, suggests that 
DC-SIGN and L-SIGN may be involved in the pathogenesis of HCV. Little is known about the 
dissemination of HCV and the role of the immune system in the pathogenesis of HCV is 
complex and largely unknown. It has been shown that HCV may affect DCs; during chronic 
HCV infection DCs are impaired in their immune function [30;31]. In contrast, a recent study 
demonstrated that monocyte-derived DCs from patients suffering from chronic HCV infection 
are functionally normal [41]. Here we demonstrate that immature DCs strongly bind to HCV 
envelope glycoproteins E1, E2 and E1/E2-VLPs through DC-SIGN, since the interactions were 
completely blocked by antibodies against DC-SIGN (Fig. 3.4B). Mature DCs also captured 
HCV E1, E2 and E1/E2-VLPs through DC-SIGN, although less efficiently as immature DCs 
(Fig. 3.4C). This may be due to the lower expression of DC-SIGN on mature DCs than on 
immature DCs (Fig. 3.4A) [23]. The complete inhibition of the interaction of both immature and 
mature DCs with HCV particles by antibodies against DC-SIGN demonstrates that DC-SIGN is 
the primary receptor for HCV on both immature and mature DCs, and not the HCV E2 receptor 
CD81 that is also expressed by DCs [23]. 
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HCV-VLPs are rapidly internalized upon capture by both DC-SIGN and L-SIGN (Fig. 3.3). 
Depending on the cell type, the captured HCV-VLPs were targeted differently to intracellular 
compartments by both C-type lectins. In the cell line THP-1, captured HCV-VLPs were 
targeted to transferrin-positive non-lysosomal compartments, whereas VLPs captured by the 
erythroleukemic cell line K562, expressing either DC-SIGN or L-SIGN, were targeted to LAMP-
1-positive lysosomal compartments (Fig. 3.3). These results demonstrate that there is a 
difference in internalization pathway between both cell lines. HCV-VLPs, captured by primary 
immature DCs through DC-SIGN, were targeted to early endosomal vesicles, where they 
reside for over 24 hours, similar to the THP-1 transfectants. This indicates that the 
internalization pathway observed in THP-1 transfectants may represent a more native situation 
as found in DCs. In addition, it was recently demonstrated that transmission of HIV-1 is also 
cell-type dependent [45]. DC-SIGN does not facilitate HIV-1 infection of DCs but protects the 
virus from degradation by internalizing the virus in non-lysosomal compartments [26;44]. The 
DC-SIGN-bound HIV-1 is efficiently transmitted to recipient CD4+ T cells upon co-culture of 
DCs with CD4+ T cells, which results in a productive infection of T cells [26]. Like DCs, THP-1 
cells expressing DC-SIGN continued to infect T cells with HIV-1 for several days, whereas DC-
SIGN expressing 293 cells were infective only for a short period. However, HIV-1 is not 
retained in early endosomal compartments as HCV, or in lysosomes, but in other, undefined, 
vesicles [44;45]. But that also HIV-1 is not targeted to the lysosomes and thus probably not 
being degraded in THP-1 cells and DCs, can explain why in these cells transmission is 
possible over a prolonged period. The internalization pathway of DC-SIGN-bound ligands is 
not only dependent on the cell type but also on the ligand, as another carbohydrate-containing 
ligand of DC-SIGN, Lewisx antigen, was rapidly internalized and targeted to the lysosomal 
compartment in both immature DCs and THP-1 transfectants (Fig. 3.5C, data not shown). 
Altogether, these results support a role for DC-SIGN in the capture of HCV virions by immature 
DCs similar to HIV-1, and show that THP-1 transfectants are a suitable model for pathogen 
internalization. A recent study suggests that the THP-1 cells used to study DC-SIGN/L-SIGN 
function have B-cell like characteristics [46]. Indeed, the THP-1 cells used in this study express 
CD19 (data not shown) and therefore may have B-cell like characteristics. Interestingly, B cells 
have a similar antigen-processing/presenting machinery as DCs and our results demonstrate 
that DC-SIGN expressed by these THP-1 cells behaves similar as on immature DCs. 
Therefore, THP-1 cells are a suitable model for studying pathogen internalization. 
Hepatocytes are productively infected by HCV, and the hepatocyte specific ASGP-R has been 
proposed as a HCV receptor [20]. However, we demonstrate here that not the hepatocytes but 
the LSECs bind HCV-VLPs in primary liver tissue (Fig. 3.6), suggesting that LSECs capture 
HCV from blood and transfers HCV to hepatocytes. Moreover, L-SIGN has been shown to 
function, similar as DC-SIGN, in HIV-1 transmission [32], and L-SIGN expressed by LSECs, 
could capture HCV from blood and transfer it to hepatocytes. A similar mechanism was 
demonstrated for another hepatic virus Hepatitis B virus [47]. This virus enters LSECs and 
Breiner et al. [47] proposed that the virus travels via endosomal compartments to the 
hepatocytes that are subsequently infected. Our data further indicate that both LSECs and 
DCs may efficiently capture and protect the virus and function as HCV reservoir. 
Our recent results suggest that mycobacteria target DC-SIGN by secreting ManLAM to 
downregulate DC-mediated immune responses and thus promote pathogen survival [29]. It is 
not clear whether viruses are able to suppress DC functions by binding DC-SIGN through a 
similar mechanism as mycobacteria. The immunosuppressive setting that characterizes 
infections with CMV and HIV-1, two viruses that interact with DC-SIGN, implies that such a 
mechanism of immuno-modulation may exist (reviewed in [43]). It was suggested that DCs 
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isolated from patients suffering from chronic HCV infections have an impaired maturation and 
immune-stimulatory function [30;31]. However, our data indicate that immature DCs are not 
affected by HCV-VLPs and furthermore, Longman et al. recently showed that DCs from 
chronic infected patients are not impaired in their immune function [41]. This suggests that 
HCV may target DC-SIGN to escape lysosomal degradation in DCs and thereby evade 
immunity. Although further investigations into the function of DC-SIGN and L-SIGN will be 
necessary to determine their importance in HCV infections, our results suggest that both DC-
SIGN and L-SIGN may be potential targets for designing strategies to combat HCV infections. 
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Abstract 
 
HCV interacts with human dendritic cells (DCs) and liver sinusoidal endothelial cells (LSECs) 
through the C-type lectins DC-SIGN and L-SIGN, respectively. These antigen-presenting cells 
efficiently internalize HCV but the virus is retained in a non-lysosomal compartment, indicating 
that this prevents efficient antigen presentation and promotes viral transmission. Here we show 
that HCV virus like particles are also susceptible for degradation by DCs, and degradation is 
more efficient in the presence of HCV-specific antibodies. We demonstrate that degradation of 
the HCV-immune complexes leads to MHC class II presentation by DCs. Strikingly, this is 
dependent on DC-SIGN, suggesting that immune complexes captured by DC-SIGN are 
internalized into lysosomal compartments for antigen processing. Moreover, induction of DC 
maturation by HCV-VLPs on an aluminium carrier strongly enhances antigen presentation of 
immune complexes by DCs. Thus, antibody targeting and maturation-induction directs DC-
SIGN-captured ligands into lysosomal compartments and efficient antigen presentation. 
Moreover, we demonstrate that L-SIGN captures HCV-immune complexes leading to antigen 
presentation to CD4+ T cells, demonstrating that L-SIGN is an antigen receptor on LSECs. 
Human LSECs express both L-SIGN and MHC class II molecules and our data suggest that 
LSECs are important as antigen presentation cells of viral antigens in the liver. 
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Introduction 
 
Hepatitis C virus (HCV) is a major health problem as about 3 percent of the world population is 
infected with this virus [1;2]. However, only in the late 80s the virus was cloned [3] and 
identified as the causative agent of non-A, non-B viral hepatitis. Infection with the hepatitis C 
virus results in chronic and persistent infection in 70% of the patients [4] and can lead to liver 
cirrhosis and end-stage liver disease [5;6]. IFN-α ribavirin based therapy is often ineffective 
and there is no vaccine available yet. Therefore, several vaccines, including dendritic cell 
based vaccines and recombinant HCV envelope based are under development. 
 
Although viral persistence is high, HCV specific antibodies can be detected in every infected 
individual. However, the presence of these antibodies does not predict the outcome of the 
infection [7]. Furthermore, virus specific CD4+ and CD8+ T cells are found in HCV infected 
patients [8;9]. Nevertheless, these T cells are insufficient to combat infections, which is 
reflected in the high persistence. There are several reasons for T-cell failure during HCV 
infection: T-cell maturation can be impaired, or T-cell dysfunction can be caused more directly 
by super activation due to high antigen exposure (reviewed in [10]). Also the virus could 
produce T-cell suppressive factors. For example, HCV core protein interacts with the 
complement receptor gC1qR [11] and thereby inhibits T-cell proliferation.  
There are also indications for impairment of dendritic cell (DC) function, which subsequently 
could result in an impaired T-cell response. DCs are potent T-cell stimulators; they capture 
antigens and process them for antigen presentation. However, in chronic HCV infection 
myeloid and plasmacytoid DC count is lower than in healthy individuals [12-15]. Maturation and 
immune stimulatory functions of these DCs are impaired, especially in inducing Th1 responses 
[12;13;16-18]. Also monocyte derived DCs of chronic HCV infected individuals are impaired in 
stimulating T cells [17-19]. In contrast, other studies demonstrated that monocyte-derived DCs 
[20;21], myeloid, and plasmacytoid DCs [14;22] from patients suffering from chronic HCV 
infection are functionally normal. Thus, more research is necessary to understand the role of 
DCs in the establishment of HCV infections. 
 
HCV, a hepacivirus of the Flaviviridae family, is an enveloped positive-stranded RNA virus [3]. 
The HCV envelope is formed by two heavily N-glycosylated type I transmembrane envelope 
glycoproteins E1 (31 kD) and E2 (70 kD) [23-25], that are expressed as heterodimers on the 
virus membrane [25]. Although there are hyper variable loops present in envelope protein E2, 
most of the glycosylation sites are well conserved as glycosylation is important for proper 
folding and heterodimerisation of the proteins [26] and for entry of the virus [27]. 
HCV mainly infects hepatocytes, however it is becoming clear that also other cells, such as 
DCs, can be infected [28;29]. DCs express the C-type lectin receptor DC-specific ICAM-3 
grabbing nonintegrin (DC-SIGN), a receptor that can bind HCV envelope proteins E1 and E2 
[30-33]. This C-type lectin is the major HCV receptor on DCs and is involved in internalization 
of HCV and in retention of the virus in early endosomes [32]. Furthermore, it has been shown 
that cell lines expressing DC-SIGN can transmit virus to hepatoma cells [34]. Therefore, DCs 
could function as HCV reservoirs and be involved in transmission of HCV to other cells. HIV-1 
is using DC-SIGN on DCs in a similar fashion to facilitate its dissemination to target cells [35]. 
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However, DC-SIGN also functions as an antigen uptake receptor leading to MHC class II 
presentation [36]. 
Liver/lymph node SIGN (L-SIGN), the homologue of DC-SIGN specifically expressed on liver 
sinusoidal endothelial cells (LSECs) [37;38], also interacts with HCV envelope proteins [30-33]. 
LSECs are specialized endothelial cells with antigen-presenting cell (APC) characteristics [39]. 
These cells possess scavenger functions and in combination with Kupffer cells, the resident 
liver macrophages, they are responsible for clearance of various substances from portal blood. 
Furthermore, LSECs have shown to mediate transcytosis of virus to hepatocytes [40]. 
Although L-SIGN is expressed on APCs, a role of L-SIGN in antigen uptake for presentation 
has not been described yet. 
 
We demonstrate here that the HCV receptors DC-SIGN and L-SIGN, expressed on APCs, can 
internalize HCV-E1-virus like particles (VLPs), resulting in antigen presentation to CD4+ T cells, 
indicating that besides DCs, also LSECs can present HCV antigens. Furthermore, we 
demonstrate that HCV is targeted more efficiently to lysosomes for degradation in the 
presence of HCV specific antibodies. Finally, HCV-E1 on an aluminium carrier (HCV-E1-Alum) 
induces DC maturation and potentiates antigen presentation by DCs. 
 
 
 
Materials and methods 
 
Antibodies and proteins. 
The following antibodies were used: AZN-D1 and AZN-D2 (mouse IgG1, anti-DC-SIGN and anti-DC-
SIGN and L-SIGN respectively) [41;42]; DCN46.1 (mouse IgG2b, anti-DC-SIGN, BD); L19 (anti-CD18 
mouse IgG1) [43], mouse anti-L-SIGN (R&D Systems, Minneapolis, MN, USA), human and mouse anti-
HCV E1 (1C4 and 23C12 respectively, Innogenetics, Ghent, Belgium) and mouse anti-E2 antibody 
(4H6B2, Innogenetics, Ghent, Belgium), mouse anti-CD80-PE, anti-CDD86-PE, and anti-HLA-DR-PE 
(BD Pharmingen, San Diego, CA, USA), mouse anti-CD83-PE (Beckman Coulter) goat anti-human IgG1 
conjugated with FITC and HRP (Jackson Immunoresearch, West Grove, PA, USA), goat anti-mouse 
conjugated with FITC (Zymed Laboratories Inc., South San Francisco, CA, USA) goat anti-mouse 
conjugated with Alexa Fluor® 488 and 594 and streptavidin Alexa Fluor® 488 (Molecular Probes, 
Eugene, OR, USA). 
 
Cells. 
Human blood monocytes were isolated as described before [44] from haplotyped buffy coats, obtained 
from blood bank donors. In short, PBMCs were isolated by a Ficoll gradient and monocytes were 
isolated from the PBMCs using anti-CD14 microbeads (Miltenyi Biotec, Auburn, CA). Immature DCs 
were generated by culturing monocytes in RPMI 1640/10% FCS in the presence of IL-4 (500 U/ml; 
Schering-Plough, Kenilworth, NJ, USA) and GM-CSF (800 U/ml; Schering-Plough) for 5-8 days. At day 6 
the phenotype of the cultured DCs was confirmed by flow cytometric analysis. The DCs expressed high 
levels of MHC class I and II, CD11b, CD11c and ICAM-1, and low levels of CD80 and CD86. 
HLA-DR1 typed immortalized B cells (Epstein Barr virus-transformed human B lymphocytes) were 
generated by lentiviral transduction with LV-DC-SIGN or L-SIGN (kind gift of Vincent Piquet). 
Transduction efficiency was tested by staining with AZN-D1 and AZN-D2 antibodies. 
Hd7, a CD4+ T cell clone that recognizes a peptide derived from mouse IgG1 antibody in HLA-
DR0101/DQw1 [45], was maintained in RPMI supplemented with 5% human serum, penicillin, 
streptomycin, glutamine and 1000 U/ml recombinant human IL-2. 
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HCV envelope glycoproteins. 
HCV E1 envelope glycoprotein was expressed in the yeast Hansenula polymorpha. The glycoprotein is 
derived from the structural region of a genotype 1b isolate and lacks the C-terminal membrane anchor 
(aa 192-326). 
After lysis of the cells and sulphonation of the protein the monomeric E1 is recovered in the presence of 
the detergent Empigen® (Albright & Wilson Ltd, UK) from. Finally, the Empigen is exchanged for PBS-
betain and the E1 assembles in to particles with a size ranging from 10-100 nm. HCV-E1/E2-VLPs were 
generated as described before [32]. 
For formulation on aluminium the E1 is formulated to Alhydrogel® (Superfos Biosector A/S, Denmark) in 
a ratio of 50 µg protein to 0.13% Al2O3. 
 
Antigen presentation. 
Antigen-presenting cells (DCs or immortalized B cells, 10,000 cells/well) were pre-incubated with serial 
dilutions of antibodies or HCV-E1-VLP-antibody complexes for 2 hours at 37°C, washed and cocultured 
with 20,000 Hd7 T cells. After 24h, IFN-γ production was measured using a commercial human IFN-γ 
ELISA (cytoset, Biosource, Camarillo, CA, USA). Specificity of DC-SIGN and L-SIGN binding was 
determined by blocking with an anti-DC/L-SIGN mIgG2b antibody or mannan. 
 
Maturation induction. 
Immature DCs (day 5) were cultured with the indicated stimuli (10 µg/ml) with or without LPS (10 ng/ml) 
for 24h at 37°C. Maturation was measured by staining the cells for CD80, CD83 and CD86 expression 
using PE-conjugated antibodies. 
 
Liver section staining. 
Human liver tissue was obtained from biopsies of therapeutic surgeon and cryofrozen. 4 µm sections 
were placed on gelatine-coated slides and stored at -80°C. Sections were fixed with acetone. Sections 
were stained with anti-L-SIGN antibody and anti-HLA-DR antibody. As secondary antibodies, rabbit-anti-
mouse IgG2b, goat anti rabbit Alexa Fluor® 488, and goat anti mouse IgG1-Alexa Fluor® 594 were 
used. Microscopical analysis was performed with a Leica TCS SP2 AOBS confocal laser-scanning 
microscope (Leica Microsystems, Heidelberg, Germany). 
 
HCV degradation. 
Dendritic cells were incubated with HCV-E1/E2-VLPs with or without anti-HCV envelope antibodies at 
room temperature for 45 minutes. The cells were washed and placed at 37°C. At the designated time 
points, samples were taken and cells were lysed in lysis buffer. HCV content in the samples was 
determined using a sandwich ELISA. Human anti-HCV-E1 antibodies (1C4, 2 µg/ml) were coated on a 
NUNC-maxisorb plate, and the plate was incubated with the cell lysates. HCV-E1/E2-VLPs were 
detected with a mouse anti-E2 antibody (4H6B2). HCV-E1/E2-VLP content was quantified using a 
standard series dilution. 
 
 
 
L-SIGN is, like DC-SIGN, expressed on antigen-presenting cells.  
L-SIGN and HLA-DR are co expressed on liver sinusoidal endothelial cells. Cryosections of liver tissue were stained 
with anti-L-SIGN (green) and anti-HLA-DR (red). Sections were analyzed with confocal microscopy. Original 
magnification 63x. 
Chapter 4 
64 
 
 
 
Results 
 
L-SIGN is expressed on antigen-presenting cells. 
DC-SIGN is specifically expressed on DCs, and shown to function as an antigen receptor. Its 
liver specific homologue L-SIGN is expressed on specialized endothelium in liver sinusoids 
[37;38]. L-SIGN-positive LSEC in human, in contrast to conventional endothelium, 
constitutively express HLA-DR, needed for antigen presentation to CD4+ T cells (Fig. 4.1). 
Human LSEC also express CD40, however they lack CD80 and CD86 [46]. This indicates that 
in human liver, L-SIGN is expressed on cells with antigen presenting cell characteristics, but 
lacking some costimulatory molecules, indicating that these cells could present antigen to T 
cells, but T-cell activation might be erroneous. 
 
L-SIGN can mediate uptake and presentation of antigens to CD4+ T cells. 
As L-SIGN is expressed on antigen presenting cells, we investigated antigen uptake and 
presentation by L-SIGN. In order to investigate antigen presentation of L-SIGN ligands, 
immortalized B cells transduced with L-SIGN were incubated with anti-L-SIGN antibody (AZN-
D2, IgG1) as a ligand and cocultured with the mouse IgG1 specific human CD4+ T-cell clone, 
Hd7. The antibody to L-SIGN was internalized, processed and presented to T cells, as the T 
cells were activated, measured by IFN-γ production (Fig. 4.2A). The presentation was an L-
SIGN specific process and not mediated by Fc receptors, as an irrelevant antibody (anti-DC-
SIGN, IgG1) was not processed and presented to T cells (Fig. 4.2A). Immortalized B cells 
transduced with DC-SIGN could internalize, process and present both DC-SIGN and DC-
SIGN/L-SIGN specific antibodies (Fig. 4.2A and [36]). Mock-transduced B cells could not 
activate the T cells when incubated with an anti-L-SIGN/DC-SIGN or an anti-DC-SIGN 
antibody (Fig. 4.2A), confirming specificity. Furthermore, uptake of antibodies by membrane 
turnover was excluded since the L19 antibody (IgG1) specific for CD18/LFA1, which is highly 
expressed on the immortalized B cells (Fig. 4.2B, histogram), was not presented to the CD4+ T 
cells (Fig. 4.2B). Hd7 specificity for mouse IgG1 was further confirmed since DC-SIGN+ cells 
incubated with DC-SIGN specific mouse IgG2b antibody DCN46.1 did not result in T-cell 
activation (Fig. 4.2B). This indicates that both DC-SIGN and L-SIGN can function as an 
antigen uptake and presentation receptor. 
 
L-SIGN and DC-SIGN mediate uptake and presentation of HCV antigens to CD4+ T cells. 
We have shown before that both L-SIGN and DC-SIGN are HCV binding receptors due to their 
high affinity for envelope proteins E1 and E2 and that L-SIGN and DC-SIGN mediated 
internalization of HCV-VLPs results in retention of the VLPs in non-lysosomal compartments 
[32]. Our findings that both L-SIGN and DC-SIGN can mediate antigen presentation to CD4+ T 
cells (Fig. 4.2), initiated our investigation whether also HCV envelope antigens were taken up 
and presented. Because of the lack of HCV envelope specific T cell clones, we used the 
mIgG1 specific T-cell clone Hd7. We used B cells transduced with L-SIGN or DC-SIGN and 
HCV-E1 immune complexes (HCV-E1-IC). HCV-E1-IC were made from HCV-E1 virus like 
particles using mouse anti-HCV envelope specific IgG1 antibodies. The B cell-line expressing 
DC-SIGN or L-SIGN were incubated with these HCV-E1-IC and cocultured with the IgG1 
specific Hd7. Cells expressing DC-SIGN or L-SIGN presented HCV-E1-IC peptides on HLA- 
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L-SIGN, like DC-SIGN, can function as an antigen receptor.  
(A) Antigen presentation of L-SIGN and DC-SIGN specific antibody AZN-D2 (IgG1) and DC-SIGN specific AZN-D1 
(IgG1) by B cells expressing L-SIGN or DC-SIGN. Immortalized B cells were transduced with lentiviral vectors 
containing DC-SIGN or L-SIGN and stained with DC-SIGN specific AZN-D1 (mIgG1, continuous lines in 
histograms), DC-SIGN & L-SIGN specific AZN-D2 (mIgG1, dashed lines in histograms) to confirm expression. Filled 
histograms are representing isotype staining. The cells were incubated with the designated antibodies and 
cocultured with mIgG1 specific Hd7 T cells. After 24 hours, IFN-γ production as a measure for T-cell activation was 
determined by sandwich ELISA. Error bars represent standard deviations (n=3). (B) Immortalized B cells do not take 
up and process anti-LFA-1 antibodies, Hd7 does not recognize mouse IgG2b DC-SIGN antibody DCN46.1. Mock-
transduced B cells or B cells transduced with DC-SIGN were incubated with AZN-D2 (anti-DC-SIGN-mIgG1, light 
grey bars), DCN46.1 (anti-DC-SIGN-mIgG2b, white bars), or L19 (anti-LFA-1-mIgG1, dark grey bars), and 
cocultured with Hd7 T cells. Error bars represent standard deviations (n=3). Expression of LFA1 on immortalized B 
cells was determined by flow cytometry (black line in histogram).  
 
 
DR1 in a dose dependent way. The parental, mock transduced, cell line did not present HCV-
E1-IC derived antigens to the T cells (Fig. 4.3). Therefore our data demonstrate that, although 
HCV particles captured by DC-SIGN and L-SIGN are retained in early endosomes [32], part of 
the captured antigens are degraded for antigen presentation. 
 
DC-SIGN on DCs mediates uptake and presentation of HCV antigens to CD4+ T cells. 
As HCV-E1-IC derived antigens are presented by DC-SIGN transfectants, we investigated the 
presentation of HCV derived antigens by primary DC-SIGN positive cells DCs. We incubated 
HLA-DR1+ haplotype matched DCs with HCV-E1-IC made from HCV-E1 and mouse IgG1 HCV 
envelope specific antibodies, and cocultured these with the Hd7 T cells. After 24 hours of 
incubation IFN-γ production was measured. The DCs incubated with HCV-E1-IC elicited T-cell 
activation in a dose dependent way as measured by IFN-γ production (Fig. 4.4). Presentation 
of HCV by DCs has been shown before to be DC-SIGN independent [47]. However here we 
show that antigen presentation of HCV is DC-SIGN dependent, since it was blocked by a DC-
SIGN specific antibody or mannan.  
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L-SIGN and DC-SIGN mediate HCV-
E1-IC antigen presentation to CD4+ 
T cells. Presentation of HCV-E1-IC 
antigens by B cells expressing L-SIGN 
or DC-SIGN was determined by 
incubation of B cells with HCV-E1-IC. 
HCV-E1-IC were formed by incubating 
HCV-E1-VLPs with mouse IgG1 anti-
HCV antibodies (200 ng/ml). 
Immortalized B cells transduced L-
SIGN or DC-SIGN or mock-
transduced B cells were incubated 
with the HCV-E1-IC and cocultured 
with Hd7 T cells. Activation of T cells 
was determined after 24 hours by 
measuring IFN-γ production with 
sandwich ELISA. Error bars represent 
standard deviations (n=3). 
 
 
DCs degrade HCV-IC more rapidly than non-complexed HCV-VLPs. 
Previously we have shown that hepatitis C virus is retained in early endosomes in dendritic 
cells [32] and in this way it could circumvent lysosomal degradation and subsequent antigen 
presentation. However, HCV specific T cells are present in HCV infected people [48], and we 
demonstrate here that DCs present HCV-E1-IC derived antigens indicating that HCV is 
degraded by DCs. We therefore quantified the degradation of HCV-VLPs and HCV-immune 
complexes in DCs. DCs were incubated with HCV-VLPs, either complexed or not with mouse 
anti-HCV antibodies or human anti-HCV antibodies. After binding of HCV-VLPs at room  
temperature for 45 minutes, DCs were transferred to 37°C to allow internalization. Samples 
were taken at different time-points, and after cell lysis, HCV-VLP content was measured using 
a sandwich ELISA. As shown in figure 4.5, HCV-VLP content in all cells decreased over time. 
However, in the presence of an anti-HCV antibody the amount of HCV decreased more rapid 
than without an antibody. Both the mouse and the human antibody could elicit this enhanced 
degradation (Fig. 4.5). These data suggest that although after 24 hours of incubation a 
substantial amount of HCV is still intact in DCs, HCV has also been degraded. This 
degradation is enhanced in the presence of HCV specific antibodies, probably due to the 
involvement of Fc receptors. 
 
HCV-E1-Alum induces maturation of DCs. 
HCV-VLP degradation was enhanced in the presence of HCV specific antibodies, which 
implies DCs target HCV more efficiently to lysosomes and thereby more efficiently present 
antigens to T cells. However, upon the first encounter of HCV with DCs in the body, antibodies 
to HCV are not abundant. Furthermore, in order to stimulate naive T cells, DCs should have a 
mature phenotype. HCV-VLPs do not induce DC maturation [32] and therefore DCs incubated 
with HCV-VLPs probably will not be able to provoke a good T cell response by naive T cells. 
To enhance antibody responses, several vaccination strategies have been investigated. One 
method of inducing an enhanced antigen specific response is administration of the antigen 
conjugated to an aluminium-based adjuvant. HCV-E1-Alum has already been used in a clinical 
trail as a therapeutic vaccine [50]. Therefore we investigated the effect of HCV-E1-Alum on 
DCs in vitro. The interaction of DCs with HCV-E1 did not induce maturation and LPS induced 
maturation was not enhanced nor blocked by HCV [32]. However, after incubation of immature 
DCs with HCV-E1-Alum, DCs matured as reflected in an increase of the maturation markers 
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DC-SIGN on DCs mediates HCV-E1-IC 
Ag presentation to CD4+ T cells. 
Presentation of HCV antigens by DCs was 
determined by incubating DCs with HCV-
E1-IC and coculturing with Hd7. Activation 
of T cells was determined after 24 hours by 
measuring IFN-γ production (white 
diamonds). DC-SIGN specificity was 
determined by blocking DC-SIGN with a 
DC-SIGN specific antibody DCN46.1 
(IgG2b, 5 µg/ml, black triangles) and 
mannan (200 µg/ml, black squares). Error 
bars represent standard deviations (n=3). 
 
 
 
 
 
 
 
CD80, CD83, and CD86 (Fig. 4.6A). The presence of anti-HCV antibodies alone did not 
influence HCV-E1-Alum induced maturation (data not shown). This indicates that HCV-E1-
Alum is a good candidate to enhance DC based T-cell activation. 
 
HCV-E1-Alum enhances antigen presentation by DCs. 
To investigate the effect of the aluminium carrier on antigen presentation, we compared HCV-
E1 and HCV-E1-Alum in the antigen presentation assay. Both HCV-E1 and HCV-E1-Alum 
were allowed to form immune complexes with HCV specific antibodies. These immune 
complexes were incubated with DCs and Hd7 T cells. Both HCV-E1 and HCV-E1-Alum-IC 
derived antigens were presented to the CD4+ T cells, however the presentation of HCV-E1-
Alum antigens was much more efficient than that of HCV-E1 (Fig. 4.6B). This could be caused 
by the maturation of DCs induced by aluminium (Fig. 4.6A). In order to investigate the effect of 
DC maturation on activation of the T cell clone, we performed the antigen presentation assay 
with immature DCs incubated with HCV-E1, with or without LPS. Antigen presentation during 
these conditions was compared with antigen presentation of HCV-E1-Alum. The presence of 
LPS during the assay did not alter activation to T cells compared to DCs incubated only with 
HCV-E1-IC (Fig. 4.7A). Strikingly, when the expression of maturation markers was measured 
after 18 hours, all DCs showed a similar degree of maturation (Fig. 4.7B). To investigate in a 
different way whether enhanced antigen presentation of HCV-E1-Alum is the result of induced 
maturation, we compared presentation of HCV-E1-Alum-IC with HCV-E1-IC by immortalized B 
cells. Antigen presentation of HCV-E1-Alum-IC by B cells was not increased when compared 
to HCV-E1-IC (Fig. 4.7C). This indicates that enhanced presentation of HCV-E1-Alum-IC 
derived antigens is DC specific and could be caused by differences in maturation state during 
antigen presentation or by enhanced uptake of HCV-E1-Alum. 
 
 
 
Discussion 
 
L-SIGN is expressed on sinusoidal endothelial cells in the liver. These cells constitutively 
express HLA-DR, but not co-stimulatory molecules like CD80 and CD86 [46]. We demonstrate 
here that L-SIGN expressed in cell lines is able to internalize ligands for presentation to CD4+  
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HCV is partially degraded in DCs.  
DCs were incubated with HCV-E1/E2-VLPs 
(black squares) or with HCV-E1/E2-VLPs in 
combination with human (black circles) or 
mouse anti-HCV (white circles) antibodies as 
immune complexes. At different time point 
samples were taken and HCV content in cell 
lysates was tested using a sandwich ELISA 
using a monoclonal human anti-HCV-E1 and a 
mouse monoclonal anti-HCV-E2 antibody. 
Amount of intact HCV-E1/E2-VLPs was 
calculated using a standard series of HCV-
E1/E2-VLP dilutions. One representative 
experiment out of three is shown. 
 
 
 
T cells. This presentation was L-SIGN mediated, as irrelevant antibodies were not presented to 
the T cells. Furthermore, the uptake of the L-SIGN specific antibody was not due to membrane 
turnover, as anti LFA-1 antibodies bound to the membrane of the B cells were not presented to 
the T cells. Before it was suggested that L-SIGN lacks the capacity to internalize antigens for 
antigen presentation, and that L-SIGN functions merely as an adhesion receptor [51]. We 
demonstrate here that L-SIGN is indeed, like DC-SIGN, functioning as an antigen uptake 
receptor. Additionally, we demonstrate that L-SIGN can present HCV antigens, indicating that 
L-SIGN positive LSECs in the liver are important for presentation of antigens from hepatotropic 
HCV virus. 
DCs express the HCV binding receptor DC-SIGN. Upon interaction with DC-SIGN, HCV is 
internalized, retained in non-lysosomal compartments [32], and could be transmitted to 
hepatocytes [34]. However, besides protection and transmission, DCs also mediate HCV 
antigen presentation to CD4+ and CD8+ T cells [47]. In contrast with this previous report, in 
which a DC-SIGN independent mechanism of HCV uptake and presentation by DCs was 
described [47], we demonstrate that this uptake and presentation of HCV derived antigen is 
DC-SIGN specific. In the previous report by Barth et al., the binding of HCV-like particles 
produced in a baculovirus-insect cell expression system could not be blocked by using anti-
DC-SIGN antibodies or mannan [47]. However, this binding study was performed in the 
absence of calcium, and the lack of calcium has been demonstrated to prevent DC-SIGN 
function [32]. We clearly demonstrate that both HCV-VLP binding [32] and presentation by 
DCs is dependent on DC-SIGN. 
We previously described that HCV is retained in early endosomes in DCs after uptake via DC-
SIGN [32]. Here we quantified HCV-VLP retention in DCs, and demonstrate that after 24 hours 
of incubation 30% of HCV-VLPs is still intact (Fig. 4.5). This remaining part is probably retained 
in the early endosomes as previously shown [32]. Furthermore we demonstrate that in the 
presence of HCV specific antibodies, the degradation of HCV-E1/E2-VLPs in DCs is enhanced 
to 95% compared to the 70% without antibodies. This suggests that after initial DC-SIGN 
binding, Fc receptors are participating in targeting of HCV-IC to lysosomes. This implies that 
DCs can process and present HCV antigens more efficiently when HCV is bound by HCV 
specific antibodies, and thereby increasing T-cell stimulation by DCs. 
DCs are good targets for vaccines and several groups are trying to find a suitable way to target 
DCs and get a proper immune response. One method to enhance immune responses is the 
use of aluminium adjuvants. Aluminium adjuvants are composed of aluminium hydroxide or 
aluminium phosphate gels, and have been used since 1926 [52]. Aluminium adjuvants 
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HCV-E1-Alum potentiates antigen 
presentation.  
(A) DC maturation by HCV-E1-Alum. 
Immature DCs were incubated with 
HCV-E1-Alum and after 24 hours 
maturation was determined by 
measuring expression levels of 
costimulatory molecules CD80, CD83 
and CD86. Expression levels on DCs 
incubated with LPS were a positive 
control (dashed histograms). (B) 
HCV-E1-Alum is presented more 
efficiently than HCV-E1 by DC. 
Presentation of HCV-E1-IC (open 
circles) and HCV-E1-Alum-IC (filled 
squares) derived antigens was 
determined by incubating DCs with 
HCV-E1-IC or HCV-E1-Alum-IC and 
coculturing with Hd7 T cells. IFN-γ 
production as a measure of T cell 
activation was determined by ELISA 
after 24 hours. Error bars represent 
standard deviations (n=3). 
 
 
 
 
preferentially promote humoral immune responses [53] and fail to stimulate cell mediated 
immune responses [54]. The HCV vaccine composed of recombinant E1 conjugated to an 
aluminium carrier is a potent antibody and helper T-cell inducing vaccine, which lead to 
stabilization or reduction of liver fibrosis [50]. 
We demonstrate here that HCV-E1-Alum can induce DC maturation. Previously it has been 
shown that mouse DCs are not affected by aluminium adjuvants; mouse DCs did not 
upregulate maturation markers and also did not display an enhanced antigen presentation [55]. 
However another study showed that uptake of antigen on aluminium adjuvants by murine DCs 
is enhanced [56]. We demonstrate here that uptake and presentation of HCV-E1-Alum is 
greatly enhanced compared to HCV-E1. Although DCs mature upon antigen presentation to T 
cells, enhanced presentation of HCV-E1-Alum derived antigens could be due to maturation 
caused by the aluminium, as immortalized B cells were not affected by HCV-E1-Alum. 
However, enhanced presentation could also be caused by enhanced uptake of HCV when it is 
associated with the aluminium-containing carrier. 
Taken this together, HCV-E1-Alum is a good candidate as HCV vaccine, especially because 
HCV-E1 does not show the strain-to-strain hypervariability, that is seen in E2 [57]. Promising 
results have been shown in a clinical trail using the HCV-E1-Alum as a therapeutic vaccine 
[50], and here we demonstrate that in vitro HCV-E1-Alum has a great capacity to enhance DC 
mediated T-cell activation.  
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Increased antigen 
presentation of HCV-E1-
Alum is not solely due 
to maturation.  
(A) Presentation of HCV-
E1-Alum was compared 
to HCV-E1 in combination 
with LPS to induce DC 
maturation. DCs were 
incubated with HCV-E1-
Alum-IC (filled squares), 
HCV-E1-IC (filled circles), 
or HCV-E1-IC with LPS 
(open circles), and 
cocultured with Hd7 T 
cells. IFN-γ production as 
a measure of T cell 
activation was 
determined by ELISA 
after 24 hours. Error bars 
represent standard 
deviations (n=3). (B) DC 
maturation induced upon 
antigen presentation. 
DCs were incubated with 
HCV-E1-Alum, HCV-E1, 
or HCV-E1 and LPS. 
Expression of maturation 
markers CD80, CD83, 
and CD86, after coculture 
with Hd7 T cells for 24 
hours was measured with 
flow cytometry. One 
representative 
experiment out of three is 
shown. (C) B cells 
present HCV-E1 and 
HCV-E1-Alum-IC in a 
comparable way. 
Immortalized B cell 
transduced with DC-SIGN 
or mock-transduced B 
cells were incubated with 
HCV-E1-IC or with HCV-
E1-Alum-IC and 
cocultured with Hd7 T 
cells. DC-SIGN specificity 
was confirmed by 
blocking with mannan. 
Error bars represent 
standard deviations 
(n=3). 
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Abstract 
 
The interaction of DC-SIGN with gp120 provides an attractive target for intervention of HIV-1 
transmission. Here, we have investigated the potency of gp120 antibodies to inhibit the DC-
SIGN-gp120 interaction. We demonstrate that although the V3 loop is not essential for DC-
SIGN binding, antibodies against the V3 loop partially inhibit DC-SIGN binding, suggesting that 
these antibodies sterically hinder DC-SIGN binding to gp120. Polyclonal antibodies raised 
against non-glycosylated gp120 inhibited both low and high avidity DC-SIGN-gp120 
interactions in contrast to polyclonal antibodies raised against glycosylated gp120. Thus, 
glycans present on gp120 may prevent the generation of antibodies that block the DC-SIGN-
gp120 interactions. Moreover, the polyclonal antibodies against gp120 efficiently inhibited HIV-
1 capture by both DC-SIGN transfectants and immature dendritic cells. Therefore, non-
glycosylated gp120 may be an attractive immunogen to elicit gp120 antibodies that block the 
binding to DC-SIGN. Furthermore, we demonstrate that DC-SIGN binding to gp120 enhanced 
CD4 binding, suggesting that DC-SIGN induces conformational changes in gp120, which may 
provide new targets for neutralizing antibodies.  
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Introduction 
 
Human immunodeficiency virus type 1 (HIV-1) establishes persistent infections in humans, 
caused by the destruction of CD4+ T cells, which results in the development of AIDS. Entry of 
HIV-1 into T cells requires the interaction of the envelope glycoprotein gp120 with the CD4 
receptor and chemokine co-receptors, leading to membrane fusion and virus entry. Upon 
primary infection, dendritic cells (DCs) in mucosal tissues are thought to be the first cells to be 
encountered by HIV-1. The presence of DCs greatly enhances the efficiency of HIV-1 infection 
of CD4+ T cells, although DCs themselves are infected poorly [1;2]. Recently, the DC-specific 
intercellular adhesion molecule-3 (ICAM-3) grabbing nonintegrin (DC-SIGN) has been 
identified to mediate the initial capture of HIV-1 through its binding of gp120 [3]. After capture, 
DC-SIGN transmits virus very efficiently to T cells in trans [3]. The captured HIV-1 particles are 
internalized by DCs, and remain in an infectious form in an endocytic compartment for several 
days [3;4]. Transmission to T cells can take place through an ‘infectious synapse’, where 
internalized HIV-1 is concentrated at the interface between DC and T cell [5]. The putative 
importance of DC-SIGN in initial infection and dissemination suggests that inhibiting the DC-
SIGN-gp120 interaction provides an attractive approach for intervention of HIV-1 transmission.  
DC-SIGN is a type II transmembrane protein that belongs to the C-type lectin family [6], and 
specifically binds to a characteristic internal feature of high-mannose carbohydrate structure 
[7]. In the HIV-1 envelope glycoprotein gp120 five relative conserved (C1-C5) regions and five 
variable regions (V1-V5) have been identified [8]. Gp120 contains a relatively large number of 
N-linked carbohydrates and approximately 50% of the mass of gp120 can be attributed to 
carbohydrate structures [9;10]. Since carbohydrates are clustered together on the outer 
domain of the gp120 molecule, this region is weakly immunogenic and known as the ‘silent’ 
face [8;11]. Furthermore, it has been implicated that the carbohydrate cluster forms a ‘glycan 
shield’ preventing neutralizing antibodies from binding through steric inhibition [12]. Differential 
glycosylation of the envelope glycoproteins affects DC-SIGN binding and enhancement [13]. 
Even though it is likely that high-mannose structures on gp120 are recognized by DC-SIGN 
[13-15], protein-protein interactions may also be important in binding [16].  
Strategies targeting DC-SIGN could help in combating HIV-1 dissemination by blocking the 
DC-SIGN-HIV-1 interaction. However, DC-SIGN is involved in important cellular functions [17], 
and we have demonstrated that using antibodies against DC-SIGN to block HIV transmission 
will also prevent the cellular functions of DC-SIGN [3;6;18]. Therefore, antibodies against 
gp120 may provide a powerful alternative to block DC-SIGN-HIV-1 interaction.  
Here we have investigated the potency of a panel of monoclonal antibodies with defined 
epitopes on gp120 to inhibit the DC-SIGN-gp120 interaction. We demonstrate that although 
the V3 loop is not essential for DC-SIGN binding, antibodies against the V3 loop partially inhibit 
DC-SIGN binding. To investigate whether carbohydrates on gp120 prevent the generation of 
blocking antibodies, we compared the potency of polyclonal antibodies raised against either 
glycosylated gp120 or non-glycosylated gp120 to block the interaction of DC-SIGN with gp120. 
Interestingly, polyclonal antibodies against non-glycosylated gp120 could specifically block the 
high avidity DC-SIGN-gp120 interaction without affecting the immunological role of DC-SIGN. 
In future vaccination strategies, this non-glycosylated gp120 may be used as an immunogen to 
elicit blocking antibodies for the DC-SIGN-gp120 interaction. Finally, our data indicate that DC-
SIGN induces conformational changes in gp120 to enhance CD4 binding, which may 
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contribute to the DC-SIGN-mediated enhancement of HIV-1 infection. These putative 
conformational rearrangements in gp120 induced by DC-SIGN may provide new targets for the 
generation of neutralizing antibodies. 
 
 
 
Material and methods 
 
Proteins and plasmids. 
The following proteins were obtained through the NIH AIDS Research and Reference Reagent Program, 
Division of AIDS, NIAID, NIH: HIV-1IIIB gp120, HIV-1BaL gp120, and HIV-1CM235 gp120, whereas sCD4 
was from dr. Norbert Schuelke. Recombinant HIV-1SF2 gp120 [19-22] (lot 33MJE191) expressed in CHO 
cells and HIV-1SF2 gp120 (Env 2-3) [23;24] (lot 11 MGC014), a full-length non-glycosylated polypeptide 
analogue of gp120 produced in yeast, were obtained from Chiron Corporation, Emeryville, CA. Plasmid 
encoding the gp120-Fc from the JR-FL isolate was obtained through the NIH. Plasmids encoding the 
gp120∆V1/V2 protein from the HIV-1YU2 isolate, lacking the 52 N-terminal residues and the V1/V2 
variable loops, and the gp120∆V1/V2∆V3 (∆298-329), containing a deletion of the V3 variable loop of 
gp120, were a generous gift from dr. J. Sodroski, Dana-Farber Cancer Institute, Boston [25]. Plasmids 
encoding CD4-Fc and ICAM-3-Fc were kindly provided by dr. D.L. Simmons, Institute of Molecular 
Medicine, Oxford, United Kingdom.  
 
Antibodies. 
The following monoclonal antibodies against HIV-1 were obtained through the NIH AIDS Research and 
Reference Reagent Program: 257-D IV, 268-D IV [26;27], 447-52D [28], 697-D [29], 654-D [30], and 
670-D [30] from Dr. Susan Zolla-Pazner F425 A1g8, F425 B4a1, F425 B4e8 [31] and F105 [32;33] from 
Dr. Marshall Posner and Dr. Lisa Cavacini, 2G12 [34] from Dr. Hermann Katinger, 48d [35;36] from Dr. 
James Robinson, IgG1b12 [37] from Dr. Dennis Burton and Carlos Barbas. Polyclonal antibodies 
against HIV-1SF2 gp120 and polyclonal antibodies against non-glycosylated HIV-1SF2 gp120 were 
obtained from Chiron Corporation, Emeryville, CA [19-22]. The polyclonal antibodies were pooled 
bleedings from nine animals, and contained similar amounts of IgG (data not shown). The polyclonal 
sheep antibody D7324, raised against a synthetic peptide representing the 15 C-terminal amino acids of 
HIV-1IIIB gp120 was purchased from Aalto Bio Reagents (Dublin, Ireland).  
The mouse anti-DC-SIGN antibodies AZN-D1 and AZN-D2 were generated in our laboratory [3;6]. The 
mouse antibody DC28, directed against the neck domain of the repeat region of DC-SIGN, was a 
generous gift from dr. J.A. Hoxie, Department of Medicine, University of Pennsylvania, Philadelphia. The 
mouse anti-CD4 antibody CD4v4 was obtained from Becton Dickinson (Alphen aan de Rijn, The 
Netherlands). A horseradish peroxidase (HRP) labelled goat-anti mouse IgG antibody (Jackson 
Immunoresearch, West Grove, PA, USA) was used to detect the above-mentioned antibodies. The 
HRP-labelled goat-anti human IgG antibody (Jackson Immunoresearch) was used to detect DC-SIGN-
Fc in the soluble DC-SIGN-Fc adhesion assays. HRP-labelled mouse-anti goat IgG antibody (Sigma-
Aldrich, Zwijndrecht, The Netherlands) was used to detect the polyclonal antibodies against HIV-1SF2 
gp120 and non-glycosylated HIV-1SF2 gp120. 
 
Cells. 
Immature DCs were cultured from monocytes in the presence of 500 U/ml IL-4 and 800 U/ml GM-CSF 
(both from Schering-Plough, Amstelveen, The Netherlands) as previously described [6].  
 
Transient expression of gp120 variants. 
Transient transfection of 4 µg of the plasmid encoding either the gp120∆V1/V2 protein or the 
gp120∆V1/V2∆V3 protein, with 1 µg of the plasmid encoding the HIV-1 Tat protein, or 4 µg of the 
plasmid encoding gp120JR-FL-Fc protein, or CD4-Fc protein or ICAM-3-Fc protein in the 293T cell line 
were carried out using Lipofectamin (Invitrogen, Carlsbad, CA) according to the manufacturers 
instructions. At 3 days post transfection, culture supernatants containing the proteins of interest were 
collected, cleared by centrifugation and stored at -20°C. 
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Fluorescent beads adhesion assay. 
Carboxylate-modified TransFluorSpheres (488/645 nm, 1.0 µm; Molecular Probes, Eugene, OR) were 
coated with native gp120, or CD4-Fc, gp120-Fc or ICAM-3-Fc proteins containing medium of the 
transient transfection in 293T cells. The beads were prepared as previously described [3;16]. DC-SIGN 
binding characteristics of gp120-Fc-beads from the HIV-1JR-FL strain were similar as observed with native 
gp120-coated beads. Specificity was determined in the presence of 80 µg/ml anti-DC-SIGN antibody 
AZN-D2. Binding of CD4-coated beads to immature DCs was carried out in the presence of 5 µg/ml 
gp120MN. The fluorescent beads adhesion assay was performed essentially as described [3;16]. 
 
Soluble DC-SIGN-Fc adhesion assay. 
All experiments were carried out with a soluble recombinant DC-SIGN-Fc chimera and gp120IIIB, unless 
stated otherwise. DC-SIGN-Fc consists of the extracellular portion of DC-SIGN fused at the COOH 
terminus to a human IgG1-Fc fragment [16] and is produced in CHO cells. This soluble DC-SIGN-Fc 
chimera is functional as previously demonstrated [16]. In the DC-SIGN-Fc adhesion assay, flat bottom 
microtiter-plate wells (Maxisorb; Nunc, Copenhagen, Denmark) were coated overnight at 4°C with gp120 
(0.5 µg/ml) or gp120 antibody D7324 directed to the C5 region (Aalto Bioreagents) at a concentration of 
10 µg/ml (500 ng/well) diluted in 0.2 M NaHCO3 buffer pH 9.2, followed by blocking with 1% bovine 
serum albumin for 30 min at 37°C. If D7324 was used, gp120 (0.5 µg/ml) was subsequently captured for 
60 minutes at room temperature. Soluble DC-SIGN-Fc supernatant (1.5 µg/ml) diluted 1:2 in TSM (20 
mM Tris-HCl (pH 8.0), 150 mM NaCl, 1 mM CaCl2, 2 mM MgCl2) was added, and adhesion was 
performed for 90 min at 37°C. Bound DC-SIGN-Fc was detected with HRP labelled goat-anti human IgG 
antibody. Specificity was determined in the presence of 80 µg/ml AZN-D1, 5 µg/ml mannan or 5 mM 
EGTA. 
To assess the ability of gp120 antibodies to compete with binding of DC-SIGN-Fc to gp120, gp120-
coated wells were incubated with the indicated gp120 antibodies (50 µg/ml, 1:100 dilutions for antibody 
supernatants) for 90 minutes at room temperature to obtain maximal binding, followed by soluble DC-
SIGN-Fc supernatant diluted in TSM incubation for another hour at room temperature. DC-SIGN-Fc 
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bound to gp120 was detected using the DC28 antibody (1 µg/ml), followed by HRP labelled goat-anti-
mouse IgG antibody. 
 
ELISA.  
Flat bottom microtiter-plate wells (Maxisorb; Nunc, Copenhagen, Denmark) were coated overnight at 
4°C with gp120 (0.5 µg/ml) as indicated or gp120 antibody D7324 directed to the C5 region (Aalto 
Bioreagents) at a concentration of 10 µg/ml (500 ng/well) diluted in 0.2 M NaHCO3 buffer pH 9.2, 
followed by blocking with 1% BSA for 30 min at 37°C. If D7324 was used, culture supernatants 
containing proteins of interested diluted 1:2 in TSM were subsequently captured for 60 minutes at room 
temperature. Next, antibodies of interest were added for 60 minutes at room temperature. Bound 
antibodies were detected with a suitable HRP labelled secondary antibody. 
 
CD4-DC-SIGN-Fc binding assay. 
For the CD4-DC-SIGN-Fc binding assay, gp120 was captured with D7324, and DC-SIGN-Fc (0.75 
µg/ml) was added and incubated for 1 hour at room temperature. After washing, the wells were 
incubated with sCD4 (0.5 µg/ml) for 1 hour at room temperature. CD4 binding was detected using 
CD4v4 antibody (1 µg/ml), followed by HRP labelled goat-anti-mouse IgG antibody depleted of cross-
reactivity to human IgG1 (Jackson Immunoresearch, West Grove, PA, USA). To assess the modulation 
of CD4 upon binding of DC-SIGN-Fc to gp120, no wash was performed after addition of DC-SIGN-Fc. 
Specificity was determined by pre-incubation of DC-SIGN for 15 minutes with mannan (5 µg/ml). 
 
HIV-1 capture by immature DCs. 
Cells (100,000) were incubated with HIV-1 JR-CSF (100 ng of p24gag) for 60 minutes at 37°C. Specificity 
was determined in the presence of 20 µg/ml anti-DC-SIGN antibody AZN-D1, polyclonal antiserum 
against non-glycosylated gp120 (1:50), or EGTA (5 mM). The cells were washed twice and 
subsequently lysed and virus binding was determined by measuring the p24 concentration using the 
p24gag detection kit as described by the manufacturers (Beckman-Coulter, Mijdrecht, The Netherlands). 
 
 
 
Results 
 
Effect of gp120-specific antibodies on the DC-SIGN-gp120 interaction. 
The interaction of DC-SIGN with gp120 provides an attractive target for intervention with HIV-1 
transmission. A specific anti-DC-SIGN antibody can inhibit DC-SIGN function, as a anti-DC-
SIGN antibodies efficiently inhibit gp120 binding in low or high avidity interactions assays, the  
ELISA-based DC-SIGN-Fc and the fluorescent beads adhesion assays respectively [3;16].  
However, blocking the role of DC-SIGN in HIV-1 transmission will inhibit the immunological 
function of DC-SIGN [3;6]. Therefore we investigated the ability of antibodies against gp120 to 
block the interaction with DC-SIGN. A panel of monoclonal antibodies with defined epitopes on 
gp120 was used to compete with DC-SIGN for binding to gp120. The ability of antibodies in 
saturating concentrations to block the DC-SIGN-gp120 interaction was measured in a low 
avidity DC-SIGN-Fc adhesion assay. As summarized in table 5.1, although some gp120 
antibodies were able to reduce the binding of DC-SIGN to gp120, we did not observe a 
complete block of the DC-SIGN-gp120 interaction.  
 
The gp120 V3 loop antibodies.  
The gp120 V3 loop antibodies, 257-D IV, 268-D IV and 447-52D, interfered most strongly with 
DC-SIGN binding to gp120 BaL. Similar results were obtained when using gp120 derived from 
HIV-1 IIIB (data not shown). Combinations of the V3 antibodies did not result in better inhibition 
compared to the individual antibodies (data not shown), which may be due to the overlapping 
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DC-SIGN binding to the HIV-1 gp120∆V1/V2 ∆V3 mutant.  
The ability of DC-SIGN to bind the gp120∆V1/V2 and gp120∆V1/V2/∆V3 mutants was assessed in a DC-SIGN-Fc 
adhesion assay. (A) The captured gp120 glycoproteins, gp120∆V1/V2 (black bars), gp120∆V1/V2/∆V3 (gray bars) 
were incubated with the indicated gp120 antibodies (1 µg/ml), and detected as described with HRP-labelled goat-
anti human IgG antibody. (B) DC-SIGN-Fc (0.75 µg/ml) binding to captured gp120 glycoproteins was measured 
(black bars) and inhibition was investigated using the anti-DC-SIGN antibody AZN-D1 (gray bars) and the anti-
gp120 antibody 2G12 (white bars). One representative experiment out of three is shown. (C) Cellular DC-SIGN 
binds the gp120 mutants ∆V1/V2 and ∆V1/V2/∆V3. DC-SIGN transfectants were incubated with gp120-coated 
beads and the binding was measured by flow cytometry. Specificity was determined using antibodies against DC-
SIGN (AZN-D1, gray bars). One representative experiment out of two is shown. 
 
 
epitopes of the antibodies. The epitopes of these antibodies are located between residues 305 
to 315 of gp120, at the tip of the V3 loop. The gp120 V3 loop, together with a highly conserved 
element in the C4 domain, has been implicated in chemokine receptor binding [38-40]. 
Inhibition was not observed for the V3 loop antibodies F425 B4a1 and F425 B4e8, which are  
directed to epitopes at the base of the V3 loop [31]. A decrease in DC-SIGN binding to gp120  
was observed with the 697-D antibody directed to a conformational epitope in the V2 loop. A 
combination of the blocking V3 257-D IV and V2 697-D antibodies did not result in a stronger 
inhibition (data not shown). The 670-D antibody directed to the C5 region also exerted a minor 
inhibition, although this was not observed using gp120 derived from other HIV-1 strains (data 
not shown). In summary, only the V3 loop antibody 447-52D could significantly inhibit binding 
of DC-SIGN. This suggests that interactions of DC-SIGN with gp120 may take place in close 
proximity of the V3 loop. 
To further analyze the role of the gp120 V3 loop in the DC-SIGN-gp120-interaction, we tested 
binding of DC-SIGN to a V3 loop deletion mutant of gp120. This deletion was introduced in the 
gp120∆V1/V2 protein of the HIVYU2 strain that lacks the V1/V2 variable loops of the gp120 
glycoprotein [38]. Both the gp120∆V1/V2 and gp120∆V1/V2∆V3 mutant proteins were 
transiently produced by transfection of 293T cells. Integrity of the V3 loop deletion mutant was 
confirmed by binding of CD4 binding site (CD4bs) antibody IgG1b12 to the gp120∆V1/V2∆V3 
mutant protein and absence of the V3 loop antibody 447-52D epitope (Fig. 5.1A). The CD4 
induced (CD4i) antibody 48d also did not bind, as previously reported [25] (Fig. 5.1A). Both 
recombinant DC-SIGN and cellular DC-SIGN were able to bind the gp120 mutants ∆V1/V2 and 
∆V1/V2∆V3 (Fig. 5.1B and 1C). Binding could specifically be inhibited with the anti-DC-SIGN 
antibody AZN-D1, but not with the antibody 2G12 (Fig. 5.1B and 1C). Notably, although the V2 
loop antibody 697-D interfered with DC-SIGN binding to gp120 (Table 5.1), DC-SIGN was able 
to bind the gp120∆V1/V2 protein, lacking the V1/V2 loops. 
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Binding of DC-SIGN and 2G12 to gp120 glycoproteins 
of different HIV-1 strains.  
Binding of the 2G12 antibody (1 µg/ml; black bars) to 
gp120 glycoproteins of HIV-1 strains BaL and CM235 (1 
µg/ml gp120) was assessed by ELISA. Using the soluble 
DC-SIGN-Fc adhesion assay, binding of soluble DC-
SIGN-Fc was also evaluated (gray bars). Binding could 
be blocked by pre-incubation of DC-SIGN-Fc with anti-
DC-SIGN antibody AZN-D1 (white bars). 
 
 
 
 
 
 
 
 
 
 
 
 
These data indicated that both the V3 loop antibodies and the V2 loop antibody presumably 
sterically hinder the DC-SIGN-gp120 interaction, as both the V2 loop and the V3 loop are not 
essential for DC-SIGN binding to gp120. 
 
The CD4bs and CD4i antibodies.  
The CD4bs antibodies F105 and IgG1b12 that compete with CD4 for binding gp120 [41], did 
not block the binding of DC-SIGN. The 654-D antibody caused a decrease in DC-SIGN binding 
to gp120. Carbohydrates are implicated in the 654-D epitope, which could explain the 
interference of the 654-D antibody with the DC-SIGN binding to gp120 [27].  
CD4 binding to gp120 exposes epitopes that are recognized by the CD4i antibody F425 A1g8. 
This antibody can also bind in the absence of CD4 with a lower affinity and inhibits binding of 
gp120 to the chemokine receptor [25]. We observed no significant interference with the DC-
SIGN-gp120 interaction using the CD4i antibodies (Table 5.1). These data demonstrate that 
CD4bs and CD4i antibodies do not efficiently block the DC-SIGN-gp120 interaction, indicating 
that the CD4 binding site and the CD4i epitope are not directly involved in the interaction with 
DC-SIGN. 
 
The carbohydrate-dependent antibody 2G12. 
The human monoclonal antibody 2G12 has previously been demonstrated to bind to a 
carbohydrate-dependent epitope on gp120 [42]. 2G12 has a multivalent interaction with a 
conserved cluster of Man(α)1-2Man-linked high-mannose type carbohydrates on gp120 [43]. A 
similar structure is present in the mannose-cap of ManLAM, a mycobacterial cell wall 
component that is a known ligand for DC-SIGN [44]. 
 However, 2G12 was not able to block the binding of DC-SIGN to gp120 (Table 1). Next, we 
investigated binding of both 2G12 and DC-SIGN to gp120 glycoproteins of another HIV-1 
strain, since it has been demonstrated that 2G12 does not recognize clade E HIV-1 strains 
[42]. Indeed, we did not observe binding of 2G12 to the clade E gp120CM235 (Fig. 5.2), whereas 
DC-SIGN efficiently interacted with the clade E gp120CM235 glycoprotein, indicating that the 
2G12 epitope is not recognized by DC-SIGN.  
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Binding characteristics of the polyclonal antibodies raised against wild type and non-glycosylated gp120.  
Binding of polyclonal antibodies raised against wt gp120 (open) and non-glycosylated gp120 (filled) to gp120 
(circles) and non-glycosylated gp120 (squares) by ELISA. Different dilutions of the polyclonal antibodies were 
tested. Binding was detected with an HRP-labelled mouse-anti goat IgG antibody. 
 
 
Polyclonal antibodies raised against non-glycosylated gp120 can block the DC-SIGN-gp120 
interaction.  
Monoclonal gp120 antibodies only gave partial inhibition of the DC-SIGN-gp120 interaction. 
Moreover, the antibodies able to interfere with DC-SIGN-Fc binding to gp120 were not able to 
interfere with gp120 binding to cellular DC-SIGN due to the high avidity of cellular tetrameric 
DC-SIGN for gp120. We hypothesized that the glycan shield of gp120 may prevent the 
generation of blocking antibodies. Therefore, we compared the potency of polyclonal 
antibodies raised against either glycosylated gp120 or non-glycosylated gp120 to block the 
interaction of DC-SIGN with gp120.  
The binding characteristics of polyclonal antibody mixtures raised against gp120 and non-
glycosylated gp120 were assessed by means of ELISA (Fig. 5.3). The polyclonal antibodies 
raised against gp120 recognized both glycosylated and non-glycosylated gp120. Binding to 
both forms of gp120 was also observed for the polyclonal antibodies raised against non-
glycosylated gp120, demonstrating that epitopes recognized by the polyclonal antibodies 
raised against non-glycosylated gp120 are exposed in glycosylated gp120. Furthermore, the 
antibodies raised against both non-glycosylated and glycosylated gp120 bound to a similar 
extent to glycosylated gp120.  
Next, we investigated the potency of these polyclonal antibodies to block the DC-SIGN-gp120 
interaction. Polyclonal antibodies raised against both glycosylated and non-glycosylated gp120 
were equally efficient in inhibiting the DC-SIGN-gp120 interaction in the low avidity DC-SIGN-
Fc adhesion assay (Fig. 5.4A).  
Since both polyclonal antibodies mixtures were as efficient in blocking the recombinant DC-
SIGN binding, we tested inhibition of cellular DC-SIGN binding to polyvalent gp120 by the 
polyclonal antibody mixtures in the high avidity fluorescent beads adhesion assay (Fig. 5.4B). 
Strikingly, gp120 binding to immature DCs was inhibited in the presence of polyclonal 
antibodies raised against non-glycosylated gp120 to a similar extent as an antibody against  
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Polyclonal antibodies raised against non-glycosylated gp120 inhibit HIV-1 binding to DC-SIGN.  
(A) For the DC-SIGN-Fc adhesion assay, gp120-coated wells were incubated with the polyclonal antibodies (1:100 
dilution) or AZN-D1 (80 µg/ml), followed by DC-SIGN-Fc, without washing. (B) For the fluorescent beads adhesion 
assay, immature DCs were incubated with the polyclonal antibodies (1:10 dilution). Next, binding of the gp120-
coated beads (black bars) and ICAM-3-coated beads (gray bars) in the presence of the polyclonal antibodies to 
cellular DC-SIGN was assessed. (C) The polyclonal antibodies against non-glycosylated gp120 specifically block 
the gp120-DC-SIGN interaction. Fluorescent gp120-coated beads were preincubated with the antisera for 20 
minutes at 37°C. The beads were washed and added to DC-SIGN transfectants (THP-DC-SIGN). Adhesion is 
measured after 45 minutes at 37°C. (D) The polyclonal antibodies against non-glycosylated gp120 inhibit binding of 
DC-SIGN to different strains of HIV-1 gp120. The binding assay was performed as described in figure 5.4B. (E) The 
polyclonal antibodies against non-glycosylated gp120 inhibit HIV-1 binding to cellular DC-SIGN. Both immature DCs 
and THP-DC-SIGN transfectants are incubated with HIV-1 JR-CSF (p24 100 ng/100,000 cells) for 60 minutes at 
37°C in presence of different antibodies. Binding is measured after washing and lysing the cells using a p24 ELISA. 
 
 
DC-SIGN. This inhibition was specific since the polyclonal antibodies did not block binding of 
DC-SIGN to the cellular ligand ICAM-3. In contrast, the addition of the polyclonal antibodies  
raised against glycosylated gp120 caused only a minor inhibition of the binding of gp120 to 
immature DCs. In order to investigate the specificity of the polyclonal antibodies for gp120 and 
exclude any other components that may interfere with DC-SIGN binding, DC-SIGN 
transfectants were incubated with gp120-coated beads, which had been pre-incubated with the 
different antibodies and extensively washed to remove unbound antibodies (Fig. 5.4C). DC-
SIGN-gp120 binding was blocked by treating the gp120-coated beads with polyclonal 
antibodies against non-glycosylated gp120, whereas both polyclonal antibodies against gp120 
and pooled normal goat serum did not inhibit the interaction (Fig. 5.4C). As expected, 
antibodies against DC-SIGN were only able to inhibit the interaction when pre-incubated with 
cells but not with gp120 beads (Fig. 5.4C). These results demonstrate that polyclonal 
antibodies against non-glycosylated gp120 block the gp120 interaction with DC-SIGN by 
specifically binding to gp120. Moreover, the polyclonal antibodies raised against non-
glycosylated gp120 SF-2 demonstrated a broad specificity, since the antibodies inhibited DC-
SIGN binding to gp120 derived from different HIV-1 strains (Fig. 5.4D).  
In order to asses their ability to prevent DC-SIGN binding to trimeric gp120 as present on 
viruses, we investigated the ability of the antibodies to inhibit HIV-1 capture by both DC-SIGN 
transfectants and immature dendritic cells. DC-SIGN transfectants captured whole HIV-1 
virions as measured by a p24gag ELISA (Fig. 5.4E). The capture was blocked by the polyclonal 
antibodies against non-glycosylated gp120 to a similar extent as observed with both EGTA and 
antibodies against DC-SIGN (Fig. 5.4E). Moreover, the polyclonal antibodies against non- 
glycosylated gp120 also completely inhibited virus capture by immature DCs, similarly as 
antibodies against DC-SIGN (Fig. 5.4E).  
In summary, the polyclonal antibodies raised against non-glycosylated gp120 could specifically 
block the DC-SIGN-gp120 interaction, and prevent HIV-1 capture by DCs. These promising 
results may lead to the use of non-glycosylated gp120 as an immunogen to elicit blocking 
antibodies to prevent HIV-1 capture by DC-SIGN.  
 
Distinct binding sites on gp120 for DC-SIGN and CD4. 
The receptor binding site for CD4 on gp120 is a highly conserved region and has been 
characterized extensively [8]. As the CD4bs antibodies were not able block the DC-SIGN-
gp120 interaction (Table 5.1), we analyzed binding of soluble human CD4 (sCD4) to gp120 in 
the presence of DC-SIGN using an ELISA-based binding assay. Binding of sCD4 to gp120 
was examined using a CD4 antibody that does not interfere with the gp120 binding site on 
CD4. As seen in figure 5.5A, binding of sCD4 to gp120 was not inhibited by pre-incubation of 
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Simultaneous binding of CD4 and DC-SIGN to gp120.  
(A) Binding of sCD4 (0.5 µg/ml) to gp120-coated wells in the presence of DC-SIGN-Fc, was determined using the 
CD4v4 antibody that does not bind to the gp120 binding site on CD4. Standard deviation < 0.02. (B) Simultaneous 
binding of DC-SIGN and CD4 to gp120 was also determined using the fluorescent beads adhesion assay. 
Monomeric gp120 (5 µg/ml) was added to K652-DC-SIGN stably transfected with DC-SIGN, the non-transfected cell 
line K652 and immature DCs. Binding of the CD4-coated fluorescent beads to gp120 was analyzed. CD4 binding in 
the absence of gp120 (white bars); CD4 binding in the presence of gp120 (black bars); binding of CD4 was absent 
when cells were pre-incubated with anti-DC-SIGN antibody AZN-D1 (20 µg/ml) (gray bars). One representative 
experiment of three is shown. 
 
 
gp120 with DC-SIGN, demonstrating that DC-SIGN binding to gp120 did not interfere with the 
interaction of CD4 with gp120. Next, we examined whether CD4 could bind to gp120 that has 
been captured by cellular DC-SIGN (Fig. 5.5B). We observed binding of CD4 to immature DCs 
when gp120 was present, but not when gp120 was absent. This corroborates our observation 
with the ELISA-based binding assay, demonstrating that simultaneous binding of DC-SIGN 
and CD4 to gp120 can take place. Binding was inhibited when cells were pre-incubated with 
an anti-DC-SIGN antibody that blocks the binding of gp120 to DC-SIGN, demonstrating that 
binding was specific for DC-SIGN. Thus, we have demonstrated that CD4 and DC-SIGN have 
distinct binding sites on gp120.  
 
Enhanced CD4 binding to gp120 induced by DC-SIGN. 
Next, we examined whether DC-SIGN binding to gp120 could modulate binding of CD4 to 
gp120 in an ELISA-based binding assay. The molecular mechanism by which DC-SIGN 
enhances the infection of T cells is not fully understood. Therefore, besides concentrating virus 
particles on the surface of DCs, DC-SIGN may induce conformational changes in gp120 that 
enable a more efficient interaction of gp120 with CD4 by influencing conformational masking. 
The DC-SIGN-dependent enhancement of HIV-1 infection led us to investigate whether DC-
SIGN binding to gp120 induces an increase of CD4 binding to gp120 [3]. 
As seen in figure 5.6, binding of CD4 to gp120 was increased upon DC-SIGN interaction with 
gp120. We demonstrate that in the presence of DC-SIGN, less CD4 was required for a similar 
extent of binding to gp120 compared to CD4 alone, suggesting that DC-SIGN binding to gp120 
increased binding of CD4 to gp120. The increase is not due to cross-reactivity of the 
secondary anti-mouse antibody to the human IgG1-Fc region of DC-SIGN-Fc, since no binding 
is observed in the absence of sCD4. The increased binding is specific for DC-SIGN binding to  
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Enhancement of CD4 binding 
to gp120 by the DC-SIGN-
gp120 interaction.  
CD4 binding to gp120 captured 
onto microtiter wells using the 
D7324 antibody was assessed in 
the presence of DC-SIGN (0.75 
µg/ml), with or without the DC-
SIGN inhibiting polysaccharide 
mannan using different 
concentrations of sCD4. One 
representative experiment of 
three is shown. 
 
 
 
 
 
 
 
 
 
 
gp120 since it was not observed when DC-SIGN binding to gp120 was inhibited with the 
polysaccharide mannan (Fig. 5.6). In the presence of DC-SIGN, an increase in CD4 binding to 
gp120 of 145 to 200% was repeatedly observed. The gp120 glycoprotein is very flexible and it 
seems likely that conformational changes in gp120 are induced upon binding of DC-SIGN 
thereby enhancing CD4 binding. This appears analogous to CD4 that triggers conformational 
reorganization in gp120 allowing high-affinity binding to the chemokine receptor [45;46]. 
 
 
 
Discussion 
 
The important role of DC-SIGN in HIV-1 transmission makes it an attractive target to intervene 
with HIV-1 dissemination. Blocking antibodies against DC-SIGN inhibit HIV-1 capture by DCs 
[3], but also interfere with the immunological role of DC-SIGN [3;18]. Therefore, inhibitors 
targeting HIV-1 gp120 to prevent DC-SIGN capture seem warranted to interfere with HIV-1 
dissemination. More knowledge on the DC-SIGN-gp120 interaction is essential for 
development of these inhibitors. Here, we have investigated the potency of monoclonal and 
polyclonal antibodies against gp120 to inhibit this interaction.  
We have evaluated specific competition of DC-SIGN with antibodies against gp120. Our 
results demonstrate that defined monoclonal gp120 antibodies could not completely inhibit the 
interaction of DC-SIGN with gp120. V3 loop antibodies that recognize the tip of the loop [47] 
reduced binding of DC-SIGN up to 50%, in contrast to the V3 loop antibodies directed to the 
base of the loop that had no effect on DC-SIGN binding to gp120. However, the V3 loop itself 
is not involved in the interaction with DC-SIGN, as DC-SIGN binding was not affected by 
deletion of the V3 loop from gp120. Thus, V3 loop antibodies might modulate DC-SIGN binding 
by sterically hindering DC-SIGN from accessing its binding site. N-linked glycosylation high 
mannose structures, but not complex oligosaccharide structures, are specifically recognized by 
DC-SIGN [7], and studies on the gp120 carbohydrate composition indicate that high mannose 
structures are observed on the gp120 core closely clustered to the V3 loop [10]. Our inhibition 
data indicate that DC-SIGN interacts with these carbohydrates in relative close proximity to the 
V3 loop. The 2G12 gp120 antibody binds to specific conserved cluster of high-mannose type 
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carbohydrates on gp120 in proximity of the V3 loop, which could be involved in DC-SIGN 
binding. However, we did not observe inhibition of the DC-SIGN-gp120 interaction by 2G12.  
This data was supported by results showing that DC-SIGN binds to clade E gp120CM235 that 
lacks the 2G12 epitope. This is in agreement with the data of Hong et al. [14], demonstrating 
that DC-SIGN and 2G12 have distinct binding sites on gp120. Future studies could include the 
use of antigen-binding fragments of the antibody instead of the entire antibody to minimize the 
effect of steric hindrance caused by the size of the antibody.  
Our data demonstrate that monoclonal gp120 antibodies do not block the DC-SIGN-gp120 
interaction efficiently. We hypothesized that the presence of a glycan shield may prevent the 
generation of blocking antibodies. Therefore, we have investigated the potency of polyclonal 
antibodies raised against both glycosylated and non-glycosylated gp120 to inhibit binding of 
DC-SIGN to gp120. Although both polyclonal antibodies raised against either glycosylated and 
non-glycosylated gp120 reacted similarly to glycosylated gp120 (Fig. 5.3), we observed 
differences in the blocking of the DC-SIGN-gp120 interaction (Fig. 5.4).  
Polyclonal antibodies against glycosylated gp120 inhibited the DC-SIGN-gp120 interaction in 
the low avidity interactions ELISA-based DC-SIGN-Fc adhesion assay, but not in the high 
avidity fluorescent beads adhesion assay requiring binding of polyvalent gp120 to cellular DC-
SIGN. In contrast, polyclonal antibodies raised against non-glycosylated gp120 inhibited 
binding of gp120 to DC-SIGN in both assays. Thus polyclonal antibodies raised against non-
glycosylated gp120 have a high affinity for gp120 or may be directed to gp120 structures that 
become exposed when carbohydrates are absent. This suggests that the glycan shield formed 
by the carbohydrate cluster on gp120 [48], in addition to preventing binding of neutralizing 
antibodies, might also prevent the generation of gp120 antibodies against the DC-SIGN 
binding site. 
DC-SIGN plays an important cellular function by mediating adhesion of DCs to T cells through 
ICAM-3 binding. Antibodies raised against non-glycosylated gp120 inhibit the gp120-DC-SIGN 
interaction without altering the immunological function of DC-SIGN (Fig. 5.4). These polyclonal 
antibodies evidently bind gp120 in a way that inhibits DC-SIGN binding. Furthermore, the 
polyclonal antibodies against non-glycosylated gp120 were able to inhibit capture of HIV-1 by 
both DC-SIGN transfectants and immature DCs, to a similar level as observed with antibodies 
against DC-SIGN (Fig. 5.4). Thus, the polyclonal antibodies efficiently block the interaction of 
DC-SIGN to both monomeric and trimeric gp120 as present on viruses. Even though the 
precise nature of the blocking capability of the polyclonal antibodies against the non-
glycosylated gp120 remains yet to be identified, these data hold promise for the future. In 
vaccination strategies, it may be feasible to target a defined structure on gp120 to block DC-
SIGN binding to elicit blocking antibodies, while the binding of cellular ligands to DC-SIGN 
remains unaffected.  
It has recently been suggested that CD4 and DC-SIGN compete for gp120 binding [49]. In 
contrast, we have demonstrated that the primary HIV-1 receptor CD4 and DC-SIGN can bind 
simultaneously to gp120, establishing that the DC-SIGN binding site is distinct from the CD4 
binding site on gp120 (Fig. 5.5). Similar results were obtained with a K562 transfectant 
expressing DC-SIGN (data not shown). This was supported by data demonstrating that CD4bs 
antibodies did not block the DC-SIGN-gp120 interaction (Table 5.1). 
Binding of DC-SIGN to gp120 on HIV-1 is implicated to increase the local concentrations of 
virus particles on the DC surface in the proximity of entry receptors [5;50-52]. Here we have 
demonstrated that DC-SIGN binding to gp120 increases CD4 binding to gp120, suggesting 
that DC-SIGN induces conformational changes that favour CD4 binding. Hence, DC-SIGN may 
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not merely act to concentrate virus at the cell surface but may also increase CD4 binding to 
gp120. 
Furthermore, besides a glycan shield to mask the potential vulnerable CD4 receptor binding 
site on gp120 to escape neutralization, conformational masking has been suggested to protect 
the receptor binding site [53]. This conformational masking influences the efficiency with which 
CD4 binding site antibodies are generated. It is tempting to speculate that this strategy to 
evade recognition by the immune system, might also affect the binding of the CD4 receptor 
itself. Therefore, DC-SIGN may play an essential role by enhancing CD4 binding to gp120. 
Taken together, the observed increased binding of gp120 to CD4 provides an additional 
explanation for DC-SIGN in enhancement of HIV-1 transmission. Future studies are required to 
investigate this intriguing possibility.  
In summary, this study contributes to further understanding of the DC-SIGN-gp120 interaction. 
More importantly, these data will be valuable in the development of novel inhibitory agents to 
prevent capture of HIV-1 by DC-SIGN in future vaccination strategies. 
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Abstract 
 
DC-specific ICAM3-grabbing nonintegrin (DC-SIGN), which is expressed on DCs, can interact 
with a variety of pathogens such as HIV-1, hepatitis C, Ebola, cytomegalovirus, Dengue virus, 
Mycobacterium, Leishmania, and Candida albicans. We demonstrate that human milk can 
inhibit the DC-SIGN-mediated transfer of HIV-1 to CD4+ T lymphocytes as well as viral transfer 
by both immature and mature DCs. The inhibitory factor directly interacted with DC-SIGN and 
prevented the HIV-1 gp120 envelope protein from binding to the receptor. The human milk 
proteins lactoferrin, α-lactalbumin, lysozyme, ß-casein, and secretory leukocyte protease 
inhibitor did not bind DC-SIGN or demonstrate inhibition of viral transfer. The inhibitory effect 
could be fully alleviated with an Ab recognizing the Lewisx (Lex) sugar epitope, commonly found 
in human milk. Lex in polymeric form or conjugated to protein could mimic the inhibitory activity, 
whereas free Lex sugar epitopes could not. We reveal that a Lex motif present in human milk 
can bind to DC-SIGN and thereby prevent the capture and subsequent transfer of HIV-1 to 
CD4+ T lymphocytes. The presence of such a DC-SIGN-binding molecule in human milk may 
both influence antigenic presentation and interfere with pathogen transfer in breastfed infants. 
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Introduction 
 
DCs can capture an array of infectious agents and present their antigens to T lymphocytes. 
DCs express, among other receptors, the DC-specific ICAM3-grabbing nonintegrin (DC-SIGN) 
receptor, a C-type lectin, which contains an external calcium-dependent mannose-binding 
lectin domain [1;2]. DC-SIGN interacts with the envelope glycoprotein gp120 of HIV-1, HIV-2, 
and SIV [3-8], as well as other pathogens such as hepatitis C [9;10], Ebola [11], 
cytomegalovirus [12], Dengue virus [13], Mycobacterium [14-16], Leishmania [17;18], Candida 
albicans [19], and Helicobacter pylori [20;21]. DC-SIGN has been implicated as playing an 
important role in HIV-1 transmission and the establishment of infection [4;6;22-25]. The 
interaction of HIV-1 with DC-SIGN can lead to infection of the DCs, or alternatively the virus 
can be internalized into a trypsin-resistant compartment prior to undergoing transfer to its main 
target cells, and this mechanism has been shown to greatly enhance infection of T cells in vitro 
[26;27].  
Mother-to-child transmission (MTCT) of HIV-1 accounts for the majority of HIV-1 infections 
among children [28]. Transmission can occur either in utero, intrapartum, or through 
breastfeeding [29]. It has been recognized that HIV-1 transmission via breastfeeding accounts 
for 40% of all MTCTs of HIV-1 [30;31]. Relatively little is known with regard to HIV-1 present 
within human milk and how the virus is transmitted from mother to child. Children exposed to 
HIV-1 through breastfeeding will encounter both free viral particles as well as cell-associated 
virus [32;33]. Macrophages in human milk are found at varying concentrations during lactation 
[34] and are preferentially infected with viruses that utilize the CCR5 coreceptor for viral entry 
(R5) and that are typically associated with HIV-1 transmission [35;36]. Mammary epithelial cells 
are present in human milk, and these cells are predominantly infected with viruses utilizing the 
CXCR4 coreceptor (X4), virus strains that seldom undergo transmission [37;38]. CD4+ T 
lymphocytes are also present in human milk, and these cells can be infected with both R5 and 
X4 strains, depending on the cellular phenotype and cell activation status [39;40]. MTCT of 
HIV-1 via breastfeeding is likely to require the transfer of virus across a mucosal barrier or via 
breaches in the mucosal surface. The interaction of the HIV-1 gp120 protein with DCs, shown 
to be present at high concentrations in the tonsils, the upper rim of the oesophagus [41;42], 
and the intestinal tract [43], may therefore heighten virus capture and transmission. Although 
DC-SIGN expression has not been analyzed on DCs from all the above-mentioned anatomical 
sites, high levels of expression have been reported in tonsil material [6].  
Several of the proteins present in human milk have been shown to possess antimicrobial 
activity. Lactoferrin [44-46], lysozyme [47], and secretory leukocyte protease inhibitor (SLPI) 
[48;49] have all been shown to exhibit anti-HIV-1 properties in vitro. On the contrary, ß-casein 
has been shown to enhance HIV-1 infection of CD4+ T lymphocytes [44]. Oligosaccharides 
present in human milk include lactodifucotetraose; lacto-N-fucopentaose (LNFP) I, II and III; 
and monofucosyllacto-N-hexaose III; among others [50-52]. A number of sugar epitopes to be 
found in human milk are composed of the Lewis group of antigens, including Lewisx (Lex) and 
Lewisy (Ley) [53], which can be part of a larger oligosaccharide, regardless of whether the 
sugar is protein associated or not. The Lex epitope (Galß1-4[Fucα1-3]GlcNAc-R) is also 
included within the LNFP III sugar moiety. This same sugar epitope has been identified in 
bodily fluids, including saliva, blood, and human milk and has also been shown to be present in 
a number of pathogens [21] and pathogen extracts [54]. Some of the human milk 
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oligosaccharides have been shown to protect against toxins and pathogens involved in 
childhood diseases [55]. 
 
 
 
Material and Methods 
 
Cells.  
The Raji control cell line and the cell lines expressing either DC-SIGN (Raji-DC-SIGN) or L-SIGN (Raji-L-
SIGN) were cultured as previously described [4]. PBMCs were isolated from buffy coats by standard 
Ficoll-Hypaque density centrifugation, activated with phytohemagglutinin (3 µg/ml), and cultured in RPMI 
medium containing 10% FCS, penicillin (100 units/ml), and streptomycin (100 units/ml). On day 3 the 
cells underwent CD4+ enrichment by incubation with CD8 immunomagnetic beads (Dynal Biotech) and 
were negatively selected according to the manufacturer’s instructions and cultured with IL-2 (100 U/ml). 
DCs for the single-cycle transmission assay were generated from fresh PBMCs with cells layered on a 
standard Percoll gradient (Amersham Pharmacia). The light fraction with predominantly monocytes was 
collected, washed, and seeded in 24 well or 6 well culture plates at a density of 500,000 or 250,000 cells 
per well, respectively. After 60 minutes at 37°C, the adheren t cells were cultured to obtain iDCs in 
Iscove’s modified Dulbecco’s medium (IMDM) with gentamicin (86 µg/ml) and 10% foetal clone serum 
(HyClone) supplemented with GM-CSF (500 U/ml) and IL-4 (250 U/ml). Culture medium was refreshed 
on day 3, with cell maturation induced at day 6 by culturing with poly(I:C) (20 µg/ml; Sigma-Aldrich). After 
2 days, mature CD14-CD1b+CD83+ DCs were obtained, washed, and utilized. The culture conditions for 
LuSIV cells with an integrated long terminal repeat-luciferase reporter construct have been described 
previously [56]. 
 
Viruses.  
Replication-competent HIV-1 stocks were generated by the passage of viruses through CD4+ 
lymphocytes, with tissue culture infectious dose (TCID50/ml) determined by limiting dilution on CD4+-
enriched lymphocytes [57]. Subtype B molecular cloned viruses JR-CSF (R5), LAI (X4), and SF-162 (R5) 
and subtype B primary isolates NSI-18 (R5) and SI-19 (X4) were used in the experiments.  
 
Human milk fractions and commercial milk products.  
Internal review board approval was not required because samplings were taken from discarded material 
from a single time point. Human milk samples were sequentially centrifuged at 400g and 530g for 10 
minutes, with pipette removal of the lipid layers. Samples were sterilized by filtration through both 0.45 
µm and 0.2 µm syringe filters (Schleicher & Schuell BioScience Inc.) and stored at -80°C. Human 
lactoferrin (Sigma-Aldrich), bovine lactoferrin (Sigma-Aldrich), human α-lactalbumin (Sigma-Aldrich), 
bovine ß-casein (NIZO Food Research), human lysozyme (Sigma-Aldrich), LNFP III (Calbiochem), SLPI 
(Sigma-Aldrich), Lex trisaccharide (Calbiochem), Lex-BSA, 14-atom spacer (Calbiochem), PAA-Lex 
(Syntesome), anti-human Lex (mouse) IgM (Calbiochem), and anti-human ARA-LAM (mouse) IgM were 
used. All compounds were utilized at physiologically relevant concentrations by dilution in PBS 
containing 10% FCS.  
 
Direct HIV-1 infection assay.  
Enriched CD4+ lymphocytes were plated in 96 well plates at 500,000 cells/well in IL-2-containing culture 
medium. Cells were incubated for 2 hours with human milk diluted in PBS containing 10% FCS and 
spiked with 3.7 log TCID50/ml of HIV-1. After 2 hours the cells were washed and fresh medium added. 
Alternatively, after a 2-hour incubation of human milk with HIV-1, the spiked milk was diluted with PBS 
containing 10% FCS before addition to CD4+ T lymphocytes. On day 7 of culture, viral capsid (CA-p24) 
levels were determined by ELISA.  
 
DC-SIGN-mediated HIV-1 transfer assay.  
The Raji and Raji-DC-SIGN cells were plated at 20,000 cells/well in a 96-well format. Dilutions of human 
milk or human milk compounds were made in PBS containing 10% FCS and spiked with 3.7 log 
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TCID50/ml of the appropriate virus before addition to the Raji-DC-SIGN cells. As a control, PBS 
containing 10% FCS was spiked with the same TCID50/ml of the corresponding virus before addition to 
Raji or Raji-DC-SIGN cells. After incubation the culture was washed with PBS before addition of CD4+-
enriched T lymphocytes at a concentration of 100,000 cells/well, with CA-p24 determined on day 7. 
 
 
DC-SIGN-specific Ab binding after exposure to human milk.  
Human milk was incubated with 50,000 Raji-DC-SIGN or iDCs for 15 minutes at 37°C, after which the 
cells were washed with TSM (20 mM Tris, 150 mM NaCl, 1 mM CaCl2, 2 mM MgCl2) and the cells were 
incubated at 4°C for 45 minutes with 5 µg/ml of the specific DC-SIGN Ab, AZN-D1 [6], AZN-D2 [12], or 
anti-stalk 4. Subsequently, the cells were washed and incubated with goat anti-mouse FITC for 45 
minutes at 4°C. The cells were washed  and resuspended in 100 µl TSM containing 0.5% BSA (Fraction 
V, Fatty Acid-Free; Calbiochem), and the adhesion was measured by flow cytometry (BD Biosciences). 
 
 
DC-SIGN binding assay.  
For preincubation of HIV-1 with human milk, a 1:4 dilution of human milk or PBS containing 10% FCS 
was incubated with a high virus titer (5.6 log TCID50/ml) of SF-162 for 1 hour at 37°C  before diluting the 
mixture to 1:667 by addition of 270,000 Raji-DC-SIGN cells in a 24-well format. The cells were incubated 
for 2 hours at 37°C before washing with PBS and add ition of CD4+ T lymphocytes at a concentration of 1 
x 106 cells/ml followed by measuring CA-p24 production on day 15. For preincubation of Raji-DC-SIGN 
cells with human milk, a dilution of the human milk (1:4) or PBS containing 10% FCS was incubated with 
270,000 Raji-DC-SIGN cells in a 24-well format for 1 hour at 37°C  before washing with PBS and addition 
of SF-162 (2.8 log TCID50/ml). The cells were incubated for 2 hours before washing and adding 1 x 106 
cells/well of CD4+-enriched lymphocytes, with CA-p24 production measured on day 15. 
 
 
gp120 bead adhesion assay.  
Beads were prepared as previously described [6]. In short, streptavidin was covalently coupled to 
carboxylate-modified TransFluoSpheres (488/645 nm excitation/emission, 1.0 µm; Invitrogen Corp.). The 
streptavidin beads were incubated with biotinylated F(ab')2 fragment goat-anti-human IgG (6 µg/ml; 
Jackson ImmunoResearch Laboratories Inc.) and subsequently incubated overnight with gp120-Fc 
chimera. 50,000 Raji-DC-SIGN cells, iDCs, or Raji-L-SIGN cells were preincubated with human milk or 
milk compounds, AZN-D1 [6], AZN-D2 [12], EGTA, or mannan for 30 minutes at room temperature. The 
ligand-coated beads (20 beads/cell) were added to the preincubated cells and incubated for 30 minutes 
at 37°C, after which the cells were washed with TSM  containing 0.5% BSA. After washing, the cells were 
resuspended in 100 µl TSM-BSA buffer, and the adhesion was measured by flow cytometry (BD 
Biosciences). 
 
 
DC-SIGN-Fc binding ELISA.  
This assay utilized the DC-SIGN-Fc chimera, which contained the extracellular portion of DC-SIGN 
(amino acids 64-404) fused at the C terminus to a human IgG1 Fc fragment as previously described [58]. 
Human milk or human milk compounds were diluted in 0.2 M NaHCO3, coated on ELISA plates 
(Maxisorp plate; Nunc), and incubated overnight at 4°C or 2 hours at 37°C. This was followed by 
blocking with TSM containing 1% BSA for 30 minutes at 37°C before addition of soluble DC-SIGN-Fc (5 
µg/ml) for 2 hours at room temperature; the binding was determined by incubation of a peroxidase-
labelled anti-IgG1 Ab for 30 minutes at room temperature. DC-SIGN-Fc binding specificity was 
determined by preincubation of the DC-SIGN-Fc with either 50 µg/ml DC-SIGN-specific mouse Ab AZN-
D1 [6] or 10 mM EGTA. 
 
 
Single-cycle-replication transmission assay.  
The assay was performed as previously described [59]. In short, mDCs and iDCs were incubated in a 96 
well plate (35,000 to 50,000 DCs/well) with human milk for 30 minutes at 37°C  before addition of virus (5 
ng CA-p24/well), which was incubated for 2 hours at 37°C. The DCs were washed twice with  PBS before 
addition of 50,000 LuSIV cells. After 24 hours, LuSIV cells were harvested and resuspended in 50 µl 
lysis buffer (25 mM Tris-Cl 7.8, 2 mM DTT, 2 mM CDTA, 10% glycerol, 1% Triton X-100). The cells were 
then incubated for 45 minutes at room temperature while shaking, followed by 10 minutes centrifugation 
at 3,200g. The supernatant was transferred to a white-solid 96 well plate (Costar; Corning), and 150 µl of 
buffer (100 µg/ml BSA, 6.6 mM ATP, 15 mM MgSO4, 25 mM glycylglycine) was added. One hundred 
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microliters of DE(-)Luciferin (Roche Diagnostics GmbH) was injected per well (0.28 mg/ml lucibuffer 
excluding ATP). LuSIV cells (50,000) grown without DC or HIV-1 were used to obtain the background 
luciferase value. 
 
 
Capture assay.  
To measure the capture of HIV-1 by iDCs, the cells were incubated in a 96 well plate (50,000 DCs/well) 
with human milk for 30 minutes at 37°C before addition of the virus (5 ng CA-p24/well), which was 
incubated for 2 hours at 37°C. The iDCs were washed  twice with PBS before the CA-p24 concentration 
was determined by standard ELISA. 
 
 
Statistics.  
All statistical comparisons were performed using ANOVA. P<0.01 and P<0.05 were considered 
statistically significant. 
 
 
 
Results 
 
The effect of human milk on direct HIV-1 infection of CD4+ T lymphocytes and DC-SIGN-
mediated HIV-1 transfer.  
We investigated the effect of human milk on direct infection of CD4+ T lymphocytes by 
incubating HIV-1 in the presence of several dilutions of human milk from an HIV-1-negative 
donor taken 6 months into lactation. The 2-fold dilution of human milk demonstrated a 
significant degree of viral inhibition (>90%; P<0.05) in comparison with the PBS control (Fig. 
6.1A), which corresponds with previous reports [44-49]. We also identify an enhancement to 
infection at the 1:10 dilution similar to findings from a previous study [38]. Preincubation of the 
same human milk sample (1:2) with HIV-1 before addition to CD4+ T lymphocytes (Fig. 6.1B) 
showed no inhibitory effect in comparison to the PBS control, indicating that the inhibition 
shown in figure 6.1A is not due to a direct virucidal effect of the milk and that the effect is likely 
conferred on the CD4+ lymphocyte. The experiments were repeated with human milk from 2 
other mothers, with equivalent results obtained (data not shown).  
DC-SIGN-expressing cells can enhance infection of CD4+ T lymphocytes [4;8]. To study the 
effect of human milk on DC-SIGN-mediated transfer of HIV-1, we utilized the Raji cell line 
expressing the DC-SIGN receptor (Raji-DC-SIGN) [8]. The same human milk sample as used 
in the direct infection assay or PBS spiked with HIV-1 primary isolates was incubated with the 
Raji-DC-SIGN cells for 30 minutes or 2 hours, after which the cells were washed and incubated 
with activated CD4+ T lymphocytes and the culture monitored for viral replication. Raji-DC-
SIGN cells preincubated with PBS spiked with HIV-1 showed efficient transfer to CD4+ T 
lymphocytes (Fig. 6.2A, black line). The Raji cell line not expressing DC-SIGN showed no viral 
transfer, demonstrating that the effect we observed is DC-SIGN dependent (data not shown). 
Surprisingly, preincubation of Raji-DC-SIGN cells with HIV-1-spiked human milk significantly 
reduced or blocked transfer of HIV-1 depending on the incubation time (Fig. 6.2A, gray line). 
Through testing cell viabilities, we demonstrated that the observed inhibition was not due to 
induced cell death of Raji-DC-SIGN by human milk (data not shown). The transfer experiment 
revealed that human milk blocks the transfer of HIV-1 by Raji-DC-SIGN cells irrespectively of 
viral coreceptor phenotype. We next performed limiting dilutions of the same human milk 
sample and found that R5 and X4 HIV-1 variants were completely inhibited at a 1:128 but not at 
a 1:512 dilution (Fig. 6.2B). Similar results were observed with the same assays using human 
milk from 2 other HIV-1-negative donors (data not shown).  
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Direct infection of CD4+ T lymphocytes in the presence of human milk.  
(A) PBS or several dilutions of human milk from an uninfected mother were spiked with LAI (X4) and added to CD4-
enriched T lymphocytes. After a 2-hour incubation, the CD4+ T lymphocytes were washed, and fresh medium was 
added. (B) LAI (X4) was incubated with a 1:2 dilution of human milk or PBS for 2 hours, after which several dilutions 
were made and added to CD4+ T lymphocytes. For both experiments the CA-p24 concentration was determined on 
day 7. * P<0.05 compared with the PBS control. 
 
 
Human milk compound(s) bind to DC-SIGN, thereby preventing transfer of HIV-1 to CD4+ T 
lymphocytes.  
To determine whether the inhibitory effect of human milk on Raji-DC-SIGN-mediated viral 
transfer was caused by interaction of human milk with HIV-1 or DC-SIGN, we conducted 
preincubation experiments of either Raji-DC-SIGN cells or HIV-1 with human milk. To test for 
binding of the inhibitory factor to Raji-DC-SIGN cells, we preincubated the cells with either a 
known inhibitory concentration of human milk (1:4) or PBS before washing and then adding 
virus and subsequently CD4+ T lymphocytes. Alternatively, to test binding of components in  
human milk to the virus, we incubated a high-titer virus stock with either PBS or human milk,  
after which the Raji-DC-SIGN cells were added, thereby diluting the milk to a noninhibitory 
concentration (1:667); CD4+ T lymphocytes were then added. Preincubation of virus with 
human milk demonstrated a slight reduction in viral transfer compared with the PBS control 
(Fig. 6.3A), likely reflecting residual inhibitory effects of the human milk. In contrast, 
preincubation of the Raji-DC-SIGN cells with human milk provided a highly significant reduction 
in viral transfer compared with the PBS control (P<0.01; Fig. 6.3B). To test whether the 
observed inhibition was due to downmodulation of DC-SIGN expression, we investigated the 
surface expression of DC-SIGN in the presence of human milk. We demonstrate that with 2 
DC-SIGN-specific mAbs, AZN-D2 and anti-stalk 4, cell surface expression was not altered, 
whereas the binding of AZN-D1 was reduced when DC-SIGN cells were preincubated with 
human milk (Fig. 6.3C). These results suggest that the inhibitory effect is mediated via the 
binding of factor(s) in human milk to the DC-SIGN molecule and prevention of its interaction 
with HIV-1 as opposed to the downmodulation of the DC-SIGN molecule at the cell surface. 
To show direct binding of human milk compound(s) to DC-SIGN, we introduced 2 previously 
described assays [6;58], the gp120 bead adhesion assay and the DC-SIGN-Fc binding ELISA.  
In the gp120 bead adhesion assay, the effect of human milk on the binding of gp120-coated 
fluorescent beads to cellular DC-SIGN was studied. The binding of the gp120 beads to both 
Raji-DC-SIGN and immature DCs (iDCs) was inhibited by human milk in comparison with the 
control (P<0.01; Fig. 6.4A and B, respectively). To demonstrate DC-SIGN-specific binding, the 
cells were preincubated with a DC-SIGN-specific Ab (AZN-D1), the DC-SIGN-binding sugar 
mannan, and the Ca2+ chelator EGTA. These agents were found to block binding of gp120 
beads to the DC-SIGN-expressing cells to the same extent as human milk (Fig. 6.4A, B). To
Chapter 6 
 
100 
 
DC-SIGN–dependent transfer 
of HIV-1 to CD4+ T 
lymphocytes is inhibited in 
the presence of human milk. 
(A) A 1:2 dilution of human milk 
of an uninfected mother or PBS 
was spiked with primary isolates 
NSI-18 (R5) or SI-19 (X4) 
before addition to Raji-DC-SIGN 
cells. After an incubation of 30 
minutes or 2 hours, the cells 
were washed, and activated 
CD4+ T lymphocytes were 
added. Viral replication was 
measured on days 7, 9, 12, and 
14 after infection by determining 
CA-p24 values using a standard 
ELISA. The bars represent 
maximum and minimum CA-p24 
values. (B) PBS or serial 
dilutions of human milk were 
spiked with JR-CSF (R5) or LAI 
(X4) before addition of Raji-DC-
SIGN cells; after an incubation 
of 2 hours, the cells were 
washed with PBS, and 
stimulated CD4+ T lymphocytes 
were added. At day 7, CA-p24 
concentrations were determined 
by standard ELISA. Percent 
inhibition was determined in 
reference to the CA-p24 
concentration of the 
corresponding spiked PBS 
control. 
 
 
 
 
confirm the direct interaction of DC-SIGN with human milk, we performed a DC-SIGN-Fc 
binding ELISA where we demonstrated that DC-SIGN-Fc binding to human milk was specific, 
since preincubation of DC-SIGN-Fc with AZN-D1 or EGTA completely abrogated binding 
(P<0.01; Fig. 6.4C). 
The liver and lymph node-specific homolog of DC-SIGN (liver and lymph node-specific ICAM3-
grabing nonintegrin (L-SIGN)) is also capable of interacting with HIV-1 and enhancing viral 
infectivity [60]. To investigate the effect of human milk on the interaction of L-SIGN and gp120, 
we incubated Raji cells expressing the L-SIGN molecule (Raji-L-SIGN) with human milk in the  
gp120 bead adhesion assay, and as a control, the cells were preincubated with AZN-D1, AZN- 
D2 (an L-SIGN-specific Ab), mannan, and EGTA. The results demonstrated that human milk 
did not inhibit the interaction of gp120 with L-SIGN (Fig. 6.4D), indicating a specificity of the 
human milk compound for DC-SIGN.  
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The human milk compound(s) interact 
with the DC-SIGN receptor, which 
does not lead to DC-SIGN 
downmodulation.  
(A) Human milk (1:4) or PBS was 
preincubated with a high-titer stock of 
LAI before adding to Raji-DC-SIGN cells 
at a dilution known not to inhibit viral 
replication. After incubation, the cells 
were washed, and CD4+ T lymphocytes 
were added, with CA-p24 values 
measured on day 15 by standard ELISA 
(P>0.01). (B) Human milk (1:4) or PBS 
were incubated with Raji-DC-SIGN, after 
which the cells were washed to remove 
unbound human milk components before 
addition of LAI. After incubation, the cells 
were washed again, and CD4+ T 
lymphocytes were added, with the CA-
p24 values measured on day 15 by 
standard ELISA. * P<0.01. (C) Raji-DC-
SIGN cells were incubated with TSM or 
human milk (1:2) before the binding of 
AZN-D1, AZN-D2, and anti-stalk 4 DC-
SIGN-specific Abs were determined. The 
filled histograms represent the isotype 
control; the black lines represent the Ab 
binding without human milk 
preincubation; and the dotted lines 
represent the Ab binding after the cells 
were incubated with human milk. 
 
 
Human milk inhibits both iDC- and mature DC–dependent transfer of HIV-1.  
To study the biological relevance of the inhibitory properties of human milk, we utilized 
apreviously described single-cycle HIV-1 transmission assay [59] using both iDCs and mature 
DCs (mDCs). Either iDCs or mDCs (matured by poly(I:C)) were incubated with several dilutions 
of human milk before addition of HIV-1 LAI (X4) and target cells. After 24 hours, luciferase 
activity was measured, representing transmission of HIV-1 to the LuSIV cells. Human milk was 
found to inhibit HIV-1-mediated transfer by both iDCs and mDCs (Fig. 6.5A) in a dose-
dependent manner, with the 2- and 5-fold dilutions showing significant inhibition for both cell 
types (P<0.01). Washing after the preincubation of mDCs with human milk (1:2) before addition 
of HIV-1 also showed a significant reduction (P<0.01) in HIV-1 transfer in comparison to the 
PBS control (data not shown), indicating that the observed inhibition shown in figure 6.5A was 
not due to a direct virucidal effect of the human milk. We also demonstrated that a 1:2 and 1:5  
dilution of human milk significantly reduces HIV-1 capture by iDCs (P<0.01; Fig. 6.5B). We also 
tested for DC-SIGN downmodulation through cell-surface staining with the different Abs 
directed against DC-SIGN (AZN-D1, AZN-D2, and anti-stalk 4) in the presence or absence of 
human milk. Both AZN-D2 and anti-stalk 4 showed no significant difference in binding before 
and after human milk exposure, indicating that the DC-SIGN receptor is not downmodulated by 
the interaction with human milk (Fig. 6.5C), while AZN-D1 does show a reduced binding after 
human milk exposure. We expect that similar results would be obtained with an R5 virus and a 
CCR5-expressing cell, since we demonstrated that R5 and X4 viruses are equally inhibited with 
human milk (Fig. 6.2).  
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Major human milk proteins do not bind DC-SIGN nor inhibit HIV-1 transfer to CD4+ T 
lymphocytes.  
Since inhibition by human milk is present at relatively high dilutions (Fig. 6.2B), we 
hypothesized that one of the major proteins present in human milk may be responsible for the 
activity. We therefore tested human lactoferrin, bovine ß-casein, human lysozyme, human α- 
lactalbumin, and human SLPI, which have been shown to posses modulatory effects on HIV-1 
replication in vitro [44-49]. All these compounds were tested in the gp120 bead adhesion assay 
and the DC-SIGN-Fc binding ELISA (Fig. 6.6). None of the tested human milk compounds  
could inhibit gp120 binding to Raji-DC-SIGN or iDCs (Fig. 6.6A and B, respectively). 
Furthermore, DC-SIGN-Fc showed no binding to the selected milk compounds (Fig. 6.6C). As 
a control, bovine lactoferrin was used, which has previously been shown to bind DC-SIGN and 
prevent viral transfer [59]. 
 
Preincubation of human milk with an anti-Lex Ab lifted the inhibition of HIV-1 transfer.  
Since DC-SIGN can bind sugars, we hypothesized that one of the abundant sugar motifs in 
human milk may provide the inhibitory activity [50-52]. The fact that we demonstrated that 
gp120 binding to L-SIGN could not be inhibited with human milk (Fig. 6.4D) and it is known that 
L-SIGN does not bind Lex motifs, we predicted that Lex could be contributing to the observed 
inhibition. To test our hypothesis, we preincubated human milk with an anti-Lex IgM Ab or an  
 
 
 
 
 
 
 
 
 
 
 
 
 
DC-SIGN-Fc binding ELISA and the 
gp120 bead adhesion assay demonstrate 
the interaction of the human milk 
compound(s) with DC-SIGN.  
(A and B) Raji-DC-SIGN cells or iDCs, 
respectively, were incubated with human 
milk (1:20) before addition of fluorescent 
gp120-coated beads. DC-SIGN-positive 
cells and mock Raji cells were incubated 
with buffer as controls. To determine the 
specificity of the observed binding, the cells 
were incubated with AZN-D1, EGTA, and 
mannan before addition of the gp120 
beads. * P<0.05 compared with the PBS 
control. (C) Human milk (1:20) was coated 
before addition of DC-SIGN-Fc. The 
specificity of the observed binding was 
determined by the preincubation of DC-
SIGN-Fc with AZN-D1 and EGTA. ** P<0.01 
compared with the noninhibitory control. (D) 
Raji cells expressing the L-SIGN receptor 
were incubated with buffer, human milk 
(1:20), AZN-D1, AZN-D2, or mannan before 
addition of the gp120 fluorescent beads. # 
P<0.01 compared with the binding without 
an inhibitor. 
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IgM isotype control before use in the culture transfer assay. The results demonstrated a dose-
dependent lifting of the inhibitory effects of human milk on viral transfer after a preincubation 
with the Lex-specific Ab but not with the control Ab (Fig. 6.7A). In contrast, the gp120 bead 
adhesion assay did not show reduced binding of DC-SIGN with Lex Ab (data not shown). The 
most likely explanation for this difference is that the low-affinity Lex-specific Ab was unable to 
block the high-avidity interaction of cellular multimeric DC-SIGN to the unknown human milk  
component. The DC-SIGN-Fc binding ELISA (Fig. 6.7B) demonstrated a reduction in DC-
SIGN-Fc binding after preincubation of the coated human milk with the Lex-specific Ab but 
again not with the control Ab. These results indicate that Lex is critical for the human milk 
compound that binds to the DC-SIGN molecule. 
 
Not all Lex-containing complexes can inhibit HIV-1 interacting with the DC-SIGN receptor. 
We tested several compounds containing one or more Lex epitopes for inhibitory and DC-SIGN 
binding activity. In the transfer culture assay, Lex coupled to biotinylated polyacrylamide (PAA-
Lex) and Lex-BSA were both able to inhibit DC-SIGN-mediated HIV-1 transfer (Fig. 6.8A). On 
the contrary, both LNFP III, a Lex-containing oligosaccharide present in human milk, and the 
Lex trisaccharide itself were unable to prevent HIV-1 transfer (Fig. 6.8A), even though LNFP III 
has been shown previously to bind DC-SIGN [61]. The compounds were also tested in the 
gp120 bead adhesion assay, but none of the tested compounds were able to block the 
interaction between DC-SIGN and gp120 (data not shown). Most likely, PAA-Lex and Lex-BSA  
are able to block the trimeric gp120 interaction, while binding of DC-SIGN to monomeric gp120 
 
 
Human milk inhibits the transfer of HIV-1 by iDCs and mDCs.  
(A) Both iDCs and mDCs from the same donor were incubated with several dilutions of human milk for 30 minutes 
before addition of LAI (X4). After 2 hours the cells were washed, and LuSIV cells were added; after 24 hours the 
LuSIV cells were washed, and the luciferase activity was determined as described in Methods. The asterisks 
represent statistical differences in infections (P<0.05). (B) After an incubation of iDCs with human milk or PBS, the 
cells were washed and LAI was added. After an incubation of 2 hours, the cells were washed again, and captured 
CA-p24 levels were monitored via ELISA. ** P<0.05 compared with the corresponding control value for both 
experiments. (C) iDCs were incubated with TSM or human milk (1:2) before the binding of AZN-D1, AZN-D2, and 
anti-stalk 4 DC-SIGN-specific Abs were determined. The filled histograms represent the isotype control; the black 
lines represent the Ab binding without human milk preincubation; and the dotted lines represent the Ab binding after 
the cells were incubated with human milk. 
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The major milk proteins are not 
responsible for the inhibitory 
effect of human milk.  
(A and B) Raji-DC-SIGN cells or 
iDCs were incubated with the 
major milk proteins before 
addition of fluorescent gp120-
coated beads; control cells were 
incubated with buffer. To 
determine the specificity of the 
observed binding, the cells were 
incubated with AZN-D1, EGTA, 
and mannan before addition of 
the gp120 beads. The asterisks 
represent P<0.01 compared with 
noninhibitory control. (C) The 
major milk proteins were coated 
on ELISA plates, and DC-SIGN-
Fc binding was measured. To 
determine the specificity of the 
observed binding, the DC-SIGN-
Fc was preincubated with AZN-
D1 and EGTA. * P<0.01 
compared with both the AZN-D1 
and EGTA control. In all 
experiments the major proteins 
were diluted to a 1:20 dilution of 
their physiological concentration 
in human milk. 
 
 
 
 
 
 
 
expressed on the fluorescent beads is still possible. Due to the inability to coat saccharides 
onto plates in the DC-SIGN-Fc binding ELISA, we only tested Lex-BSA and the BSA control. 
Lex-BSA indeed demonstrates binding to DC-SIGN-Fc, whereas BSA showed no binding, 
indicating that the DC-SIGN-Fc binding is Lex specific (Fig. 6.8B). 
 
 
 
Discussion 
 
C-type lectins, such as the DC-SIGN molecule, expressed on DCs have been postulated to 
play an important role in HIV-1 transmission and the establishment of initial HIV-1 infection 
[1;2;4;6;22-25]. The interaction of DC-SIGN with the HIV-1 gp120 surface antigen can result in 
the efficient presentation of the virus to its target cells and can greatly heighten infection and  
virus replication [4;6;22-25]. This mechanism is likely to play a role in MTCT of HIV-1 through 
breastfeeding, since virus transfer is required across a mucosal barrier. Virus present in human 
milk will likely encounter DCs situated at high concentrations within the tonsils, the oesophagus 
[41;42], and the intestines [43] that will thereby aid virus capture and subsequent transfer to 
CD4+ lymphocytes at the site of infection or in localized lymph nodes. In this study we 
demonstrate that human milk has a strong inhibitory effect on the DC-SIGN-mediated transfer 
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Incubation of human milk (1:20) with 
Lex IgM Ab relieves the inhibitory 
properties of human milk on DC-SIGN-
mediated transfer of HIV-1 to CD4+ T 
lymphocytes.  
(A) A 1:200 dilution of human milk was 
incubated alone, with IgM control Ab 
(4,000 ng/ml), or with serial dilutions of 
Lex IgM Ab (4,000 to 32.7 ng/ml) before 
addition of Raji-DC-SIGN cells. LAI was 
added, and following a short incubation, 
the cells were washed, and activated 
CD4+ T lymphocytes were added, with 
CA-p24 values determined at day 7. * 
P<0.05 compared with the Raji-DC-SIGN 
control. (B) Human milk (1:200) was 
coated and preincubated with anti-Lex IgM 
Ab (4,000 ng/ml) or an IgM control Ab 
(4,000 ng/ml) before addition of DC-SIGN-
Fc to determine binding. DC-SIGN-Fc was 
preincubated with AZN-D1 and EGTA to 
determine the specificity of the observed 
binding. ** P<0.01 compared with the 
human milk binding without Ab present. 
 
 
 
 
 
 
virus replication [4;6;22-25]. This mechanism is likely to play a role in MTCT of HIV-1 through 
breastfeeding, since virus transfer is required across a mucosal barrier. Virus present in human 
milk will likely encounter DCs situated at high concentrations within the tonsils, the oesophagus 
[41;42], and the intestines [43] that will thereby aid virus capture and subsequent transfer to 
CD4+ lymphocytes at the site of infection or in localized lymph nodes. In this study we 
demonstrate that human milk has a strong inhibitory effect on the DC-SIGN-mediated transfer 
of HIV-1 to CD4+ T lymphocytes, with R5 and X4 viruses being inhibited to the same extent. A 
component in human milk is interacting with the DC-SIGN molecule that prevents HIV-1 from 
binding to the receptor. We showed that lactoferrin, α-lactalbumin, lysozyme, ß-casein, and 
SLPI were not responsible for the observed inhibition of HIV-1 interaction with DC-SIGN, even 
though these proteins can alter the direct infection of CD4+ T lymphocytes in vitro [44-49]. Our 
results demonstrating that multimeric and protein-associated Lex motifs can mimic the 
inhibitory activity of human milk and that the activity could be alleviated with a mAb recognizing 
the Lex epitope suggest that a Lex component in human milk is providing for the inhibition.  
In the majority of our experiments, we utilized the DC-SIGN-expressing cell line (Raji-DC-
SIGN) and the control Raji cell lacking DC-SIGN in order to demonstrate the DC-SIGN 
specificity of our results [8]. We have also shown that human milk inhibits transfer of HIV-1 by 
both iDCs and mDCs, illustrating the biological relevance of the phenomenon, again with the  
inhibition being due to prevention of binding rather than DC-SIGN downmodulation. The 
expression levels of DC-SIGN have previously been shown to be higher on iDCs than mDCs 
[62]; however, the human milk inhibited viral transfer by both cell types. This result indicates  
that the observed inhibition of mDC-dependent transfer may reflect the ability of human milk to  
block transfer of HIV-1 by other C-type lectins, such as the mannose receptor or the 
unidentified trypsin-resistant receptor [63]. Whether the same Lex-containing compound(s) or 
whether other sugar motifs in human milk can bind to other C-type lectin receptors remains to  
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Multimeric and protein-associated Lex inhibits DC-SIGN-mediated viral transfer.  
(A) Several Lex-containing compounds showed a difference in their ability to block DC-SIGN-dependent transfer of 
HIV-1 to CD4+ T lymphocytes. The Lex trisaccharide, LNFP III, PAA-Lex, Lex-BSA, and control BSA were tested in 
the Raji-DC-SIGN culture transfer assay at concentrations of 10 µg/ml. The inhibition is depicted as a percentage of 
the Raji-DC-SIGN incubated with PBS. (B) Lex-BSA and BSA as a control were coated before addition of DC-SIGN-
Fc to determine the binding. DC-SIGN-Fc was preincubated with AZN-D1and EGTA to determine the specificity of 
the observed binding. * P<0.01 compared with both the AZN-D1 and EGTA control. 
 
 
be determined. We did demonstrate, however, that the binding of HIV-1 to the DC-SIGN 
homologue L-SIGN is not inhibited by human milk. Our result corresponds with the previous 
observation that Lex present in Schistosoma mansoni egg antigens [54] is able to interact with 
DC-SIGN but not with L-SIGN [64], reconfirming Lex as a candidate for the observed inhibition 
of DC-SIGN-mediated transfer of HIV-1.  
PAA-Lex and Lex-BSA successfully inhibited the DC-SIGN-mediated transfer of HIV-1. 
Conversely, both monomeric Lex trisaccharide and LNFP III, a human milk sugar, do not inhibit 
viral transfer. Even though LNFP III has been shown previously to bind to DC-SIGN [61], this 
interaction does not lead to sufficient blocking of the HIV-1 interaction with DC-SIGN nor 
prevent viral transfer to CD4+ T lymphocytes. Multimeric Lex was not able to inhibit gp120-
coated beads binding to cellular DC-SIGN, possibly due to the high avidity of this interaction or 
the difference in interaction of the monomeric expression of gp120 on the fluorescent beads in 
comparison to trimeric expression of gp120 on the HIV-1 particle. The observed difference in 
the ability of Lex Ab to block the inhibitory effect of human milk in the Raji-DC-SIGN transfer 
assay and the ELISA assay is possibly the result of differences in DC-SIGN configuration. On 
the cell surface, DC-SIGN is present as a tetramer, whereas in the DC-SIGN-Fc ELISA, the 
receptor is most likely a monomer or dimer, possibly leading to a weaker interaction. These 
differences in the configurations of the DC-SIGN molecules tested in the different assays 
suggest that caution should be applied when interpreting the results. It has been reported in 
previous studies that the Lex and the gp120 binding sites are distinct but overlapping 
[54;58;65]. An explanation for our observed inhibition by human milk could be that the larger 
compounds block the interaction of gp120 and DC-SIGN through steric hindrance by the larger 
tail. DC-SIGN forms a tetrameric structure on the cell surface [1] which could also cause 
occlusion of the gp120 binding site by interaction of several Lex residues with different 
monomeric DC-SIGN receptors. Most likely the interaction of several Lex motifs with the 
tetrameric DC-SIGN leads to a much stronger interaction of the compound and again prevents 
sufficient binding of gp120 and subsequent viral transfer.  
It has been previously demonstrated that DC-SIGN can interact with an array of other 
pathogens, including hepatitis C [9;10], Ebola [11], cytomegalovirus [12], and Dengue virus 
[13], as well as Mycobacterium [14-16], Leishmania [17;18], Candida albicans [19], and 
Helicobacter pylori [20;21]. Interaction of Lex-containing human milk compounds with DC-SIGN 
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may influence the immune responses mounted in the child to incoming pathogens by 
preventing their interaction with the DCs and thereby prevent the presentation of pathogen-
specific antigens and the subsequent activation of CD4+ T lymphocytes. This may be a 
mechanism whereby levels of immune activation are buffered in a newborn to prevent 
overstimulation of the immune system or to skew specific immune responses in a certain 
direction. Indeed, it has previously been reported that mice immunized intranasally with LNFP 
III-HSA demonstrated a stronger induction of Th2-type immune responses versus Th1 [66]. 
This result corresponds with the fact that Lex-positive Helicobacter pylori interactions with DC-
SIGN can block Th1-induced cell responses, which results in a relative enhancement of the 
Th2 cell response [21], suggesting that Lex compounds can influence the immune responses 
generated and that Lex compounds in human milk can function as immunomodulatory factors. It 
will therefore be interesting to investigate whether breastfed versus bottle-fed infants have 
differences in their immune responses mounted against orally transmitted pathogens. It has 
also been reported that the baseline activation of lymphocytes is higher in bottle-fed than in 
breastfed infants [67]. A number of explanations have been hypothesized, including differences 
in exposure to foreign proteins or a higher variety in intestinal microflora. Another possibility is 
that human milk compounds containing the Lex motif buffers the immune response by binding 
DC-SIGN and that these compounds are absent in formula or cow milk.  
Future work will have to determine the biological significance of the interaction of the Lex-
containing compounds with DC-SIGN with regard to the stimulation of the immune system and 
the relevance for MTCT of HIV-1 and other pathogens. Further identification and 
characterization of the specific Lex-containing compound(s) interacting with DC-SIGN may 
have major implications for the development of antimicrobial agents aiming at preventing HIV-1 
transmission not only through breastfeeding but also through sexual activity. 
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Abstract 
 
Early during infection neutrophils are the most important immune cells that are involved in 
killing of pathogenic bacteria and regulation of innate immune responses at the site of 
infection. It has become clear that neutrophils also modulate adaptive immunity through 
interactions with dendritic cells (DCs) that are pivotal in the induction of T cell responses. Upon 
activation, neutrophils release TNF-α and induce maturation of DCs that enables these 
antigen-presenting cells to stimulate T cell proliferation and to induce T helper 1 polarization. 
DC maturation by neutrophils also requires cellular interactions that are mediated by binding of 
the DC-specific receptor DC-SIGN to Mac-1 on the neutrophil. Here, we demonstrate that also 
CEACAM1 is an important ligand for DC-SIGN on neutrophils. Binding of DC-SIGN to both 
CEACAM1 and Mac-1 is required to establish cellular interactions with neutrophils. DC-SIGN is 
a C-type lectin that has specificity for Lewisx, and we show that DC-SIGN mediates binding to 
CEACAM1 through Lewisx moieties that are specifically expressed on CEACAM1 derived from 
neutrophils. This indicates that glycosylation-driven binding of both Mac-1 and CEACAM1 to 
DC-SIGN is essential for interactions of neutrophils with DCs and enables neutrophils to 
modulate T cell responses through interactions with DCs. 
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Introduction 
 
Neutrophils are important in early immunity to bacterial infection. The early arrival of 
neutrophils at the site of infection depends on their ability to rapidly respond to chemotactic 
stimuli released by bacteria and inflamed epithelium. At the infection site the main function of 
neutrophils involves phagocytosis of bacteria and killing of phagocytized and extracellular 
bacteria by anti-bacterial enzymes and reactive oxygen species [1]. Besides this role in innate 
immune defence, neutrophils have also been implicated in the modulation of adaptive immune 
responses. Through the release of chemokines such as MIP-1α, MIP-3α and MIP-3β and 
chemotactic peptides such as α-defensin neutrophils are able to selectively attract other 
immune cells like T cells, monocytes, macrophages and dendritic cells (DCs) [2-4]. Moreover, 
in mice, effective T-cell responses against Candida albicans, Legionella pneumophila, and 
Helicobacter pylori depend on the presence of neutrophils [5-7]. Depletion of neutrophils 
abolishes polarization of T cells towards T helper 1 (Th1) cells and results in development of 
ineffective Th2 responses [5-7]. Recently, we have shown in humans that neutrophils may 
modulate T-cell responses through interactions with DCs [8]. DCs are antigen-presenting cells 
that play a pivotal role in the induction of T-cell responses, as they capture pathogens in the 
periphery, carry these to the lymph nodes, and present peptides derived from these pathogens 
to T cells [9]. DCs require maturation signals to effectively stimulate T cells. We and others 
have shown that activated neutrophils are able to induce maturation of DCs [8;10]. 
Furthermore, the cross-talk with neutrophils induces DCs to strongly activate T-cell 
proliferation and to instruct Th1 polarization [8]. This indicates that neutrophils may regulate 
adaptive immune responses indirectly through interactions with DCs.  
We have reported previously that the interaction between DCs and neutrophils is mediated by 
DC-SIGN and Mac-1 (CD11b/CD18) [8]. Here, we describe that DC-SIGN not only binds Mac-
1, but also CEACAM1 on neutrophils. Similar to Mac-1, CEACAM1 is a strong ligand of DC-
SIGN, and binding of DC-SIGN to both Mac-1 and CEACAM1 is required to establish cellular 
interactions with neutrophils. DC-SIGN is a C-type lectin, and has specificity for high-mannose 
and Lewisx moieties [11-13]. DC-SIGN mediates interactions of DCs with ICAM-2 on 
endothelial cells and with ICAM-3 on T cells through high-mannose moieties that are 
expressed on these counterstructures [13;14]. In contrast, CEACAM1 has recently been 
described to contain Lewisx moieties on neutrophils [15], and interactions between DC-SIGN 
and neutrophil CEACAM1 are completely mediated by these Lewisx moieties. This indicates 
that interactions of DC-SIGN with Mac-1 and CEACAM1 define a novel pathway of cellular 
adhesion between DCs and neutrophils that may play a crucial role in bridging the innate and 
the adaptive immune response.  
 
 
 
Materials and methods 
 
Antibodies and reagents. 
The following monoclonal antibodies were used: 12A2 (mouse IgG1 isotype control) [16], F3 (mouse 
IgM isotype control, Calbiochem, La Jolla, CA), SPV-L7 (LFA-1) [17], KIM225 (Mac-1, kind gift of M. 
Robinson, Celltech Inc., Slough, UK), CLB-gran/10 (CEACAM1, CEACAM3 and CEACAM6, Sanquin, 
Amsterdam, Netherlands), col-1 (CEACAM3, Beckton Dickinson, San Jose, CA), 9A6 (CEACAM6, 
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Genovac GmbH, Freiburg, Germany), 6H3 (Lewisx, kind gift of B.J. Appelmelk, VU University Medical 
Centre, Amsterdam, Netherlands), AZN-D1 (DC-SIGN) [13] and AZN-D2 (DC-SIGN and L-SIGN) [13]. 
DC-SIGN-Fc consists of the extracellular portion of DC-SIGN (aa residues 64-404) fused at the C 
terminus to the Fc domain of human IgG1 [18]. DC-SIGN-Fc was produced in Chinese hamster ovary 
K1 cells after transfection with the DC-SIGN-Sig-pIgG1-Fc vector (20 µg). We used ICAM-3-Fc (kind gift 
of D.L. Simmons, Celltech Inc., Slough, UK) that contains an Fc-domain of the same isotype as a 
negative control (control-Fc).  
 
Cells. 
Stable transfectants of K562 expressing wildtype or mutant DC-SIGN were obtained by electroporation 
of pRC-CMV-DC-SIGN (400 V, 960 µF) as described [18;19]. EBV-DC-SIGN and EBV-L-SIGN were 
generated by lentiviral transduction of EBV cells by LV-DC-SIGN and LV-L-SIGN, respectively [20]. 
Lipofectamin (Invitrogen, Carlsbad, CA) transfection of CHO cells with pRC-CMV-DC-SIGN was used to 
create CHO-DC-SIGN. Neutrophils were isolated from fresh blood of healthy volunteers. After Ficoll 
gradient centrifugation neutrophils were cleared from contaminating erythrocytes using erylysis buffer 
(155 mM NH4Cl, 10 mM KHCO3, and 0.1 mM EDTA). Isolated neutrophils were over 95% pure (data not 
shown). Immature DCs were cultured from monocytes as described [21;22]. Briefly, monocytes were 
isolated from buffy coats of healthy donors by Ficoll centrifugation and MACS sorting for the monocyte 
marker CD14 (Miltenyi Biotec, Bergisch Gladbach, Germany). Isolated monocytes were cultured for 
seven days on RPMI 1640 10% FCS in the presence of IL-4 (600 U/ml) and GM-CSF (800 U/ml) to 
obtain 95% pure cultures of immature DCs. Immature DCs expressed high levels of DC-SIGN, low 
levels of CD80, CD86 and MHC class II and did not express the DC maturation marker CD83 (data not 
shown).  
 
Immunoblotting. 
Neutrophils were lyzed in lysis buffer (1% Triton-X-100, 10 mM TEA pH 8.2, 150 mM NaCl, 1 mM MgCl2, 
and 1 mM CaCl2) containing a cocktail of EDTA-free protease inhibitors (Roche Diagnostics, Penzberg, 
Germany) for 1h at 4°C. CEACAM1 and Mac-1 were immu noprecipitated from neutrophil lysates with 
anti-CEACAM1 and anti-Mac-1 antibodies coated onto protA sepharose beads (CL-4B, Pharmacia, 
Uppsala, Sweden). Immunoprecipitated CEACAM1 was run on SDS-PAGE (7% gel, reduced 
conditions), transferred onto blot, and stained with DC-SIGN-Fc and secondary peroxidase-conjugated 
goat anti-human antibodies (Jackson ImmunoResearch Lab. Inc., West Grove, PA) to determine DC-
SIGN-Fc adhesion to CEACAM1 and Mac-1. Similarly, DC-SIGN ligands were immunoprecipitated with 
DC-SIGN-Fc coated onto protA sepharose beads (CL-4B, Pharmacia), and immunoblotted with anti-
CEACAM1 and anti-Mac-1 antibodies and secondary peroxidase-conjugated goat anti-mouse antibodies 
(Jackson ImmunoResearch Lab. Inc.).  
 
ELISA. 
The ELISA to analyze DC-SIGN-Fc binding to native ligands from neutrophils was performed as 
described [8]. Briefly, goat anti-mouse antibodies (4 µg/ml, Jackson Immunoresearch Lab. Inc.) were 
coated onto ELISA plates (NUNC maxisorp, Nalge Nunc Int., Rochester, NY) for 1h at 37°C followed by 
incubation with TSM (20 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 mM CaCl2, and 1 mM MgCl2) 1% bovine 
serum albumin (BSA) for 30min at 37°C. Next, the EL ISA plate was incubated for 1h at 37°C with mouse 
antibodies (1 µg/ml) directed against the indicated antigens, washed, and incubated for 18h at 4°C with 
neutrophil lysate (20×106cells/ml) to allow capture of neutrophil antigens. DC-SIGN-Fc (1 µg/ml) was 
added and allowed to bind for 2h at room temperature. Unbound DC-SIGN-Fc was washed away and 
adhesion was determined using a peroxidase-conjugated goat anti-human Fc antibody (Jackson 
Immunoresearch Lab. Inc.) that was incubated for 30min at room temperature. Similarly, the expression 
of Lewisx on neutrophil-derived antigens was determined using anti-Lewisx antibodies and secondary 
goat anti-mouse IgM antibodies (Nordic Immunologic Laboratories, Tilburg, Netherlands).  
 
Fluorescent bead adhesion. 
Neutrophil-derived DC-SIGN ligands were coated onto carboxylate-modified TransFluoSpheres 
(488/645 nm, 1.0 µm, Molecular Probes, Eugene, OR) as described previously [8;23]. Briefly, 
streptavidin was covalently coupled onto TransFluoSpheres as described by manufacturer. To enable 
coupling of DC-SIGN ligands from neutrophils, streptavidin-coated beads were allowed to bind to 
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biotinylated goat anti-mouse Fc Fab2 fragments (10 µg/ml, Jackson ImmunoResearch Lab. Inc.) for 2h 
at 37°C in PBS 0.5% BSA. Subsequently, beads were w ashed, incubated for 18h at 4°C with mouse 
antibodies directed against CEACAM1 or Mac-1, washed again, and incubated for 48h at 4°C with 
neutrophil lysate (20×106 cells/ml) to capture CEACAM1 or Mac-1 onto the beads. After preincubation 
with blocking anti-DC-SIGN and anti-L-SIGN antibodies (20 µg/ml), mannan (50 µg/ml) or EGTA (10  
mM) for 10min at room temperature in TSM 0.5% BSA, cells were incubated with ligand-coated beads 
for 45 min at 37°C. After washing, bead adhesion to  the cells was analyzed by flow cytometry (FACS 
Calibur, Beckton Dickinson, San Jose, CA). 
  
Cell-cell adhesion. 
To examine cellular interactions of DC-SIGN with neutrophils CHO and CHO-DC-SIGN were grown 
overnight to confluent cultures in flat-bottom 96 well plates. Neutrophils were labelled with the green 
fluorescent dye Calcein-AM (1 µM, Molecular Probes) for 15min at 37°C and incubate d with mock and 
DC-SIGN transfected CHO cells in TSM 0.5% BSA for 2h at 37°C. To determine specific adhesion the 
CHO transfectants were preincubated with anti-DC-SIGN, anti-Mac-1 or anti-CEACAM1 antibodies (20 
µg/ml) for 30 min at 37°C. Unbound neutrophils were washed away, and remaining cells were lyzed in 
lysis buffer (50 mM Tris-HCl, pH 8.0, and 0.1% SDS). Cell-cell adhesion was measured by fluorimetry of 
cell lysates at 488 nm (Fluostar Galaxy, BMG Labtechnologies Inc., Durham, NC). Cell-cell adhesion 
was calculated as the percentage of total added neutrophils that was considered as 100% adhesion. 
  
Co-culture experiments. 
Neutrophils were pulsed for 1h with LPS (100 ng/ml), rigorously washed, and then incubated with 
allogenic immature DCs at a ratio of 3:1 for 18h at 37°C in RPMI 1640 10% FCS. Maturation of DCs was 
assessed by flow cytometry analysis of the expression of the DC maturation marker CD83, and analysis 
of the production of IL-12p40 in the supernatant using sandwich ELISA according to the manufacturer’s 
protocol (Biosource, Nivelles, Belgium).  
 
 
 
 
 
CEACAM1 is an alternative 
DC-SIGN ligand on 
neutrophils.  
(A) Neutrophil lysate was 
immunoblotted with control-Fc, 
DC-SIGN-Fc, mouse IgG1 
isotype control antibodies, anti-
CEACAM1, -3 and -6 antibodies 
(on immunoblot the anti-
CEACAM1, -3 and -6 specific 
antibody CLB-gran/10 only 
recognizes CEACAM1 [53]), 
anti-Mac-1 antibodies, mouse 
IgM isotype control antibodies 
and anti-Lewisx antibodies. (B) 
Neutrophil lysate was 
immunoprecipitated using 
mouse IgG1 isotype control 
antibodies, anti-CEACAM1, -3 
and -6 antibodies and anti-Mac-
1 antibodies, and immuno-
blotted with DC-SIGN-Fc. (C) 
Immunoblots with mouse IgG1 
isotype control antibodies, anti-
CEACAM1, -3 and -6 antibodies 
and anti-Mac-1 antibodies were 
performed on neutrophil lysate 
that had been immuno-
precipitated using control-Fc 
and DC-SIGN-Fc. 
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Results 
 
DC-SIGN binds Mac-1 and CEACAM1 on neutrophils. 
Recently, we have demonstrated that DCs interact with neutrophils through binding of DC-
SIGN to Mac-1, and that the DC-neutrophil interaction results in maturation of DCs and 
predisposes DCs to DC1 that induce Th1 responses [8]. DC-SIGN has specificity for Lewisx 
moieties that are expressed at high levels on neutrophils [11;24]. These Lewisx structures are 
present on few proteins on neutrophils, in particular on proteins of 100 and 160 kD (Fig. 7.1A). 
Mac-1 is a carrier molecule of Lewisx moieties on neutrophils and contains Lewisx on both the  
α-chain (CD11b) of 160 kD and the β-chain (CD18) of 100kD [25;26]. We have shown before  
that binding of DC-SIGN to neutrophil Mac-1 is mediated in part through its Lewisx moieties [8]. 
Neutrophils express Lewisx not only on Mac-1 but also on CEACAM1 [15;26]. Therefore, we 
investigated whether CEACAM1 is also an important ligand of DC-SIGN on neutrophils. We 
have shown that DC-SIGN binds a 160 kD ligand on neutrophils [8], of which the molecular 
weight not only corresponds to that of the previously identified DC-SIGN-ligand Mac-1, but also 
to that of the similarly-sized glycoprotein CEACAM1 (Fig. 7.1A). Although both the α- and β-
chain of Mac-1 express Lewisx, DC-SIGN specifically binds the α-chain of Mac-1, suggesting 
that expression of Lewisx does not fully predict binding of DC-SIGN [8]. To investigate whether 
DC-SIGN binds both CEACAM1 and Mac-1, we immunoprecipitated these proteins from 
neutrophils using anti-CEACAM1 and anti-Mac-1 antibodies and analyzed binding to DC-
SIGN-Fc on blot (Fig. 7.1B). DC-SIGN bound to CEACAM1 as well as to the α-chain, but not to 
the β-chain, of Mac-1 (Fig. 7.1B). The anti-CEACAM1 antibody also recognizes the 
homologous molecules CEACAM3 and -6 of 30 and 90 kD respectively, but they are not bound  
by DC-SIGN (Fig. 7.1B). Thus, both CEACAM1 and Mac-1 are ligands of DC-SIGN on  
neutrophils, and they may compete for binding to DC-SIGN. To examine whether DC-SIGN 
binds both ligands simultaneously, neutrophil lysate was immunoprecipitated with DC-SIGN-
Fc, and analyzed on immunoblot for the presence of CEACAM1 and Mac-1. We were able to 
detect CEACAM1 as well as Mac-1 on immunoblot (Fig. 7.1C), demonstrating that under these 
settings both DC-SIGN ligands do not outcompete each other. This indicates that interactions 
between neutrophils and DCs require binding of DC-SIGN to both CEACAM1 and Mac-1.  
 
CEACAM1 interacts with DC-SIGN through Lewisx moieties. 
We have recently developed an ELISA-based bindings assay that enables rapid screening of 
DC-SIGN-Fc binding to multiple potential ligands isolated from a native source [8]. Neutrophils 
express CEACAM1, -3, -6 and -8 of the immunoglobulin family of CEA-related proteins [27]. 
We were able to detect CEACAM1, -3 and -6 in neutrophil lysate using sandwich ELISA (data 
not shown). Capture of CEACAM1, -3 and -6 from neutrophil lysate and detection with DC-
SIGN-Fc showed that DC-SIGN binds CEACAM1 and possibly to the homologous molecules 
CEACAM3 and -6 (Fig. 7.2A). Binding of DC-SIGN-Fc was not observed to either CEACAM3 
or -6 that was captured from neutrophil lysate using specific antibodies (Fig. 7.2A), 
demonstrating that only CEACAM1 is a ligand of DC-SIGN. The carbohydrate recognition 
domain of DC-SIGN has specificity for high-mannose moieties and Lewis antigens [11;12]. As 
has been reported, CEACAM1 from neutrophils contains Lewisx moieties [15;26]. To examine 
the contribution of Lewisx moieties on CEACAM1 in binding to DC-SIGN, CEACAM1 was 
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DC-SIGN binds Lewisx on neutrophil 
CEACAM1.  
(A) Binding of DC-SIGN-Fc to neutrophil-
derived CEACAM1, -3 and -6 was 
analyzed using ELISA. Results are 
representative of three independent 
experiments. (B) Expression of Lewisx 
was measured using ELISA on neutrophil-
derived LFA-1 (negative control) and 
CEACAM1, -3 and -6 that was left 
untreated, or that had been treated after 
capture onto ELISA plates for three days 
with enzyme buffer (50 mM sodium 
phosphate buffer pH 5.0) in the presence 
or absence of α1-3,4-fucosidase (from 
Xanthomonas, Calbiochem, La Jolla, CA) 
at 37°C. Similar results were obtained in 
three independent experiments. (C) 
CEACAM1, -3 and -6 was incubated for 
three days in ELISA buffer, or in enzyme 
buffer with and without α1-3,4-fucosidase 
at 37°C, and analyzed for binding to DC-
SIGN-Fc using ELISA. Experiment was 
performed three times with similar results. 
(D) LFA-1 and CEACAM1, -3 and -6 were 
captured from neutrophil lysate, incubated 
with IgM isotype control antibodies or 
blocking anti-Lewisx antibodies, and 
binding to DC-SIGN-Fc was examined 
using ELISA. Three independent 
experiments with similar results were 
performed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
treated with α1-3,4-fucosidase that specifically removes the fucose moiety from Lewisx that is 
essential for DC-SIGN binding [28]. Sandwich ELISA for CEACAM1 demonstrated that 
treatment with α1-3,4-fucosidase did not disrupt integrity of CEACAM1 (data not shown). The 
enzymatic treatment removed the Lewisx epitope from CEACAM1 (Fig. 7.2B), and completely 
abrogated binding of DC-SIGN-Fc to neutrophil-derived CEACAM1, demonstrating that Lewisx 
moieties mediate binding of DC-SIGN to CEACAM1 on neutrophils (Fig. 7.2C). In addition, 
blocking anti-Lewisx antibodies inhibited binding of DC-SIGN-Fc to CEACAM1 from 
neutrophils, confirming that Lewisx moieties on CEACAM1 are essential for DC-SIGN binding 
(Fig. 7.2D). In contrast to DC-SIGN binding to neutrophil CEACAM1, binding of DC-SIGN to 
Mac-1 on neutrophils was only partially dependent on Lewisx [8].  
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T cell-derived CEACAM1 
does not bind DC-SIGN.  
(A and B) Peripheral 
blood lymphocytes (PBLs) 
were activated with IL-2 
(400 U/ml) and PHA (0.2 
µg/ml) and expression of 
isotype controls (thin 
lines) and (A) CEACAM-1 
(thick lines) and (B) 
Lewisx (thick lines) was 
determined at day 0, 2, 5 
and 8 using FACS 
analysis. (C) Binding of 
DC-SIGN-Fc to CEACAM-
1, -3 and/or -6 derived 
from neutrophils and 
CEACAM1 from PBLs 
activated for 0, 2, 5 and 8 
days with IL-2 and PHA 
was measured using 
ELISA. Experiment was 
performed three times 
with similar results.  
 
 
 
Cell-specific glycosylation of CEACAM1 regulates binding of DC-SIGN. 
In contrast to CEACAM3 and -6, CEACAM1 is not only expressed on neutrophils, but also on 
activated T cells [29;30]. However, CEACAM1 on activated T cells is differently glycosylated 
and does not contain Lewisx [30]. Indeed, activation of T cells with PHA and IL-2 induced 
expression of CEACAM1 on T cells at day 5 and 8 after stimulation (Fig. 7.3A), but did not 
upregulate Lewisx expression on these T cells (Fig. 7.3B). We were able to capture and detect 
CEACAM1 from neutrophils and T cells using sandwich ELISA (data not shown). In contrast to 
neutrophil-derived CEACAM1, CEACAM1 from activated T cells did not bind to DC-SIGN, 
which correlates with the expression levels of Lewisx on CEACAM1 (Fig. 7.3C). Thus, 
CEACAM1 is differently glycosylated on neutrophils and T cells, and the glycosylation pattern 
of CEACAM1 on these cell types regulates binding of DC-SIGN.  
 
Cellular DC-SIGN but not L-SIGN binds neutrophil-derived CEACAM1. 
DC-SIGN is present at high levels on monocyte-derived immature DCs [13]. On these cells, 
DC-SIGN is the dominant receptor that binds glycoconjugates of Lewisx, and Lewisx-
expressing pathogens such as Schistosoma mansoni and Helicobacter pylori [11;31]. Since 
Lewisx on CEACAM1 mediates binding to DC-SIGN, we investigated the adhesion of immature  
DCs to neutrophil CEACAM1. Therefore, we captured CEACAM1 from neutrophils onto  
fluorescent beads and analyzed binding of these beads to immature DCs. The antibody used  
to capture CEACAM1 onto the beads also recognizes CEACAM3 and -6, but these molecules 
do not interact with DC-SIGN (Fig. 7.2A). Monocyte-derived immature DCs bound neutrophil  
CEACAM1, and anti-DC-SIGN antibodies, the polysaccharide mannan, and the Ca2+ chelator 
EGTA blocked adhesion, demonstrating that these cells use DC-SIGN as an adhesion 
receptor for neutrophil CEACAM1 (Fig. 7.4A). The C-type lectin domain of DC-SIGN is 
involved in binding of neutrophil CEACAM1, since mutation of essential amino acids within this 
domain that mediate ligand binding and positioning of the Ca2+ ions abrogate adhesion of  
neutrophil CEACAM1 to DC-SIGN (Fig. 7.4B) [12;18]. L-SIGN (DC-SIGNR) is a close 
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CEACAM1 is recognized by cellular DC-SIGN, but not by cellular L-SIGN.  
(A) Neutrophil-derived CEACAM1, -3 and -6 was captured onto fluorescent beads, and the percentage of immature 
DCs that bound one or multiple beads was examined using FACS analysis. Specificity of adhesion was determined 
using isotype control antibodies, anti-DC-SIGN antibodies, mannan and EGTA. Similar results were obtained in 
three independent experiments. (B) Fluorescent beads coated with neutrophil CEACAM-1, -3 and -6 were incubated 
with mock-transfected K562 cells and with K562 cells transfected with wildtype or mutant DC-SIGN containing 
mutations in the C-type lectin domain, and adhesion was measured using FACS analysis. Results are 
representative of three independent experiments. (C) Adhesion of beads coated with Mac-1 or CEACAM-1, -3 and -
6 from neutrophils to EBV cells transduced with DC-SIGN or L-SIGN was analyzed using FACS. Experiment was 
performed three times with similar results. 
 
 
homologue of DC-SIGN that is not expressed on DCs, but on endothelial cells in liver and 
lymph node [16;32]. Although the binding specificities of DC-SIGN and L-SIGN are highly 
similar, Lewisx moieties are bound by DC-SIGN, but not by L-SIGN [33;34]. Since binding of 
neutrophil-derived Mac-1 and CEACAM1 to DC-SIGN is mediated by Lewisx, we analyzed 
adhesion of these proteins to L-SIGN. Therefore, we coated Mac-1 and CEACAM1 from 
neutrophils onto fluorescent beads, and measured adhesion of these beads to EBV-DC-SIGN 
and EBV-L-SIGN by FACS analysis. Neutrophil Mac-1 bound to DC-SIGN as well as L-SIGN, 
although adhesion of Mac-1 to L-SIGN was reduced compared to DC-SIGN, whereas 
neutrophil CEACAM1 bound to DC-SIGN but not to L-SIGN (Fig. 7.4C). This corresponds with 
the partial Lewisx-dependency of DC-SIGN binding to Mac-1 and the complete Lewisx-
dependency of DC-SIGN binding to CEACAM1 [8], and indicates that Mac-1 contains glycans 
other than Lewisx that are involved in binding to L-SIGN and DC-SIGN.  
 
DC-SIGN mediates cellular interactions with resting and activated neutrophils through Mac-1 
and CEACAM-1. 
Neutrophil activation induces degranulation, and this results in the release of anti-microbial 
components and the upregulation of membrane molecules. The expression levels of 
CEACAM1, -3 and/or -6 and Mac-1, but not of LFA-1 are increased on neutrophils that are 
activated with both LPS and FMLP (Fig. 7.5A). This suggests that activated neutrophils bind 
stronger to DC-SIGN than resting neutrophils. Indeed, binding of DC-SIGN-Fc is increased to 
LPS- and FMLP-activated neutrophils compared to resting neutrophils (Fig. 7.5B). Previously, 
we have shown that DC-SIGN mediates cellular interactions between immature DCs and  
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CEACAM1 and Mac-1 on resting and activated neutrophils are involved in cellular interactions with DC-
SIGN.  
(A) Resting neutrophils and activated neutrophils that were incubated for 1h with LPS and in the final 15min with 
FMLP at 37°C were analyzed on FACS for expression o f isotype control (thin line), LFA-1, Mac-1, or CEACAM-1, -3 
and -6 (thick line). Insets represent mean fluorescence intensity. (B) Binding of DC-SIGN-Fc to resting and activated 
neutrophils was examined using FACS analysis (thick line). Specificity of binding was determined using anti-DC-
SIGN antibodies (thin line). Insets represent mean fluorescence intensity. (C) CHO and CHO-DC-SIGN cells were 
incubated with Calcein-AM labelled resting or activated neutrophils, and cellular adhesion was examined after 
washing and cell lysis using fluorimetry. Specificity of adhesion was determined using isotype control antibodies and 
blocking antibodies against DC-SIGN, CEACAM1, -3 and -6, or Mac-1. The experiment was performed in triplicate 
three times with similar results. Error bars represent standard error of the mean of triplicates. (D and E) DCs were 
co-cultured with activated neutrophils during 18h to investigate neutrophil-induced DC maturation. (D) Expression of 
the DC maturation marker CD83 was examined using FACS analysis and (E) production of the cytokine IL-12p40 
was analyzed within the supernatants using sandwich ELISA. Specificity of the interaction between DCs and 
neutrophils was determined with blocking antibodies against DC-SIGN, CEACAM-1, -3 and -6, or Mac-1. Similar 
results were obtained in three independent experiments. Error bars represent standard error of the mean of 
triplicates. 
 
 
neutrophils [8]. To examine whether binding of DC-SIGN to both Mac-1 and CEACAM1 was 
required to support cellular interactions with neutrophils, we incubated neutrophils with CHO 
transfectants expressing DC-SIGN, and analyzed adhesion in the absence and presence of 
blocking antibodies. In contrast to the parental CHO cells, DC-SIGN-expressing CHO 
transfectants strongly interacted with both resting and activated neutrophils (Fig. 7.5C). 
Although DC-SIGN-Fc bound stronger to activated than to resting neutrophils, activation of 
neutrophils did not further enhance binding of neutrophils to CHO-DC-SIGN (Fig. 7.5C). 
Adhesion was inhibited in the presence of blocking anti-DC-SIGN antibodies, demonstrating 
that DC-SIGN mediated the cellular interaction with neutrophils (Fig. 7.5C). Preincubation with 
both anti-Mac-1 and anti-CEACAM1, -3 and -6 antibodies strongly blocked neutrophil adhesion 
to CHO-DC-SIGN, in contrast to preincubation with either anti-Mac-1 or anti-CEACAM1, -3 and 
-6 antibodies (Fig. 7.5C). Thus, binding to both Mac-1 and CEACAM1 is required for DC-SIGN  
to mediate cellular interactions with neutrophils. Since we have observed simultaneous binding  
of the antibodies and DC-SIGN to Mac-1 and CEACAM1 in ELISA (Fig. 7.2A), it is unlikely that 
they recognize the same epitope. This indicates that the inhibition of the anti-Mac-1 and anti-
CEACAM1, -3 and -6 antibodies in cellular adhesion is through steric hindrance. Activated but 
not resting neutrophils induce upregulation of the DC maturation marker CD83 and production 
of IL-12p40 by DCs through DC-SIGN-dependent cellular interactions (Fig. 7.5D and E) [8]. 
We investigated whether neutrophil-induced DC maturation required binding of DC-SIGN to 
both Mac-1 and CEACAM1 using blocking antibodies against these DC-SIGN ligands. 
Surprisingly, neutrophil-induced upregulation of CD83 on DCs was not inhibited with anti-Mac-
1 and anti-CEACAM1, -3 and -6 antibodies (Fig. 7.5D). In contrast, neutrophil-induced IL-
12p40 release by DCs was sensitive to anti-Mac-1, but not anti-CEACAM1, -3 and -6 
antibodies (Fig. 7.5E). This may indicate that binding of DC-SIGN to Mac-1 and CEACAM1 
does not play a role in the induction of DC maturation by neutrophils, and that DC-SIGN-Mac-1 
interactions are more important for neutrophils than DC-SIGN-CEACAM1 interactions to 
induce IL-12p40 release by DCs.  
 
 
 
Discussion 
 
Previously, we have shown that DCs interact with neutrophils through binding of DC-SIGN to 
Mac-1. The interaction results in maturation of DCs and primes these DCs to induce strong T-
cell responses of the T helper 1 type. Here, we have identified CEACAM1 as an alternative 
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ligand of DC-SIGN on neutrophils. Both CEACAM1 and Mac-1 are essential ligands on 
neutrophils for DC-SIGN to establish cellular interactions. DC-SIGN binds neutrophil-derived 
CEACAM1 through Lewisx moieties, but not high-mannose moieties. In contrast to DC-SIGN, 
the homologous molecule L-SIGN does not bind to CEACAM1 and poorly to Mac-1.  
Neutrophils have a unique glycosylation pattern, and in contrast to other leukocytes, express 
non-sialylated Lewisx carbohydrates on the cell surface [24]. Little is known on the regulation of 
this, but the differential expression of fucosyltransferases likely plays a role. These enzymes 
incorporate a fucose through α3-linkage on the N-acetyl-glucosamine moiety of a non-
sialylated lactosamine unit to form a Lewisx glycan. Neutrophils express high levels of Lewisx, 
but only few proteins on neutrophils are carrier molecules of Lewisx, and these include Mac-1 
and CEACAM1 [15;25;26]. Currently, it is unknown what determines that particularly 
CEACAM1 and Mac-1 on neutrophils express Lewisx epitopes. Neutrophils express the 
fucosyltransferases 4 and 9 that may be involved in Lewisx synthesis on neutrophil proteins 
[35], but future research is required to determine whether they are involved in the formation of 
Lewisx on CEACAM1 and Mac-1. Previously, we have described that the neutrophil-specific 
glycosylation of Mac-1 enables DC-SIGN to bind Mac-1 on neutrophils, but not on other cells 
[8]. Similar to Mac-1, CEACAM1 has a broad tissue expression and has been described on 
other leukocytes besides neutrophils such as B cells, a subset of NK cells and IL-2 activated T 
cells [30]. In contrast to CEACAM1 on neutrophils, DC-SIGN did not bind to CEACAM1 derived 
from PHA- and IL-2-activated T cells. This supports that glycosylation of CEACAM1 is cell-
specifically regulated, and that expression of Lewisx on neutrophils but not on activated T cells 
enables binding of DC-SIGN. Indeed, inhibition with fucosidase treatment and anti-Lewisx 
antibodies showed that binding of DC-SIGN to neutrophil CEACAM1 critically depended on 
Lewisx moieties. Thus, binding of DC-SIGN to neutrophil-specific glycosylation of CEACAM1 
may contribute together with DC-SIGN-Mac-1 interactions to cellular adhesion of immature 
DCs and neutrophils to enable cross-talk between the cells.  
CEACAM1 belongs to a small subfamily of immunoglobulins that in humans consists of 
CEACAM1 to -8 and 11 pregnancy specific glycoproteins. Neutrophils express the CEACAM1 
homologues CEACAM3, -6 and -8 besides CEACAM1 [27]. Consistent with the absence of the 
DC-SIGN adhesion determinant Lewisx on these molecules [36], DC-SIGN did not bind to 
CEACAM1 homologues. Carcinoembryonic antigen (CEA) is a homologue of CEACAM1 that is 
not expressed on neutrophils, but on normal colon epithelium and has retained or enhanced 
expression on colorectal cancer cells [37]. Glycosylation of CEA is distinct on normal and 
tumour colon epithelium, and the expression of Lewisx and Lewisy on colorectal cancer is 
increased compared to normal colon epithelium [38-41]. Consistent with its carbohydrate 
specificity, DC-SIGN binds to CEA from normal but not tumour colon epithelium [42]. Thus, 
glycosylation modifications that result in acquisition of Lewisx and Lewisy antigens regulate 
binding of DC-SIGN to CEACAM1 and homologues of CEACAM1.  
Neutrophils induce DC maturation through DC-SIGN-dependent interactions with immature 
DCs and the release of TNF-α. DC-SIGN may establish a cellular contact zone or synapse 
between neutrophils and DCs through interactions with Mac-1 and CEACAM1 that enable 
efficient targeting of the DC maturation-inducing factor TNF-α to DCs. [8]. We observed that 
binding to Mac-1 and CEACAM1 is required for DC-SIGN to mediate cellular interactions with 
neutrophils, indicating that these DC-SIGN ligands are involved in the induction of DC 
maturation by neutrophils. However, anti-Mac-1 and anti-CEACAM1 antibodies did not block 
DC maturation, and anti-Mac-1 antibodies, but not anti-CEACAM1 antibodies, inhibited IL-
12p40 release by DCs. Conclusions from these functional experiments should be drawn with 
caution, since anti-CEACAM1 and anti-Mac-1 antibodies may induce signalling and activate 
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neutrophils to release DC maturation factors such as TNF-α. Indeed, CEACAM1 has been 
implicated in neutrophil activation. Although CEACAM1 contains a complete inhibitory ITIM 
motif, and associates with the phosphatases SHP-1 and SHP-2 in epithelial tumour cells [43], it 
associates with the protein tyrosine kinases lyn and hck in neutrophils [44]. Antibodies that 
target CEACAM1 potentiate the oxidative burst of neutrophils in response to FMLP [45], induce 
degranulation of secondary granules containing lactoferrin [46], increase LFA-1-mediated 
adhesion of neutrophils to endothelium, and trigger upregulation of Mac-1 and shedding of L-
selectin [47]. Similarly, galectin-3 has been shown to bind CEACAM1 and to enhance the 
oxidative burst in FMLP-activated neutrophils [48]. Galectin-3 is a C-type lectin that is released 
by macrophages under inflammatory conditions, and in contrast to DC-SIGN has high affinity 
for β-galactoside in lactosamine glycans. This may indicate that cross-talk between neutrophils 
and DCs is bi-directional, and that DC-SIGN is involved in the induction of neutrophil 
activation. However, we did not observe that DC-SIGN triggered stimulation of neutrophils that 
results in production of oxygen radicals or degranulation (data not shown). This may be 
explained by binding of DC-SIGN to Lewisx on CEACAM1 that is a different epitope than those 
recognized by anti-CEACAM1 antibodies or galectin-3. During infection, neutrophils are likely 
present prior to the arrival of DCs, indicating that activation of neutrophils by inflammatory 
mediators or pathogenic stimuli is more important than activation by DCs. DC-SIGN not only 
establishes cellular interactions with resting but also with activated neutrophils. Mac-1 and 
CEACAM1 are upregulated upon activation of neutrophils, and this results in stronger binding 
of DC-SIGN to activated than to resting neutrophils. Thus, DC-SIGN may not be involved in 
activation of neutrophils, but perhaps it plays a role in regulation of later events such as 
neutrophil apoptosis, cytokine and chemokine production by neutrophils, and differentiation of 
neutrophils into DCs.  
Neutrophils are very efficient in degrading internalized antigens in contrast to DCs that keep 
antigens intact for prolonged periods in endocytic vesicles [49]. The DC-SIGN-CEACAM1 
mediated interaction may enable DCs to transfer captured bacteria to neutrophils, which would 
facilitate efficient internalization and destruction of the bacteria. Indications that neutrophils 
phagocytize bacteria tethered to other cells have been found in rat liver, in which it was shown 
that intravenously administered Listeria monocytogenes were initially bound to Kupffer cells, 
and thereafter accumulated within neutrophils [50]. Phagocytosis and processing of pathogens 
by neutrophils may provide a rich source of pathogen-derived peptides that enables DCs to 
specifically activate pathogen-specific T cells. Indeed, some evidence indicates that antigens 
that are phagocytized and processed by neutrophils are transferred to DCs for presentation to 
T cells [51;52]. Here, we have established CEACAM1 as a novel ligand of DC-SIGN that 
besides Mac-1 may be involved in interactions between neutrophils and DCs to enable cross-
talk between the cells. It will be interesting to examine whether interactions of CEACAM1 and 
Mac-1 with DC-SIGN play a role in antigen transfer from DCs to neutrophils and vice versa. 
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DC-SIGN mediates dendritic cell (DC)-PMN interactions by binding Mac-1 and CEACAM1 on 
PMN [1-3]. PMN adherence to DC-SIGN-positive cells could be blocked with anti-Mac-1 and 
with anti-CEACAM1 antibodies (Fig. 7.5C), indicating that both Mac-1 and CEACAM1 
interactions with DC-SIGN participate in the adherence of PMN to DC-SIGN. DC-SIGN 
recognizes Lewisx (Lex) and Ley moieties on Mac-1 and Lex on CEACAM1 (Fig. 7.2C, [1;3]). 
The DC-SIGN homologue L-SIGN also binds Mac-1 isolated from PMN, but does not interact 
with PMN derived CEACAM-1 (Fig. 7.4C). This discrepancy is due to the lack of Lex 
recognition by L-SIGN [4].  
Since L-SIGN only binds PMN Mac-1 and not CEACAM1, we questioned whether PMN could 
adhere to L-SIGN-positive cells. Therefore we performed a cell-cell based adhesion assay in 
which PMN were allowed to adhere to a monolayer of L-SIGN-positive cells. PMN adhered 
strongly to L-SIGN-positive cells. This interaction was L-SIGN specific since the interaction 
was specifically blocked by incubating the L-SIGN-positive cells with anti-L-SIGN antibodies or 
mannan (Fig. 7.6A). This indicates that Mac-1 on PMN is sufficient for adherence of PMN to L-
SIGN-positive cells under static conditions.  
In vivo, PMN travel in the blood stream and can encounter L-SIGN-positive sinusoidal  
 
 
L-SIGN mediates PMN adherence and rolling under flow 
conditions.  
(A) Cell-cell interactions L-SIGN transfected cells and PMN. 
Fluorescently labelled PMN were added to CHO-L-SIGN and 
mock-transduced CHO cells, and cell adhesion was measured 
after several washes. Binding specificity was confirmed using 
L-SIGN specific antibodies (20 µg/ml, dark grey bars), isotype 
control antibodies (white bars), and mannan (0.5 mg/ml, light 
grey bars). Error bars represent standard deviations (n=3). 
One representative experiment out of three is shown. (B-D) L-
SIGN mediates tethering and rolling of PMN under flow 
conditions. CHO-L-SIGN and mock transduced CHO cells 
were cultured on glass cover slides and placed in a laminar 
flow chamber. PMN were perfused through the chamber and 
adhesion (B) and rolling (C, D) of PMN was measured. 
Specificity of L-SIGN-PMN interactions was determined by 
preincubating CHO-L-SIGN and mock transduced CHO cells 
with anti-L-SIGN antibodies (40 µg/ml, grey bars) or isotype 
control antibodies (white bars). Error bars represent standard 
deviations (n=3). One representative experiment out of two is 
shown. 
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endothelial cells in the liver [5]. Under these conditions L-SIGN-PMN interactions have to resist 
shear stress induced by the blood stream, although the blood flow in the sinusoids is low. It 
has been demonstrated previously that DC-SIGN on DCs interacts with ICAM-2 and this 
interaction is strong enough to mediate adherence and rolling under shear stress [6]. This DC-
SIGN-ICAM-2 interaction is involved in trans-endothelial cell migration of DCs [6]. However, 
DC-SIGN-ICAM3 interactions are not strong enough to induce adherence under shear stress 
[6]. To investigate PMN-L-SIGN interactions under shear stress, we used a flow chamber in 
which a coverslip with a confluent monolayer of CHO-L-SIGN was placed. PMN were perfused 
into the chamber and adhesion to the cells was measured. Under flow conditions PMN 
adhered significantly more to L-SIGN-positive cells than to L-SIGN-negative cells (Figure 7.6B). 
The adherence could specifically be blocked with anti-L-SIGN antibodies but not with isotype 
control antibodies (Figure 7.6B). Furthermore we investigated rolling of PMN under these 
conditions. A significant greater number of PMN were rolling over L-SIGN-positive cells than 
over L-SIGN-negative CHO cells (Figure 7.6C). This rolling was L-SIGN dependent since 
antibodies against L-SIGN reduced the number of rolling cells to back ground levels (Figure 
7.6C). The higher number of rolling PMN was not just a reflection of the higher number of PMN 
adhering to L-SIGN-positive cells, since also the percentage of rolling PMN was increased 
compared to the percentage of PMN rolling over mock-transduced CHO cells (Figure 7.6D). 
These data indicate that L-SIGN strongly interacts with PMN, and PMN could adhere to L-
SIGN-positive LSECs in the liver. L-SIGN has also been implicated in the binding of 
hepatocytes [Chapter2] and Kupffer cells [Chapter 8], and therefore might act as a key player 
in cellular interactions in the liver. 
During inflammation PMN rapidly sequester in the liver, even when the infection is outside the 
liver [7]. Binding of PMN to L-SIGN-positive cells in the liver could therefore result in the ending  
of the inflammation by the clearance of PMN. During bacterial infections, PMN are the main 
inducers of hepatic injury [8]. In this process the binding of PMN to L-SIGN on LSECs could 
facilitate PMN transmigration across the endothelial cell layer, and induce subsequently 
hepatic damage. Since PMN have increased expression of Mac-1 upon activation, especially 
activated PMN might be trapped inside the sinusoids. 
Altogether these data suggest that PMN are retained in the liver by binding L-SIGN either 
resulting in clearance or in transendothelial migration. 
 
 
 
Materials and methods 
 
Antibodies and cells. 
The following monoclonal antibodies were used: AZN-D1 (mouse IgG1 isotype control) [9], and AZN-D2 
(DC-SIGN and L-SIGN) [9].  
CHO-L-SIGN cells were generated by lentiviral transduction of CHO cells with LV-L-SIGN [10]. 
Neutrophils were isolated from fresh blood of healthy volunteers. After Ficoll gradient centrifugation, 
neutrophils were cleared from contaminating erythrocytes using erylysis buffer (155 mM NH4Cl, 10 mM 
KHCO3, and 0.1 mM EDTA). Isolated neutrophils were over 95% pure (data not shown).  
 
Static cell-cell interaction. 
To examine cellular interactions of L-SIGN with neutrophils CHO and CHO-L-SIGN were grown 
overnight to confluent cultures in flat-bottom 96 well plates. Neutrophils were labeled with the green 
fluorescent dye Calcein-AM (1 µM, Molecular Probes) for 15 min at 37°C and incubat ed with mock and 
DC-SIGN transfected CHO cells in TSM 0.5% BSA for 2 h at 37°C. To determine specific adhesion the 
CHO transfectants were preincubated with anti-L-SIGN, or isotype control antibodies (20 µg/ml) for 30 
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min at 37°C. Unbound neutrophils were washed away, and remaining cells were lyzed in lysis buffer (50 
mM Tris-HCl, pH 8.0, and 0.1% SDS). Cell-cell adhesion was measured by fluorimetry of cell lysates at 
488 nm (Fluostar Galaxy, BMG Labtechnologies Inc., Durham, NC). Cell-cell adhesion was calculated 
as the percentage of total added neutrophils that was considered as 100% adhesion. 
 
Cell-cell interaction under flow conditions. 
CHO and CHO-L-SIGN were coated on glass coverslips, and grown confluent overnight. PMN (2 x 106 
cells/ml) were perfused over CHO(-L-SIGN) for 10 minutes at a flow rate of 100 µl/min. Wall shear stress 
was calculated to be 0.8 dyne/cm2. During perfusion, the flow chamber [11;12] was mounted on a 
microscope stage (Axiovert 25; Zeiss, Oberkochen, Germany), which was equipped with a black-and-
white charge-coupled device video camera (Sanyo, Osaka, Japan) and was coupled to a VHS video 
recorder. Video images were evaluated for the number of adherent cells, with dedicated routines made 
in the image analysis software OPTIMAS 6.1 (Media Cybernetics Systems, Silverspring, Md). PMN that 
were in contact with the surface appeared as bright white-centred cells after proper adjustment of the 
microscope during recording. L-SIGN specific interaction with PMN was determined by preincubation of 
CHO cells with anti-L-SIGN antibodies (AZN-D2, 40 µg/ml) or isotype control antibodies (AZN-D1, 40 
µg/ml). 
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Abstract 
 
Kupffer cells (KCs), the resident liver macrophages, originate from blood monocytes and 
reside in the liver sinusoids. KCs function in clearance of harmful material from the portal 
circulation in combination with liver sinusoidal endothelial cells (LSECs). Therefore they 
express several receptors. LSEC express amongst others the C-type lectins mannose 
receptor, L-SIGN in human and its homologue mSIGNR1 in mouse. These C-type lectins 
recognize carbohydrate moieties expressed on pathogens. However, most C-type lectins 
recognize both non-self and self-ligands. Here we demonstrate that cellular L-SIGN is 
recognizing a self-ligand on monocytes, the KC precursors, and these monocytes strongly 
adhere to L-SIGN-positive cells. Using an in vivo model we furthermore demonstrate that the 
murine L-SIGN homologue mSIGNR1 expressed on LSECs influences KC numbers in the 
liver, because mSIGNR1 knock out mice have reduced numbers of KC. The effect of 
mSIGNR1 on KC recruitment appears after the initial phase of KC repopulation. Altogether, L-
SIGN could be involved in the recruitment of KC precursors in the human liver. 
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Introduction 
 
Kupffer cells (KCs) are the resident macrophages of the liver, and form the largest population 
of resident tissue macrophages [1]. They reside in the liver sinusoids where they access the 
hepatocytes through the endothelial cell layer and the space of Disse [2]. KCs participate in the 
clearance of particulate and foreign material from the portal circulation [3] and phagocytosis of 
apoptotic cells [4;5]. By the release of several cytokines they modulate immune responses [6]. 
KCs are also involved in defence against tumour metastasis in the liver sinusoid [7]. The KC 
population remains constant by recruitment of monocytes from the blood that differentiate 
locally into macrophages. How the recruitment of monocytes is regulated is largely unknown. 
The life span of KC is estimated to be almost 4 days in mice. However in monocytopenic mice 
lacking monocytes, KCs are maintained in the liver for more than 6 weeks [8;9], and in human, 
donor KCs can persist in transplanted liver even for up to 1 year [10], indicating that KC have a 
long life span and might proliferate locally. 
The liver sinus is lined with liver sinusoidal endothelial cells (LSECs) which form, in contrast to 
conventional endothelium, a discontinuous, fenestrated endothelial cell layer lacking a 
basement membrane [11]. LSECs participate, in combination with KCs, in the clearing function 
of the liver. Therefore, LSECs express several scavenger receptors and C-type lectin 
receptors, such as mannose receptor (MR) and liver/lymph node specific ICAM-3 grabbing 
non-integrin (L-SIGN) [12-14]. MR binds besides pathogens, such as bacterial antigens [15], 
also self-antigens, such as serum glycoproteins [16] and thereby participates in the clearance 
of harmful exogenous and endogenous material [17]. L-SIGN is also a pathogen receptor and 
binds several pathogens, such as HCV [18-21] and HIV-1 [13;14] and can transmit these 
viruses to target cells [13;14;22]. Moreover, we have demonstrated that L-SIGN is also 
involved in antigen presentation of viral antigens to T cells [Ludwig, in preparation]. Although 
the recognition of pathogens is extensively described, the function during homeostasis of L-
SIGN on LSEC remains elusive. L-SIGN is mediating LSEC-neutrophil interactions via Mac1 
[23] and thereby it could function in clearance of PMN or in attenuating PMN responses. Here 
we demonstrate that L-SIGN interacts with monocytes, suggesting that L-SIGN might have a 
role in monocyte-LSEC interactions. Since KCs originate from monocytes and are located in 
close proximity of L-SIGN+ LSECs, we investigated the KC population in mouse liver from wild 
type and mSIGNR1 deficient mice. Strikingly, mSIGNR1-/- mice have a reduced KC population. 
Therefore, mSIGNR1, and possibly L-SIGN in human liver, is participating in KC homeostasis. 
 
 
 
Materials and methods. 
 
Mice. 
mSIGNR1-/- mice were a generous gift from A. McKenzie (Cambridge, UK). C57BL/6x129 wild type and 
mSIGNR1-/- mice were bred in the animal facility of the VU University Medical Centre under specific 
pathogen-free conditions. The Animal Care and Use Committee of the VU University approved all 
experiments. 
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Antibodies. 
The following antibodies were used: goat-anti-mSIGNR1 (R&D systems, Oxon, UK), F4/80 (eBioScience, 
San Diego, CA, USA), MOMA-2 [24], anti-DC-SIGN mouse IgG1 AZN-D1 and anti-DC-SIGN/L-SIGN 
mouse IgG1 AZN-D2 [25;26], mouse anti-L-SIGN/DC-SIGN-stalk, mouse anti-L-SIGN (R&D Systems, 
Minneapolis, MN, USA), anti-mouse CD31 (eBioScience, San Diego, CA, USA), mouse anti-human 
CD3-PE (Becton Dickinson), mouse anti-human CD4-PE (Becton Dickinson), mouse anti-human CD14 
(Becton Dickinson). 
 
Cells. 
Human PBMCs were isolated from buffy coats, obtained from blood bank donors, by centrifugation on a 
Ficoll gradient as previously described [27].  
Stable transfectants of K562 expressing L-SIGN and mSIGNR1 were obtained by electroporation of 
pRC-CMV-L-SIGN and pCR-CMV-mSIGNR1 (400 V, 960 µF) as previously described [28]. CHO-L-
SIGN cells were generated by lentiviral transduction with LV-DC-SIGN or LV-L-SIGN (kind gift of Vincent 
Piquet). Transfection and transduction efficiency was tested by staining the cells with anti-L-SIGN AZN-
D2 antibodies. 
Murine LSECs were isolated from mouse liver by perfusing the liver via the portal vein with successively 
HEPES buffer (8.3 mg/ml NaCl, 0.5 mg/ml KCl, 2.4 mg/ml HEPES) containing 0.19 mg/ml EGTA, 
HEPES buffer without EGTA and collagenase solution (3.9 mg/ml NaCl, 0.5 mg/ml KCl, 0.7 mg/ml 
CaCl2.2H2O, 2.4 mg/ml HEPES, 0.4 mg/ml collagenase). The livers were dissociated and single cell 
suspensions were made by passing the cells through a nylon mesh. Cells were washed in PBS and 
centrifuged 2 times 2 minutes at 50 g. The pellet containing hepatocytes was removed after each 
centrifugation step. The non-parenchymal cells were washed twice in PBS (350 g, 7 minutes) and 
layered on a double percoll gradient (2 ml 75%, 1.5 ml 35% percoll), and subsequently centrifuged at 
900 g for 20 minutes without brakes. The lower ring containing KCs and LSECs was collected, washed 
and seeded in serum free IMDM in 6 well plates. After 30 minutes incubation at 37°C, non-adherent 
LSECs were collected by vigorous washing and seeded on fibronectin coated culture plates. After 6 to 
10 days of cultured, purity of LSEC cultures was determined by staining for CD31 and was >90%. 
 
Cell-cell adhesion. 
To examine cellular interactions of L-SIGN with PBMC, CHO and CHO-L-SIGN were grown overnight to 
confluent cultures in flat-bottom 96 well plates. PBMC were labeled with the green fluorescent dye 
Calcein-AM (1 µM, Molecular Probes) for 15 min at 37°C and incubat ed on mock or L-SIGN transduced 
CHO cells in TSM 0.5% BSA for 1 h at 37°C. To deter mine specific adhesion the CHO cells were 
preincubated with mannan (1 mg/ml), anti-L-SIGN antibody (20 µg/ml), or an isotype control (20 µg/ml) 
for 30 min at 37°C. Unbound PBMC were washed away, and remaining cells were lyzed in lysis buffer 
(50 mM Tris-HCl, pH 8.0, and 0.1% SDS). Cell-cell adhesion was measured by fluorimetry of cell lysates 
at 488 nm (Fluostar Galaxy, BMG Labtechnologies Inc., Durham, NC). Cell-cell adhesion was calculated 
as the percentage of total added PBMC that was considered as 100% adhesion. To investigate the cell 
population adhering to the CHO cells, non-adherent cells were collected by vigorous washing and 
stained with anti-CD3, CD4, and CD14 antibodies. Expression of these markers was measured by flow 
cytometry and compared with the initial PBMC population.  
 
Beads adhesion. 
Binding of ligand-coated beads to cells was performed as described by Geijtenbeek et al. [29]. In short, 
streptavidin was covalently coupled to the carboxylate-modified TransFluorSpheres (488/645 nm, 1.0 
µm; Molecular Probes, Eugene, OR, USA). The streptavidin-coated beads were incubated with 
biotinylated F(ab’)2 fragment goat anti-mouse IgG (6 µg/ml; Jackson Immunoresearch), followed by an 
overnight incubation with mouse-anti-L-SIGN antibodies (anti-stalk) at 4°C. The beads were washed and 
incubated with K562-L-SIGN lysate overnight at 4°C. gp120 coated beads were made by incubating 
streptavidin-coated beads with biotinylated F(ab’)2 fragment goat anti-mouse IgG (6 µg/ml; Jackson 
Immunoresearch), followed by an overnight incubation with supernatant containing gp120-Fc chimera. 
The fluorescent beads adhesion assay was performed as described before [30]. In short, 50,000 cells 
were incubated with beads for 45 minutes at 37°C. Mannan (0.5 mg/ml), EGTA (10 mM) and blocking 
antibodies against L-SIGN (20 µg/ml) were used to determine specificity of adhesion. Binding was 
measured by flow cytometry. 
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Liver section staining and cell counting. 
Mouse liver tissue was obtained from wild type and mSIGNR1 knock out mice. 6 µm cryosections were 
placed on gelatine-coated slides and stored at -80°C. Sections were fixed with acetone and stained with 
goat-anti-mSIGNR1 and donkey-anti-goat-Alexa Fluor 488, or with rat-anti-mouse-CD31, F4/80 or 
MOMA-2 antibodies and counterstained with goat-anti-rat-Alexa Fluor 594. Sections were analyzed with 
a Nikon Eclipse E800 fluorescence microscope and pictures were captured with a digital NIKON 
DXM1200 camera at 20X objective. KC content was determined by counting F4/80 or MOMA-2 positive 
cells in 20 visual fields in every section for two or three sections per liver. 
 
Clodronate depletion of Kupffer cells. 
Clodronate (Roche Diagnostics, Mannheim, Germany) was encapsulated in liposomes as previously 
described. After removal of free clodronate, liposomes were resuspended in NaCl (0.9%). Depletion of 
KCs was achieved by injection of multi-lamellar clodronate liposomes (iv) [31]. Efficiency of KC depletion 
was determined by staining liver sections with F4/80. 
 
 
 
 
 
 
L-SIGN is interacting with monocytes. 
(A) CHO cells were transduced with L-
SIGN and expression levels were tested 
by staining the cells with the anti-L-SIGN 
antibody AZN-D2 (black line). Grey 
histogram represents isotype staining. (B) 
Interaction of PBMCs with L-SIGN was 
investigated by incubating calcein-AM 
labelled PBMCs on monolayers of CHO 
and CHO-L-SIGN cells. Cell-cell adhesion 
was determined after washing and cell 
lysis using fluorimetry. L-SIGN specificity 
was determined by incubating by pre-
incubation of CHO-L-SIGN cells with 
mannan (0.5 mg/ml, black bar), blocking 
anti-L-SIGN antibodies (20 µg/ml, light 
grey bar) or isotype control antibodies 
(dark grey bar). Error bars represent 
standard deviations of triplicates. One 
representative experiment out of three is 
shown. (C) The L-SIGN binding subset in 
the PBMC population was investigated by 
incubating CHO and CHO-L-SIGN cells 
with PBMC. Non-adherent cells were 
collected during washing and stained for 
CD3, CD4, and CD14. Expression was 
measured using flow cytometry. 
Expression levels of the indicated markers 
were compared for cells not adhering to 
CHO (dashed lines) or CHO-L-SIGN 
(black lines) and PBMC (filled histograms). 
One representative experiment out of 
three is shown. (D) Fluorescent beads 
coated with cell derived L-SIGN were 
incubated with PBMCs. Adhesion was 
measured by flow cytometry. T cells and 
monocytes were gated based on forward 
sideward scatter. Specificity of L-SIGN 
binding was confirmed by blocking with 
mannan and EGTA. One representative 
experiment out of three is shown. 
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Results 
 
L-SIGN interacts with human monocytes. 
L-SIGN is a pathogen receptor involved in the transmission of viruses, such as HCV and HIV-1 
[13;14;22], and also in antigen presentation of these viruses [Ludwig, in preparation]. However, 
little is known about cellular interactions mediated by L-SIGN. In order to investigate the 
interaction of L-SIGN with peripheral blood mononuclear cells (PBMC), a cell-cell adhesion 
assay with L-SIGN-positive cells (Fig. 8.1A) and PBMC was performed. PBMCs were allowed 
to adhere to a monolayer of L-SIGN-positive or mock-transduced cells and about 30% of total 
PBMC adhered to L-SIGN-positive cells (Fig. 8.1B). This cellular interaction was L-SIGN 
specific since blocking with anti-L-SIGN antibodies or mannan reduced adhesion to 
background levels (Fig. 8.1B).  
Since PBMCs are a mixed cell population, consisting of B cells, T cells and monocytes, we 
addressed the question which subset was interacting with L-SIGN. The non-adherent cells 
were collected and stained for CD4, CD3, and CD14. Cell distribution of non-adherent cells 
from parental CHO cells resembled that of the starting population of PBMCs. Strikingly, in the 
non-adherent cell population from CHO-L-SIGN cells, the CD14+, CD3-, CD4intermediate 
population was completely absent (Fig. 8.1C, Table 1) strongly indicating that the adherent 
population consists primarily of monocytes.  
To confirm specific interaction of L-SIGN with monocytes, a beads adhesion assay was 
performed. Fluorescent beads were coated with native L-SIGN, derived from L-SIGN-positive 
cells, and these beads were incubated with PBMCs. Binding was analyzed using flow 
cytometry. L-SIGN-coated beads did not interact with PBLs, but as expected, they strongly  
interacted with monocytes (Fig. 8.1D). Moreover, the interaction of L-SIGN beads with  
monocytes was specific since it was blocked by mannan and EGTA (Fig. 8.1D). Thus this 
adhesion experiment using L-SIGN-coated beads supports the cell-cell adhesion assay 
demonstrating that L-SIGN interacts with monocytes.  
 
mSIGNR1 is expressed on LSEC and functionally resembles L-SIGN. 
L-SIGN is expressed on liver sinusoidal endothelial cells in human liver [13]. Because of the 
difficulty of isolating sufficient LSECs from human tissue and the availability of an mSIGNR1 
knock out mouse, we used a mouse model in order to investigate the role of L-SIGN-monocyte 
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mSIGNR1 is the murine 
homologue of L-SIGN on LSECs.  
(A) Wild type and mSIGNR1-/- 
mouse liver sections were stained 
with anti-mSIGNR1 (green) and 
anti-CD31 (red) antibodies and 
counterstained with anti-goat Alexa 
Fluor 488 and anti-rat Alexa Fluor 
595. Sections were analyzed with 
fluorescent microscopy. (B) Wild 
type and mSIGNR1-/- mouse liver 
sections were incubated with 
dextran-FITC and subsequently 
stained for CD31 (red). Dextran-
FITC binding and antibody staining 
were analyzed with fluorescent 
microscopy. (C) LSECs were 
isolated from wild type liver by 
perfusion with collagenase and 
percoll gradient. At day 6 after 
isolation cells were incubated with 
dextran FITC and binding was 
analyzed by flow cytometry. 
Specificity of mSIGNR1 binding was 
determined by blocking with EGTA 
and mannan. One representative 
experiment out of three is shown. 
(D) K562 cells transfected with L-
SIGN or mSIGNR1 were incubated 
with gp120-coated beads. 
Specificity was determined by 
blocking with mannan (0.5 mg/ml) 
Adhesion was measured using flow 
cytometry. Error bars represent 
standard deviations of triplicates. 
One representative experiment out 
of three is shown. (E) Primary 
LSECs from wild type or mSIGNR1-
/-
 liver were, after 6 days of culture, 
incubated with gp120 coated 
fluorescent beads. Adhesion was 
measured by flow cytometry. 
Specificity of mSIGNR1 binding was 
determined by blocking with EGTA 
and mannan. Error bars represent 
standard deviations of triplicates. 
One representative experiment out 
of two is shown. 
 
 
interactions in vivo. In mice the DC-SIGN/L-SIGN homologue mSIGNR1 is also expressed on 
CD31 positive LSEC (Fig. 8.2A and [32]). Thus we used mSIGNR1 knock out mice to further 
investigate the role of mSIGNR1 in liver. mSIGNR1-/- liver sections did not stain for mSIGNR1, 
confirming that these mice were lacking any mSIGNR1 (Fig. 8.2A). 
Next we investigated whether mSIGNR1 on LSECs is functional and whether it has a similar 
binding specificity as L-SIGN. To investigate the functionality of mSIGNR1 on LSECs we 
studied binding of dextran-FITC, a known mSIGNR1 ligand, to murine liver sections. In wild 
type liver sections, a CD31 positive and a CD31 negative cell population bound dextran-FITC 
(Fig. 8.2B). In mSIGNR1-/- mice liver tissue dextran-FITC is only bound by the CD31 negative 
cell population (Fig. 8.2B). The CD31 negative cells reside in the sinusoids and probably are 
KC. The finding that in wild type mice, in contrast to mSIGNR1-/- mice, also CD31 positive cells 
bind dextran-FITC indicates that mSIGNR1 on LSEC is functional in wild type mice.  
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Next, we isolated primary LSEC from liver by perfusion with collagenase buffer and 
subsequent centrifugation on a percoll density gradient. Primary LSEC were positive for CD31 
and able to bind dextran (data not shown and Fig. 8.2C). Dextran-FITC binding was specific 
since mannan and EGTA blocked the interaction (Fig. 8.2C). Additionally, we compared 
mSIGNR1 function with L-SIGN by investigating the binding of HIV-1 envelope glycoprotein 
gp120. Recombinant gp120-Fc was coupled to fluorescent beads and adhesion to K562 cells 
transfected with L-SIGN or mSIGNR1 was investigated. Both K562-L-SIGN and K562-
mSIGNR1 cells efficiently bound gp120 beads as was previously described (Fig. 8.2D and  
LSECs (Fig. 8.2E). Furthermore, wild type LSECs displayed binding significantly above 
background levels, whereas mSIGNR1-/- cells did not, and this binding could be specifically 
blocked by mannan (Fig. 8.2E). These data indicate that mSIGNR1 resembles L-SIGN both in 
expression pattern and function on LSEC. 
 
mSIGNR1 is regulating Kupffer cell homeostasis. 
Next we investigated the role of mSIGNR1 in KC homeostasis, because we had observed that 
L-SIGN interacts with monocytes, which are precursors of KCs. KCs are in close proximity of 
mSIGNR1-positive LSECs in the liver sinusoids. Therefore we compared KC population of wild 
type mice and mSIGNR1 knock out mice by staining liver cryosections with the KC markers 
F4/80 and MOMA-2. Sections were analyzed and quantified by fluorescent microscopy (Fig.  
8.3A). Strikingly, mSIGNR1-/- mice had less KC in liver compared to wild type mice (Fig. 8.3B).  
The amount of KCs was decreased with 40% in the absence of mSIGNR1. Thus mSIGNR1 in 
mouse liver sinusoids is participating in the maintenance of KC population.  
KCs originate from monocytes that enter the liver sinusoid through the bloodstream and locally  
differentiate to macrophages. The KC population furthermore is maintained constant by local  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KC population in liver is decreased in mSIGNR1-/- 
mice.  
(A and B) Liver sections of wild type (left panels) and 
mSIGNR1-/- (right panels) mice were stained with F4/80 
(A) or MOMA-2 (B) antibodies and counterstained with 
goat-anti-rat Alexa Fluor 594 and analyzed with 
fluorescence microscopy. (C) F4/80 or MOMA-2 positive 
cells were counted in 10 visual fields of three sections 
per liver. Error bars represent standard deviations. 
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proliferation of cells that are already present in the liver sinusoid. As mSIGNR1 seems 
necessary for KC homeostasis (Fig. 8.3), we hypothesized that mSIGNR1 is either involved in 
the recruitment of monocytes or in the proliferation of KCs. In order to address the question 
whether mSIGNR1 is involved in the recruitment of KCs we depleted all KCs from the liver by 
i.v. administration of liposome-encapsulated clodronate. With the administration of liposome-
encapsulated clodronate, macrophages are specifically removed, as these cells phagocytose 
the liposomes and after lysosomal degradation cytotoxic clodronate is released [34]. Mice were 
sacrificed at different days after clodronate administration, livers were removed, and the 
amount of KCs was quantified. Four days after clodronate injection, almost no KCs were 
present in the sections (Fig. 8.4A). Onwards, the KC population gradually increased over time 
and reached normal numbers after 8 to 16 days after KC depletion. Until day 8, KC 
repopulation kinetics were similar in both wild type and mSIGNR1-/- mice (Fig. 8.4B and C), 
suggesting that mSIGNR1 is not involved in the initial repopulation of KCs in the liver. After this  
initial phase, when KC number in mSIGNR1-/- liver has reached its maximum, the KC  
population in wild type mice increased further (Fig. 8.4C). These data suggest that KC 
repopulation in a KC deprived liver is a biphasic process of which the first phase is mSIGNR1 
independent and the second phase is mSIGNR1 dependent resulting in more KC in the liver in 
the presence of mSIGNR1. This could be due to the recruitment of more monocytes to the liver 
or by influencing turnover of residing KC. 
 
Kupffer cell repopulation is identical in wild type and mSIGNR1-/- mice.  
Wild type and mSIGNR1-/- mice were given liposome-encapsulated clodronate or PBS i.v.. In two separate 
experiments livers were removed at day 4, 6 and 8, or at day 4, 8 and 16, and liver sections were stained with F4/80 
to stain KCs. F4/80 positive KCs were counted in 10 randomly chosen visual field at 20 times magnification of two 
sections per liver. One mouse out of two per group is shown. Error bars represent standard deviations.  
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Discussion 
 
C-type lectin receptors, like MR and DC-SIGN, are acting as pathogen recognition receptors 
on DCs to take up antigens for presentation. However, C type lectins also interact with self- 
ligands. MR binds to bacterial products [15], but also to endogenous ligands [16]. DC-SIGN is 
recognizing several pathogens like HIV-1, HCV, and mycobacterium tuberculosis and self 
ligands on endothelial cells, T cells and neutrophils [35-37]. The DC-SIGN homologue L-SIGN 
has a comparable binding pattern to DC-SIGN, although due to the lack of Lex recognition L-
SIGN does not bind Lex containing ligands [38]. Little is known about the cellular function of L-
SIGN. Here we demonstrate that L-SIGN, present on LSEC in the liver, interacts with 
monocytes and the murine L-SIGN homologue mSIGNR1 affects the KC population, which 
differentiate from monocytes, in the liver. 
The origin of KCs, the resident liver macrophages, remains elusive. It has been hypothesized 
that KCs are derived from recruited monocytes that differentiate locally into KCs in response to 
chemokines. This is in line with the theory of the mononuclear phagocyte system [39].  
According to this theory, all macrophages derive from non-proliferating monocytes which are  
differentiated via promonocytes from monoblasts. However, although the estimated life span of 
KC in mice is about 4 days, in monocytopenic mice lacking monocytes, and therefore have no 
monocyte recruitment to the liver, KC reside in the liver for up to 6 weeks [8;9]. This argues for 
a proliferative capacity of KCs that contributes to keeping the KC population constant.  
We demonstrate here that the lack of mSIGNR1 in the liver results in a reduced amount of KCs 
in the liver (Fig. 8.3). mSIGNR1 and L-SIGN are both expressed on LSECs in the liver in mice 
and human respectively (Fig. 8.2, [13;32]) and have comparable binding patterns (Fig. 8.2, 
[33]). Therefore, it is possible that the decrease of KCs in the absence of mSIGNR1 can be  
accounted to the importance of mSIGNR1-monocyte interactions, promoting monocyte arrest 
in the liver sinusoid. The interaction of murine monocytes with mSIGNR1 is not investigated 
yet, but the reduced numbers in KCs are indicative for this interaction. It is demonstrated that 
L-SIGN-positive cells promote neutrophil rolling and adhesion under shear stress [Ludwig, 
chapter 7 addendum], a mechanism that could also function in monocyte-L-SIGN interactions.  
Upon depletion of all macrophages from the liver with clodronate liposomes, the initial KC 
repopulation is similar in both wild type and mSIGNR1-/- mice, suggesting that mSIGNR1 is not 
involved in the initial recruitment of monocytes to the liver. Furthermore, because of the small 
diameter of the liver sinusoids, incoming monocytes might not even need initial attachment to 
stay in the sinusoids. Indeed, passing leukocytes can roll over sinusoidal endothelium 
independent of selectin-adressin interactions normally needed due to the small size and low 
and intermittent blood flow [40], before adherence to the endothelial cell layer. Therefore 
recruitment of monocytes after depletion of all KC, might occur independent of cellular 
interactions and chemokines. Our data implicate that the return of KC in a KC depleted liver is 
a biphasic process and the difference in KC numbers between wt and mSIGNR1-/- mice is due 
to differences in the second phase of KC repopulation. In this second phase, mSIGNR1 might 
influence KC homeostasis in several ways. First, mSIGNR1 might create more binding sites for 
monocytes entering the sinusoid, besides mSIGNR1 independent binding sites. After the initial 
‘filling’ phase, when all other sites are occupied, monocytes will pass the liver without retention 
in the absence of mSIGNR1. However in the presence of mSIGNR1, more monocytes could 
be retained in the sinus. Second, mSIGNR1 could influence the cell turn over of the KC 
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present in the sinusoids, by reducing apoptosis or promoting proliferation. However, this 
hypothesis only holds when the mSIGNR1/L-SIGN ligand expressed by monocytes is still 
expressed after differentiation into KCs. Although the precise mechanism is not known, these 
data indicate for a role of C-type lectins in monocyte binding and KC homeostasis. 
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General discussion 
 
DC-SIGN is a C-type lectin expressed by DCs that recognizes self, altered-self and pathogen-
derived ligands, such as cellular ICAM-2, tumour associated CEA, HIV-1 and HCV [1-4]. DC-
SIGN functions as an adhesion molecule but upon binding, particulate ligands can also be 
internalized, resulting in antigen processing and presentation to CD4+ T cells [5;6]. DC-SIGN 
also mediates cross presentation of antigens to CD8+ T cells [7]. The cytoplasmic domain of 
DC-SIGN contains three putative internalization motifs; a tyrosine-based YxxL motif, a di-
leucine based motif and a triacidic cluster [8]. These motifs are associated with internalisation 
of receptor-ligand complexes and targeting to lysosomes. However, mutagenesis of these 
motifs demonstrated that only the di-Leucine motif is necessary for internalization [9;10].  
The DC-SIGN homologue L-SIGN contains two internalization motifs, the di-leucine motif and 
a triacidic cluster, but it lacks the tyrosine based motif. L-SIGN is expressed on specialized 
endothelial cells in the liver. These liver sinusoidal endothelial cells (LSECs) can act as APC. 
The cells have a great internalisation capacity and contain large amounts of lysosomal 
enzymes [11] [12]. In mice, LSECs have shown to be able to present antigens to T cells, both 
CD4+ and CD8+, without the need of prior activation [13;14]. In contrast to conventional 
endothelial cells, LSECs constitutively express MHC class II [15;16], and mouse LSECs also 
express the costimulatory molecules CD40, CD80 and CD86 [17;18]. Strikingly, human LSECs 
express CD40 but lack expression of CD80 and CD86 [19]. Previously, it was suggested that 
L-SIGN lacks the capacity to internalise antigens for antigen presentation, and that L-SIGN 
merely functions as an adhesion receptor [20]. However, we have demonstrated that L-SIGN is 
able to internalise ligands [chapter3 [3]] resulting in presentation to CD4+ T cells [chapter 4]. 
Thus L-SIGN functions also as an antigen uptake receptor. The presentation of antigens by 
LSECs might result in tolerance, as these cells lack the expression of some co-stimulatory 
molecules. Concomitantly, in mice, LSEC promote the induction of tolerogenic CD4+ and CD8+ 
T cells [13;14]. Therefore, it has been hypothesized that pathogens target L-SIGN for 
internalization by LSECs and thereby inducing tolerance. 
 
 
 
Carbohydrate recognition profile of DC-SIGN and L-SIGN 
 
The amino acid similarity of the carbohydrate recognition domains of DC-SIGN and L-SIGN is 
over 80%, and both lectins contain the EPN motif associated with the recognition of mannose 
and fucose structures [8;21]. DC-SIGN recognizes high mannose and fucose-containing 
carbohydrates such as Lewisa (Lea), Lewisb (Leb), Lewisx (Lex), and Lewisy (Ley) [20;22-24]. 
Sulfation of Lea and Lex does not abrogate DC-SIGN recognition, whereas sialylation of these 
Lewis antigens results in loss of recognition [22;24]. This specificity has been confirmed with 
different assays using both soluble recombinant DC-SIGN [20;22] and cellular DC-SIGN 
[22;24]. In spite of the high homology between the CRDs of DC-SIGN and L-SIGN there are 
differences in carbohydrate recognition. Soluble recombinant L-SIGN was shown to bind only 
high mannose containing glycoconjugates [20]. In contrast, L-SIGN expressed on cells was 
shown to recognize also fucose-containing glycoconjugates, Lea, Leb and Ley [24]. The 
discrepancy is most likely due to incorrect clustering of the soluble L-SIGN. In contrast to DC-
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SIGN, L-SIGN is not able to interact with Lex. The disparity in Lex binding between DC-SIGN 
and L-SIGN is based on one amino acid difference in the CRD [25]. Whereas DC-SIGN has a 
valine at position 351 (Val351), L-SIGN has at this same position a serine (Ser363) [20;25]. Lex 
binding capacity is restored by replacing Ser363 in L-SIGN with a Valine residue, thereby 
creating a hydrophobic pocket [25]. 
Besides this dissimilarity in Lex binding, there is yet another difference in carbohydrate binding 
profile. L-SIGN recognizes particular sialic acid containing glycoconjugates [chapter2], in 
contrast to DC-SIGN carbohydrate recognition, which is abrogated upon sialylation of 
carbohydrates [22;24]. Recognition of these sialylate carbohydrates is dependent on the 
specific protein backbone, since sialylated glycoconjugates on a polyacrylamide carrier were 
neither recognized by soluble L-SIGN [20] nor L-SIGN expressed on cells [24]. 
In conclusion, high mannose and certain fucose-containing structures are recognized by both 
DC-SIGN and L-SIGN. DC-SIGN and L-SIGN specificity is distinct in their recognition of Lex 
and sialylated carbohydrates. Thus, although the binding specificity of Dc-SIGN and L-SIGN is 
very similar, both DC-SIGN and L-SIGN can interact with specific pathogens and self-
structures based on their exclusive recognition of Lex and sialic acids respectively. 
 
 
 
Cellular interactions of DC-SIGN and L-SIGN 
 
DC-SIGN and L-SIGN interactions with neutrophils. 
During homeostasis polymorphonuclear neutrophils (PMN) and DCs are located in different 
compartments, in the bloodstream and in peripheral tissue respectively. However, during 
infection they both are located at the site of inflammation. Upon microbial infection, PMN 
produce chemokines that attract immature DCs [26]. Recently it has been shown that 
neutrophils and DCs form clusters when cocultured [27;28]. This suggests that PMN and DC 
scan each other’s surface continuously when they are near each other. The interaction with 
PMN induces maturation of DC as shown by the upregulation of costimulatory molecules HLA-
DR, CD86 and CD40. Besides the maturation of DCs, PMN also induce IL-12 production by 
DCs [27]. This results in a greater capacity of these ‘primed’ DCs to activate T cells [28]. The 
maturation of DCs is mediated by TNF-α production by neutrophils. However, when PMN and 
DCs are in direct contact the effect is greatly enhanced [28;29]. This implicates that cell-cell 
interactions have an additional effect on the effect of TNF-α. 
 
Direct cell-cell contact between PMN and DCs is dependent on CD18 [28]. CD18 is expressed 
in heterodimers with CD11b, forming Mac-1, and with CD11a forming LFA1. Recently it was 
shown that the C-type lectin DC-SIGN on DCs can interact with the CD11b/CD18 heterodimer 
Mac-1 [27], and CEACAM1 [chapter7][30;31]. Indeed, DC maturation by PMN was shown to  
be dependent on DC-SIGN on the DC side [27]. There is some controversy about the 
activation state of the PMN that can induce DC maturation. Whereas van Gisbergen [27] 
shows that only activated PMN, which have increased Mac-1 expression, can induce DC 
maturation, others [28] show that also non-activated PMN are able to induce DC maturation. 
This can be due to differences in isolation methods resulting in an already activated state of 
the PMN, resulting in an upregulation of Mac-1, CEACAM1 and TNF-α expression. Whereas 
probably low expression of Mac-1 and CEACAM1 is sufficient for clustering, a stronger 
interactions and TNF-α is needed to induce DC maturation.  
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DC interaction with PMN.  
DCs and PMN influence each other. DC-SIGN binds Mac-
1 and CEACAM on PMN and induces cell survival. Via 
this interaction and TNF-α production by PMN, DCs are 
instructed to regulated T-cell differentiation towards Th1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mac-1 (CD11b/CD18) on PMN is involved in pathogen recognition and binding and is 
redirecting them to phagosomes in PMN. Mac-1 can bind directly to several pathogens [32] but 
is also a receptor for complement and thus serves as a receptor for opsonized pathogens [32]. 
Mac-1 also functions in the regulation of apoptosis with a twofold effect: signalling of Mac-1 
alone promotes cell survival [33], whereas in combination with an apoptosis signal, Mac-1 
triggering is resulting in higher apoptosis induction [34]. The other DC-SIGN ligand on PMN, 
CEACAM1 (CD66a), mediates cell-cell adhesion via homophilic binding. This interaction 
regulates cell proliferation and it delays apoptosis of PMN [35]. CEACAM1 is expressed on 
more cells from myeloid origin, however, it differs in its glycosylation pattern between these 
different cell types [36]. CEACAM1 on PMN is expressing high amounts of Lex [37], and indeed 
DC-SIGN binding to CEACAM1 is entirely based on the expression of Lex structures on PMN 
CEACAM1 [chapter7][30]. Mac-1-DC-SIGN interactions are based on Lex and Ley expressed 
on Mac-1 [27].  
 
PMN induce DC maturation and indeed these DCs efficiently induce T-cell proliferation [27]. 
DCs matured by LPS induce a mixed type differentiation of T cells, IFN-γ producing Th1 and 
IL-4 producing Th2 cells are induced to the same extent. However, when DCs are 
simultaneously interacting with PMN, the balance is shifting from a mixed type to a Th1 based 
response [27] (Fig. 9.1). This is reflected in vivo during Crohn’s disease, a disease 
characterized by inflammation of the colon mucosa and Th1 responses. In the mucosa of 
Crohn’s disease patients DCs and PMN can be found in close vicinity [27] and both the DC-
SIGN+ and the DC-SIGN- DC population are increased [38]. However only the DC-SIGN+ DCs 
are interacting with PMN and further more these are responsible for the production of Th1 
cytokines [27;38]. This implies the importance of the interaction of PMN with DC-SIGN+ DCs in 
the development of the vigorous Th1 response in Crohn’s disease. 
 
Based on the chemokine expression pattern of DCs it was hypothesized that DCs play a role in 
the recruitment of PMN to inflamed tissues [39]. Indeed, DC conditioned medium attracts PMN. 
Both immature and mature DC can induce PNM migration, however mature DCs are more 
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potent because of higher IL-8 production [40]. Furthermore the cytokines produced by DCs 
enhance the phagocytic capacity of PMN [41]. 
DCs interact through DC-SIGN with both Mac-1 and CEACAM1 on PMN. Since both 
CEACAM1 and Mac-1 are involved in the regulation of PMN apoptosis, it is likely that binding 
of DCs to these molecules has an effect on PMN apoptosis. Indeed it was shown that 
interaction of DCs with PMN results in a lack of down regulation of several markers such as 
CD13, CD15, CD16, and CD11b/CD18 (Mac-1) on the PMN on a subset of the PMN [28]. The  
down regulation of these markers is associated with induction of apoptosis [42;43]. This 
suggests that the interaction of DCs with PMN prolongs the lifespan of neutrophils (Fig. 9.1). 
Upon DC maturation, DC-SIGN expression is decreased, and although also mature DCs are 
binding PMN, this is less than the binding of immature DCs [27]. This implies that the binding 
of an individual mature DC to a PMN is less strong than that of immature DC. It is possible that 
the decrease in binding results in a change from an anti-apoptotic signal in an apoptotic signal 
by which the inflammation is ended. 
 
L-SIGN positive cells are localized at a strategic site in the liver, and L-SIGN can mediate PMN 
adherence and rolling over liver sinusoidal endothelial cells [Chapter 7 addendum]. PMN 
rapidly sequester in the liver upon inflammation, even when the inflammation is at a remote 
site. PMN are recruited to the liver by Kupffer cell produced factors [44]. The liver functions in 
the clearance of old and redundant PMN, and the recruitment of PMN during inflammation 
could result in the ending of the inflammation by this process. Upon interaction with bacterial 
products Kupffer cells upregulate Fas ligand (FasL) expression [45]. FasL-Fas engagement on 
PMN will induce apoptosis [46]. Strikingly, PMN also induce severe hepatic injury upon 
bacterial infections. They are even the main players in this process as depletion of PMN 
protects against septic liver injury [47]. This argues that it is of utmost importance that PMN are 
cleared from the liver before they generate severe liver damage. 
 
The effect of the L-SIGN-PMN interaction in vivo remains to be elucidated; however it is 
tempting to suggest a role in apoptosis induction. L-SIGN is binding PMN, however because L-
SIGN is not able to bind to Lex, this interaction is not via CEACAM1 but only via Mac-1 
[30][chapter 7]. When PMN apoptosis is already triggered, L-SIGN association with Mac-1 
could enhance apoptosis induction. During inflammation this is likely as the phagocytosis of 
opsonized particles itself is an apoptotic signal for PMN [48;49]. Further more, Kupffer cells  
can provide an apoptotic signal as they up regulate FasL after contact with bacterial products 
[45]. However, when PMN are not programmed yet to undergo apoptosis, the interaction of 
Mac-1 with L-SIGN could have a reverse effect by inhibiting spontaneous apoptosis and even 
mediate transmigration of activated PMN across liver sinusoidal endothelium into the 
parenchyma during bacterial infections (Fig. 9.2). 
 
 
Liver cells interacting with L-SIGN 
Besides the interaction with neutrophils, L-SIGN interacts with a yet unknown ligand on 
monocytes [chapter 8]. Monocytes are adhering to both L-SIGN-positive cells and recombinant 
L-SIGN [chapter 8]. Therefore, L-SIGN could function in rolling and arrest of monocytes in the 
liver sinusoid, similar as for neutrophils [chapter 7 addendum][50]. Although in our assays no 
DC-SIGN binding to monocytes was demonstrated, others show that DC-SIGN interacts 
weakly with monocytes [51]. This binding is increased when Lex structures are exposed after  
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PMN in liver sinusoid.  
PMN are recruited to the liver by Kupffer cells were 
they role over and adhere to sinusoidal endothelial 
cells. (A) When Kupffer cells via FasL induce PMN 
apoptosis this is enhanced by L-SIGN-Mac-1 
interactions. (B) Alternatively, when an apoptotic signal 
is absent, activated PMN can role over the L-SIGN+ 
endothelial cells and induce severe hepatic injury. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
acids. Notably, we observed that mice deficient in the murine DC-SIGN/L-SIGN homologue  
neuraminidase treatment [51], indicating that most of the Lex structures are masked by sialic  
acids. Notably, we observed that mice deficient in the murine DC-SIGN/L-SIGN homologue  
mSIGNR1 had lower numbers of KCs in the liver sinusoids [chapter 8]. mSIGNR1 is expressed 
by LSEC similar as L-SIGN, and combined with the finding that KCs originate from monocytes 
it can be hypothesized that monocytes interact with L-SIGN and mSIGNR1 in order to settle in 
the liver sinusoids. These receptors might also provide a signal to the monocytes, that induces 
monocyte differentiation into KCs.  
 
We also observed that L-SIGN interacts with the well-differentiated hepatoma cell line HUH7 
through sialic acid-containing glycoconjugates [chapter 2]. Healthy hepatocytes also express 
large amount of α-2,6-sialic acid on their surface mainly confined to the sinusoidal side of 
hepatocytes [52], suggesting that L-SIGN might interact with the hepatocytes. The interaction 
between LSEC and hepatocytes, which are not connected with extracellular matrix [53], could 
contribute to maintenance of hepatic sinus architecture.  
Oncogenic transformation often results in a perturbation of the glycosylation machinery [54], 
which has severe effects on the metastatic properties of the tumour. Sialic acid expression on 
the cell membrane is lost upon malignant transformation of hepatocytes into hepatocarcinoma 
cells and sialic acids are solely expressed around the nucleus in the cytoplasm [52]. The loss 
of sialylated ligands would loosen the L-SIGN-hepatocellular carcinoma cell interaction and the 
hepatocellular carcinoma cells would more easily transmigrate into the bloodstream and form 
metastases at distant sites (Fig. 9.3). Indeed this loss of sialic acid expression is indicative for 
a poor patient survival [55]. 
 
 
Chapter 9 
 
154 
L-SIGN binds sialylated carbohydrates expressed by hepatocytes.  
(A) L-SIGN on LSEC binds to sialic acid containing glycan structures expressed by hepatocytes. (B) The surface 
expression of sialylated carbohydrates is abrogated in hepatocellular carcinoma cells, and sialylated carbohydrates 
are confined intracellular. The lack of cell surface expression of the L-SIGN ligand results in loss of interaction 
between the carcinoma cell and the endothelial cell layer, and the carcinoma cell could subsequently extravasate. 
 
 
Role of L-SIGN in metastasis of colon carcinomas 
In contrast to the loss of sialic acid glycoconjugates during malignant transformation of 
hepatocellular carcinoma cells, colon cells display an increased [56-58] or de novo [59] 
expression of sialylated carbohydrates upon malignant transformation. The increased 
expression of ST6Gal1, the enzyme catalyzing the generation of α-2,6 sialylated glycans, in 
colorectal carcinoma cells correlated to the metastasizing capacity of colon carcinomas in the 
liver [60] and negatively correlated with survival [61]. Expression of sialylated glycoconjugates 
on the cell surface metastasizing colon carcinoma cells could facilitate adherence to L-SIGN 
on LSEC, and thereby enhancing the formation of liver metastasis. Indeed, removal of sialic 
acid residues by neuraminidase treatment reduces metastatic capacity [62] and desialylation 
with the sialyltransferase inhibitor KI-8110 completely abolished liver metastasis of certain 
tumours [63]. 
 
DC-SIGN can mediate DC-tumour cell interaction by recognition of CEA and CEACAM1 on 
colon carcinoma cells [4]. Besides the upregulation of sialylation, malignant transformation of 
colon epithelial cells results also in an increased expression of Lex and Ley epitopes [64;65]. As 
a consequence, DC-SIGN can discriminate between normal and colon carcinoma tissue 
derived CEA and CEACAM1. Notably we also demonstrated an increased binding of tumour 
CEA over normal colon derived CEA to L-SIGN [chapter 2], suggesting that this interaction 
might be involved in metastation of the tumour. Metastasizing colon carcinoma cells reach the 
hepatic sinus via the blood stream and the interaction between L-SIGN and the α-2,6-sialic 
acid structures and Ley epitopes expressed by the tumour cells. This would in addition to 
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getting constricted by the narrow vasculature of the sinus, explain the frequent metastasis 
formation of colon carcinomas in the liver.  
 
In conclusion, L-SIGN mediates cellular interactions with PMN, monocytes and hepatocytes, 
important for homeostasis in the liver.  
 
 
 
DC-SIGN and L-SIGN in virus interactions 
 
DC-SIGN interacts with several pathogens such as (myco)bacteria and viruses. (Myco)bacteria 
tend to modulate DC-mediated immune responses by binding DC-SIGN. For example, 
Mycobacteria tuberculosis is preventing DC maturation [66], and both Lactobaccilus reuteri 
and Lactobacillus casei direct DCs to induce the development of IL-10 producing regulatory T 
cells [67]. Viruses, on the other hand, target DC-SIGN to infect DCs and for viral transmission 
to target cells [1;68-73]. 
DC-SIGN and L-SIGN interact with several viruses such as HIV-1, HCV, Ebola virus, and 
cytomegalovirus virus [chapter3][1;3;70;71;74-76]. All these viruses express highly 
glycosylated envelope proteins, and these carbohydrates structures exposed on the surface of 
the virus mediate interactions between the virus and the C-type lectins. The HCV envelope is 
formed by two heavily N-glycosylated type I transmembrane envelope glycoproteins E1 (31 
kD) and E2 (70 kD) expressed as heterodimers [77-79]. Most of the glycosylation sites in the 
viral envelope proteins are well conserved, since these sites are important for proper folding 
and heterodimerisation of the proteins [80], and for viral entry [81]. Indeed, besides DC-SIGN 
and L-SIGN several other receptors have been described recognizing the envelope proteins; 
CD81 [82], ASGPR [83], and SR-B1 [84]. By binding these receptors the virus not only 
mediates attachment and entry but might also interfere with immune responses. HCV E2 
interaction with CD81 on NK cells, for instance, leads to inhibition of proliferation and activation 
[85;86]. 
 
 
Dendritic cells in HCV infections. 
Although hepatocytes are the main target of the HCV virus, other cells are also affected during 
HCV infections. The effect of HCV on DC function is under debate and there are indications for 
impairment of DC function but also for normal DC function. In chronic HCV infected patients, 
myeloid and plasmacytoid DC counts are lower than in healthy individuals [87-90]. Maturation 
and immune stimulatory functions of these DCs are impaired, especially in inducing Th1 
responses [87;88;91-93]. On the contrary, in resolved HCV infections DC function and 
numbers are not impaired [92]. Also monocyte-derived DCs of chronic HCV infected 
individuals are impaired in stimulating T cells [92-94]. In contrast, other studies demonstrated 
that monocyte-derived DCs [95;96], myeloid, and plasmacytoid DCs [89;97] from patients 
suffering from chronic HCV infection are functionally normal. Thus, more research is necessary 
to understand the role of DCs in the establishment of HCV infections.  
DCs express the HCV binding receptors CD81, which recognizes E2 [82;98], and DC-SIGN, 
which binds both E1 and E2 [3;74-76]. DCs strongly interact with HCV envelope proteins, 
which is mediated by DC-SIGN since blocking DC-SIGN almost completely abrogates DC-
HCV interactions [chapter3][3;76]. Upon interaction with HCV envelope proteins, the particles 
are internalized by DCs and, in contrast to other carbohydrate ligands, targeted to non-
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lysosomal compartments [chapter3][3]. The normal routing after internalisation is directed 
through early endosomes to lysosomes. Indeed, antibodies [5] and carbohydrate ligands of 
DC-SIGN [chapter3][3] are targeted to lysosomes for degradation and presentation to T cells. 
Remarkably this specific internalization pathway of HCV is cell-type specific and only occurs in 
antigen presenting cells, both primary DCs and B-cell lines expressing DC-SIGN, but not in 
non-APC cell lines [chapter3][3]. A similar internalization pathway and cell-dependency has 
been described for the HIV-1 virus [99]. HIV-1 is also retained in non-lysosomal vesicles after 
uptake via DC-SIGN, and similar to HCV targeting this differential routing is cell type specific 
[99]. The mechanism by which this differential targeting is regulated remains elusive. 
Clustering of DC-SIGN binding sites on and the size of the internalized particle could be 
involved, by mediating the formation of DC-SIGN aggregates on the cell surface, whereas less 
multimeric ligands with less binding sites for DC-SIGN are targeted to lysosomes. A recent 
study demonstrated that the interaction of DC-SIGN with the leukocyte-specific protein-1 
(LSP1) directs DC-SIGN-captured ligands to the proteasome [100], suggesting that HCV 
interaction might modulate this interaction and prevent degradation. The retention of HCV virus 
in non-lysosomal compartments protects the virus from degradation and can lead to 
transmission to target cells [68]. 
However, besides protection and transmission, DCs also mediate HCV antigen presentation 
[101]. HCV presentation is dependent on the interaction with DC-SIGN [chapter 4]. Although 
HCV is partially protected by DC-SIGN, a part is diverted to the lysosomes, processed and  
derived antigens are presented to CD4+ T cells [chapter 4]. The degradation of HCV-VLPs is 
enhanced in the presence of HCV specific antibodies [chapter 4], indicating that Fc-receptors 
may participate in the internalization of HCV, and diverting HCV from the non-lysosomal route 
into the lysosomal route. This study implies that DCs process and present HCV antigens more 
efficiently through Fc interactions when HCV is bound by HCV specific antibodies.  
 
 
LSEC in HCV infections 
L-SIGN recognizes, similar to DC-SIGN both E1 and E2 viral envelope glycoproteins [3;74-76]. 
Furthermore, cell lines expressing L-SIGN rapidly internalize HCV through L-SIGN, HCV-VLPs 
are retained in early endosomes [chapter3][3], suggesting that this pathway might be involved 
in transmission of HCV. Indeed, L-SIGN mediates transmission to hepatocyte cell lines [68]. 
This is actively mediated by L-SIGN since the number of neck repeats determines the 
efficiency of virus binding and transmission [102].  
L-SIGN is expressed by LSECs and these cells form a barrier between the blood and the 
hepatocyte layer. Thus, the HCV in blood can be captured by L-SIGN and transmitted to 
hepatocytes. The transmission of a virus from LSECs to hepatocytes was also demonstrated 
for Duck hepatitis B virus [103].  
Since LSECs function as APC, uptake of HCV in LSECs can also result in antigen presentation. 
However, LSECs lack costimulatory molecules and therefore presentation of HCV antigens to 
T cells might lead to tolerance. In the liver, Th2 responses are preferentially induced, whereas 
Th1 cells are suppressed [104;105]. Indeed, LSEC presentation on MHC II leads to 
differentiation to Th2 cells [13]. Furthermore, presentation on MHC I results in tolerogenic, non- 
cytotoxic CD8+ T cells, and there are indications for liver specific selective retention and 
clearance of activated CD8+ T cells [106;107]. This tolerance induction can be overcome when  
simultaneously with antigen presentation by LSEC viral E2 binds to CD81 on the T cell [108].  
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HCV escapes immune responses by targeting CLRs on DCs and LSECs.  
(A) DC-SIGN on DCs binds HCV envelope proteins, and HCV is internalized. Upon internalization HCV is partially 
degraded in lysosomes and presented to CD4+ T cells. However, HCV may also be retained in early endosomes 
and transmitted to target cells. (B) L-SIGN on LSECs binds HCV envelope proteins and internalizes the virus. Upon 
internalization HCV can be transmitted to its main target cells, the hepatocytes. Alternatively, HCV might be 
degraded and presented to CD4+ or CD8+ T cells. 
 
 
The E2-CD81 ligation provides the co-stimulatory signals for T-cell activation. But because of 
the low viral load, the chance of simultaneous interaction of HCV and LSEC with T cells is low. 
 
DC-SIGN and L-SIGN in HIV-1 infection  
T cells are infected by HIV-1 through interaction of the envelope protein gp120 with CD4 and 
the chemokine co-receptors CCR5 or CXCR4 [109]. During sexual transmission, DCs are 
among the first cells encountered by HIV-1 in the mucosal tissues [110]. T cell infection is 
greatly enhanced by the presence of DCs, although DCs themselves are poorly infected 
[111;112]. The discovery of DC-SIGN shed light on the molecular mechanism of HIV-1 
transmission by DCs. DC-SIGN expressed by DCs, captures and internalizes HIV-1 through 
the HIV-1 envelope glycoprotein gp120 [1]. Similar to HCV, HIV-1 is retained in non-lysosomal 
vesicles [1;113]. This compartment is CD81+ and studies suggest that the virus stays infectious 
for several days [1;113]. DCs migrate subsequently to the lymph nodes, where the virus is 
transmitted to T cells. The DC-T cell interaction causes translocation of the virus to the DC-T 
cell interface, the so called ‘infectious synaps’, which leads to concentration of HIV-1 in close 
proximity to CD4, thereby facilitating infection of the target cells [114-117]. Recent data 
demonstrate that the transmission consists of two phases: initially virus is captured by DCs 
and retained intracellular for transmission, whereas the second phase is due to de novo 
synthesis of HIV-1, which is subsequently transmitted. DC-SIGN seems to be involved in both 
phases. DC-SIGN captures HIV-1 for direct transmission [118], whereas infection of DCs 
themselves is enhanced by DC-SIGN expression [119]. However, upon internalization HIV-1 is 
also partially degraded and presented to CD4+ and CD8+ T cells [6;7]. A similar role for L-SIGN 
has been suggested; L-SIGN interacts with gp120 and is able to transmit captured HIV-1 to T 
cells [120-122].  
DC-SIGN recognizes gp120 through carbohydrate structures expressed on this glycoprotein. 
Gp120 is heavily glycosylated, and carbohydrate structures compose 50% of its mass 
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[123;124]. Since carbohydrates are clustered together on the outer domain of the gp120 
molecule, this region is weakly immunogenic and known as the ‘silent’ face [125;126]. 
Furthermore, it has been implicated that the carbohydrate cluster forms a ‘glycan shield’ 
preventing neutralizing antibodies from binding through steric inhibition [127]. Differential 
glycosylation of the envelope glycoproteins affects DC-SIGN binding and enhancement 
[Chapter 5][128;129]). 
It has been suggested that DC-SIGN and CD4 compete for gp120 binding [9], however 
antibodies against the CD4 binding site do not block DC-SIGN binding and moreover there is 
enhancement of CD4 binding upon DC-SIGN interaction with gp120 [chapter5][129]. Thus DC-
SIGN binding to gp120 induces conformational changes in gp120 and is thereby enhancing 
CD4 binding to T cells [chapter5][129], and CD4 binding in turn is a prerequisite for 
CXCR4/CCR5-gp120 interactions [130].  
Thus, DC-SIGN is enhancing transmission of HIV-1 and therefore an attractive target for 
preventing HIV-1 transmission. 
 
Intervention of DC-SIGN mediated HIV transmission. 
Blocking the interaction between DC-SIGN and HIV-1 is a good strategy to reduce T cell 
infection and spreading the virus from initial infection site to the lymph node. Carbohydrate 
based ligands for DC-SIGN are good possible candidates for this purpose. The bovine 
glycoprotein lactoferrin from cow milk for instance, is efficient in blocking DC-SIGN mediated 
HIV-1 transmission [131]. Although human lactoferrin has anti-viral activity [132], human 
lactoferrin is not interfering with the DC-SIGN-HIV-1 interactions [chapter 6][133]. However 
human milk does inhibit at high concentrations direct infection of T cells, and at lower 
concentrations it efficiently abrogates DC-SIGN mediated transmission to T cells [chapter 
6][133]. Bile salt stimulated lipase (BSSL) was identified as the glycoprotein responsible for 
this inhibition [chapter 6][133;134]. BSSL has been demonstrated to have antiviral 
characteristics [135], and indeed BSSL blocks HIV-1 infectivity. However, unlike other reports 
only describing antiviral activity on the virus itself, we demonstrate that BSSL furthermore 
prevents HIV-1 transmission by competing with HIV-1 gp120 for the binding site of DC-SIGN 
[chapter 6][133]. BSSL is highly glycosylated and contains many Lex structures. These Lex 
structures are responsible for the blocking capacity of BSSL [chapter 6][133;134]. Thus human 
milk is a promising source for anti-HIV-1 therapy. However, milk is also a source of HIV-1. In 
human breast milk HIV-1 is present as free virus particles or within cells, and can be 
transmitted via the gastrointestinal tract. Infection during mother to child transmission (MTCT) 
occurs in the tonsils and mucosa [136-138], and children fed with breast milk from HIV-1 
infected mothers have an increased risk in becoming infected with HIV-1 compared to infants 
fed with formula milk [139]. However infants fed with a combination of both breast milk and 
formula milk had an even more increased risk to become infected [140], implicating that breast 
milk also has beneficial effects. 
The C-type lectin Langerin, which is expressed on Langerhans cells [141], is also interacting 
with HIV-1 gp120 [142]. In contrast to the HIV-1 interaction with DC-SIGN, which leads to viral 
dissemination, the interaction of HIV-1 with Langerin results in degradation of the virus. Even 
more, blocking Langerin result in susceptibility of Langerhans cells for HIV-1 [142]. Therefore, 
therapeutic use of BSSL for reducing HIV-1 spreading is advantageous because it impedes 
DC-SIGN mediated transmission but does not affect Langerin mediated viral degradation. 
 
Preventing HIV-1 transmission by direct blocking of DC-SIGN is a promising approach in 
combating HIV-1 infections, however these interventions also interfere with the immunological 
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role of DC-SIGN [1;2;143;144]. Therefore, inhibitors targeting HIV-1 gp120 to prevent DC-
SIGN capture seem warranted to interfere with HIV-1 dissemination. Although HIV-1 efficiently 
escapes the immune response, antibodies against HIV-1 are present in infected patients.  
Although some antibodies promote HIV-1 survival, others can block DC-SIGN-gp120 
interactions and thereby inhibit in cis and in trans infection [chapter 5][129;145;146]. Anti-V3 
loop antibodies partially block DC-SIGN-gp120 interactions although DC-SIGN is not directly 
binding to the V3 loop itself [chapter 5][129]. Especially the blocking function of the antiV3 loop 
antibody 447-52D is of interest. This antibody demonstrated the highest block of DC-SIGN-
gp120 interactions [chapter 5][129]. Although the epitope recognized by the human antibody 
447-52D is situated in a variable loop of gp120, the crown of the V3 loop is rather conserved 
[147]. Furthermore polyclonal goat serum inhibited DC-SIGN-HIV-1 interactions. HIV-1 gp120 
is highly glycosylated and this glycan shield forms a relative non-immunogenic site on gp120. 
Therefore serum from goats immunized with glycosylated or non-glycosylated, lacking the 
glycan shield, were compared for inhibition of DC-SIGN gp120 binding. Both polyclonal sera 
bound efficiently to glycosylated gp120, however polyclonal serum raised against non-
glycosylated gp120 was more efficient in blocking DC-SIGN gp120 interactions [chapter 
5][129]. 
Therefore, vaccinations could be more successful when non-glycosylated gp120 is used as a 
vaccine rendering potent neutralizing antibodies compared to vaccinations in which 
glycosylated gp120 is used. 
 
 
 
General conclusions 
 
DC-SIGN mediates several interactions with self-ligands, tumours and pathogens. The function 
of DC-SIGN on primary cells has been extensively studied and it has become clear that there 
is a delicate balance in the outcome of the DC-SIGN-mediated interactions. Therefore one 
should be careful with interfering in DC-SIGN-pathogen interactions at the side of DC-SIGN.  
We have described here that L-SIGN also mediates important interactions with cells, such as 
PMN, monocytes and tumour cells, and with pathogens. However research into the function of 
L-SIGN on primary cells has been hampered by the difficulty to isolate sufficient amounts of L-
SIGN-positive LSECs from human liver. Therefore, most studies have used cell lines 
expressing L-SIGN as a model. Here we demonstrate that L-SIGN function in vivo can be 
investigated using a mouse model. mSIGNR1 is expressed on homologues cells in the murine 
liver and has a comparable carbohydrate recognition profile [24]. Therefore, the mSIGNR1 
deficient mice will be important in further exploring the function of L-SIGN.  
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Summary 
 
The C-type lectin receptors (CLRs) DC-SIGN and L-SIGN are both expressed on antigen 
presenting cells; dendritic cells (DCs) and liver sinusoidal endothelial cells (LSECs) 
respectively. These cells capture and process ligands for antigen presentation to T cells. 
DC-SIGN and L-SIGN recognize pathogens and self-ligands through recognition of specific 
carbohydrate moieties on glycoconjugates. Due to a high degree of homology between the 
carbohydrate recognition domains of DC-SIGN and L-SIGN, both CLRs have affinity for high 
mannose structures and the fucose containing Lewisa (Lea), Leb, and Ley antigens, with the 
exception of Lex, which is only bound by DC-SIGN. 
In chapter 2 a novel L-SIGN specific carbohydrate ligand is described, which is not recognized 
by DC-SIGN. This ligand is neuraminidase sensitive, suggesting that L-SIGN recognizes a 
sialicacid containing glycan structure that is not recognized by DC-SIGN. This makes L-SIGN 
comparable to its murine homologue mSIGNR1 that similar to L-SIGN is expressed on LSECs 
in the liver and also is able to bind sialylated carbohydrates. 
 
Cellular ligands for DC-SIGN and L-SIGN 
DC-SIGN recognizes several cellular ligands on different cells, for example ICAM-2 on 
endothelial cells and ICAM-3 on T cells. Furthermore, DC-SIGN interacts with neutrophils via 
Mac-1 binding. Early during infection neutrophils are involved in killing of pathogenic bacteria 
and regulation of innate immune responses at the site of infection. It has become clear that 
neutrophils also modulate adaptive immunity through interactions with DCs. Upon activation, 
neutrophils release TNF-α and combined with Mac1-DC-SIGN interactions, induce maturation 
of DCs that enables these APCs to stimulate T cell proliferation and to induce T helper 1 
polarization. In chapter 7, we demonstrate that also CEACAM1 is an important ligand for DC-
SIGN on neutrophils. Binding of DC-SIGN to both CEACAM1 and Mac-1 is required to 
establish cellular interactions with neutrophils. L-SIGN on the other hand, only recognizes 
Mac-1 on neutrophils. Neutrophils are able to adhere to and roll over L-SIGN positive cells, 
indicating a role for L-SIGN in neutrophil homing to the liver sinusoid.  
Besides the interaction with neutrophils, L-SIGN also interact with a yet unknown ligand on 
monocytes (chapter 8). These cells are amongst others precursors of resident tissue 
macrophages like the Kupffer cells in the liver. Using an in vivo model we demonstrate that the 
murine L-SIGN homologue mSIGNR1 expressed on LSECs influences Kupffer cell (KC) 
numbers in the liver, because mSIGNR1 deficient mice have reduced numbers of KCs. The 
effect of mSIGNR1 on KC recruitment appears after the initial phase of KC repopulation, 
indicating that L-SIGN could be involved in the recruitment of KC precursors in the human 
liver. 
We furthermore demonstrate in chapter 2 that L-SIGN recognizes a carbohydrate ligand on 
hepatoma cells. Hepatocytes express high amounts of sialylated glycans, which are abrogated 
in metastasizing hepatocellular carcinoma cells. The interaction between LSEC and 
hepatocytes, which are not connected with extracellular matrix, could contribute to 
maintenance of hepatic sinus architecture. The loss of sialylated ligands would loosen the L-
SIGN-hepatocellular carcinoma cell interaction and the hepatocellular carcinoma cells would 
more easily transmigrate into the bloodstream and form metastases at distant sites. Indeed 
this loss of sialic acid expression is indicative for a poor patient survival. 
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DC-SIGN mediates interactions with colon carcinoma cells, which express high levels of Ley-
and Lex-decorated CEA and CEACAM1. In chapter 2 we show that, similar to DC-SIGN, L-
SIGN recognizes tumour derived CEA, probably because of the presence of Ley on CEA, and 
therefore could participate in colon cancer liver metastasis. Furthermore, in contrast to 
hepatocellular carcinoma cells, colon cells display an increased or de novo expression of 
sialylated carbohydrates upon malignant transformation. The binding of these tumour-
associated glycoconjugates to L-SIGN could, in addition to getting constricted by the narrow 
vasculature of the sinus, explain the frequent metastasis formation of colon carcinomas in the 
liver.  
 
DC-SIGN/L-SIGN-pathogen interactions 
Besides self ligands, DC-SIGN and L-SIGN also recognize a range of pathogens. DC-SIGN 
was originally identified as a human immunodeficiency virus 1 (HIV-1) gp120 binding receptor. 
DC-SIGN plays a key-role in the dissemination of HIV-1 by DCs through HIV-1 gp120 binding. 
Upon binding the virus is internalized and with the DC transported to the lymph node where it 
infects T cells efficiently. 
Since the capture of HIV-1 by DC-SIGN enhances T cell infection, the interaction of DC-SIGN 
with gp120 provides an attractive target for intervention of HIV-1 transmission. In chapter 5 
and 6 we describe two ways to inhibit the DC-SIGN-gp120 interactions. In chapter 6 we 
describe that human milk contains a component that inhibits the DC-SIGN-mediated transfer of 
HIV-1 to T cells. This Lex containing inhibitory factor directly interacted with DC-SIGN, and 
prevented the HIV-1 gp120 envelope protein from binding to DC-SIGN  thereby prevent the 
capture and subsequent transfer of HIV-1 to T cells. The presence of such a DC-SIGN-binding 
molecule in human milk may both influence antigenic presentation and interfere with pathogen 
transfer in breastfed infants. Interactions of L-SIGN with HIV-1 gp120 are not affected by this 
milk component since L-SIGN can not bind Lex carbohydrates. 
In chapter 5, we have investigated the potency of gp120 antibodies to inhibit the DC-SIGN-
gp120 interaction. We demonstrate that antibodies against the V3 loop partially inhibit DC-
SIGN binding, suggesting that these antibodies sterically hinder DC-SIGN binding to gp120. 
Polyclonal antibodies raised against non-glycosylated gp120 inhibited DC-SIGN-gp120 
interactions in contrast to polyclonal antibodies raised against glycosylated gp120. Thus, 
glycans present on gp120 may prevent the generation of antibodies that block the DC-SIGN-
gp120 interactions. Moreover, the polyclonal antibodies against gp120 efficiently inhibited HIV-
1 capture by both DC-SIGN transfectants and immature dendritic cells. Therefore, non-
glycosylated gp120 may be an attractive immunogen to elicit gp120 antibodies that block the 
binding to DC-SIGN. Furthermore, we demonstrate that DC-SIGN binding to gp120 enhanced 
CD4 binding, suggesting that DC-SIGN induces conformational changes in gp120, which may 
provide new targets for neutralizing antibodies.  
 
In chapter 3 and 4 the interaction of DC-SIGN and L-SIGN with the hepatitis C virus (HCV) 
glycoproteins E1 and E2 is described. HCV targets hepatocytes in the liver. However, the 
mechanism of hepatocyte infection is largely unknown. DC-SIGN and L-SIGN are important 
receptors for HCV E1 and E2. DC-SIGN is the main HCV receptor on DCs and L-SIGN is the 
main HCV receptor in liver since interaction can be inhibited by specific anti-DC-SIGN and L-
SIGN antibodies. Mutagenesis analyses demonstrates that both HCV E1 and E2 bind the 
same binding site on DC-SIGN as the pathogens HIV-1 and mycobacteria, which is distinct 
from the cellular ligand ICAM-3.  
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HCV virus-like particles (VLPs) are efficiently captured and internalized by DCs through 
binding of DC-SIGN. Interestingly, internalized HCV-VLPs are partially targeted to non-
lysosomal compartments within DCs, where they are protected from degradation similarly as 
was demonstrated for HIV-1. This suggests that HCV may target DC-SIGN to ‘hide’ within DCs 
and to facilitate viral dissemination. L-SIGN expressed by APC cell-lines internalizes HCV 
particles into similar non-lysosomal compartments, suggesting that L-SIGN on LSECs may 
capture HCV from blood and transmit it to hepatocytes, the primary target for HCV. However, 
in chapter 4 we describe that HCV-VLPs are also susceptible for degradation by DCs, and 
degradation is more efficient in the presence of HCV-specific antibodies. We demonstrate that 
degradation of the HCV-antibody complexes leads to MHC class II presentation by DCs. 
Moreover, induction of DC maturation by HCV-VLPs on an aluminium carrier strongly 
enhances this antigen presentation by DCs. Thus, antibody targeting and maturation-induction 
directs DC-SIGN-captured ligands into lysosomal compartments and efficient antigen 
presentation. Moreover, we demonstrate that L-SIGN captures HCV-antibody complexes 
leading to antigen presentation to CD4+ T cells, demonstrating that L-SIGN is an antigen 
receptor on LSECs. Human LSECs express both L-SIGN and MHC class II molecules and our 
data suggest that LSECs are important as antigen presentation cells of viral antigens in the 
liver. However this presentation may lead to erroneous T cell activation since LSEC are known 
to induce T cell tolerance. 
 
 
 
Final conclusion 
 
DC-SIGN mediates several interactions with self-ligands, tumours and pathogens. The function 
of DC-SIGN on primary cells has been extensively studied and it has become clear that there 
is a delicate balance in the outcome of the DC-SIGN-mediated interactions. Therefore one 
should be careful with interfering in DC-SIGN-pathogen interactions at the side of DC-SIGN.  
We have described here that L-SIGN also mediates important interactions with cells, such as 
neutrophiles, monocytes and tumour cells, and with pathogens. However research into the 
function of L-SIGN on primary cells has been hampered by the difficulty to isolate sufficient 
amounts of L-SIGN-positive LSECs from human liver. Therefore, most studies have used cell 
lines expressing L-SIGN as a model. Here we demonstrate that L-SIGN function in vivo can be 
investigated using a mouse model. mSIGNR1 is expressed on homologues cells in the murine 
liver and has a comparable carbohydrate recognition profile. Therefore, the mSIGNR1 deficient 
mice will be important in further exploring the function of L-SIGN.  
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Het menselijke lichaam kan zich op vele manieren goed beschermen tegen binnendringende 
ziekteverwekkers. Hierbij speelt het immuunsysteem een zeer belangrijke rol. Het 
immuunsysteem in de mens bestaat uit twee nauw met elkaar samenwerkende onderdelen: 
het aangeboren (innate) en het aangeleerde (adaptieve) immuunsysteem. Het aangeboren 
afweersysteem bestaat onder andere uit macrofagen en neutrofiele cellen. Deze cellen 
herkennen algemeen voorkomende patronen op ziekteverwekkers en zullen vervolgens de 
ziekteverwekker direct bestrijden. Het adaptieve immuunsysteem bestaat uit B en T cellen die 
zeer specifieke eiwitstructuren herkennen en een ‘geheugen’ functie hebben. Dendritische 
cellen (DCs) vormen een belangrijke brug tussen deze twee onderdelen van het 
immuunsysteem. Deze cellen zijn in staat vrij algemeen voorkomende structuren op 
ziekteverwekkers te herkennen, waarna ze de ziekteverwekker opnemen. Na opname in de 
DC wordt de ziekteverwekker afgebroken tot kleine eiwitten, zogenaamde antigenen, welke 
vervolgens op het oppervlakte worden gepresenteerd aan T cellen. Op het moment dat de DC 
deze antigenen aan de T cel presenteert, wordt de T cel niet alleen geactiveerd maar de DC 
bepaald ook hoe de T cel zijn werk zal doen. Op deze manier regiseren de DCs de zeer 
specifieke immuunrespons uitgevoerd door T cellen. De DC is onder andere gepositioneerd op 
strategische plekken in het lichaam waar veel contact is met de buitenwereld. Hier vervullen ze 
een poortwachterfunctie door continu de omgeving af te tasten. 
 
De DCs herkennen ziekteverwekkers met behulp van verschillende moleculen op hun 
celoppervlak: zogenaamde Toll like receptoren en C-type lectine receptoren. De verschillende 
Toll like receptoren herkennen vaste patronen op ziekteverwekkers zoals lipopolysaccharide 
van Gram-negatieve bacteriën. Als een TLR een ligand heeft gebonden leidt dit tot activatie 
van de DC en zal deze naar een lymfe klier verplaatsen. De C-type lectine receptoren echter 
herkennen specifieke suikerstructuren op ziekteverwekkers. DCs hebben vele verschillende C-
type lectines op hun oppervlak met elk hun eigen suikerherkenningspatroon. De C-type 
lectines zorgen voor de opname van ziekteverwekkers in de cel, waarna deze worden 
afgebroken en gepresenteerd aan T cellen. Naast ziekteverwekkers brengen ook 
lichaamseigen cellen deze suikermoleculen tot expressie. Hiermee zorgen de C-type lectines 
ervoor dat DCs kunnen communiceren met andere cellen. 
DC-SIGN is een van deze C-type lectine receptoren die voorkomen op DCs. DC-SIGN is 
ontdekt als receptor voor een eiwit dat aan de buitenkant van het AIDS veroorzakende HIV-1 
virus zit, het gp120. Door binding van DC-SIGN aan de suikermoleculen op dit HIV-1 eiwit, 
wordt het virus in de cel opgenomen. Deels zal het virus vervolgens worden afgebroken en 
gepresenteerd aan T cellen. Maar het virus heeft ook een methode ontwikkeld waardoor het 
zich in de DC kan verschuilen. Het virus wordt vervolgens door de DC naar de T cel rijke lymfe 
knopen getransporteerd. Hier wordt het virus door de DC overgegeven aan de T cel, de ideale 
gastheer cel voor het HIV-1 virus. Op deze manier verhoogt het HIV-1 virus via de binding aan 
DC-SIGN de infectie van de T cellen.  
 
In de lever komt een receptor voor die heel erg lijkt op DC-SIGN, L-SIGN genaamd. De lever is 
een belangrijk orgaan, dat een rol speelt bij de zuivering van het bloed dat komt vanaf het 
maagdarmstelsel. In de lever bevinden zich verschillende soorten gespecialiseerde cellen die 
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er voor zorgen dat dit zo goed mogelijk gebeurt. De hepatocyten zijn voornamelijk 
verantwoordelijk voor het omzetten van stoffen. Van veel van de niet hepatocyten wordt 
gedacht dat ze een immunologische rol spelen. Veel lichaamsvreemde materialen passeren 
de lever als ze het lichaam via de maag zijn binnen gekomen. Deze lichaamsvreemde 
materialen zijn over het algemeen niet gevaarlijk en de lever zorgt ervoor dat het lichaam deze 
stoffen niet aanvalt. In de lever bevinden zich verschillende soorten cellen die hier aan mee 
werken. Een van deze celtypen is de lever sinusoid endotheel cel (LSEC). Deze LSEC vormen 
de begrenzing tussen de hepatocyten en het passerende bloed. In tegenstelling tot andere 
endotheel cellen, zitten deze specifieke endotheel cellen niet vast aan een onderliggende 
matrix en hebben ze vele ‘vensters’ die een soort zeefplaten vormen. Hierdoor zijn ze in staat 
om actief te bepalen welke materialen uit de bloedbaan de hepatocyten bereiken. De LSECs 
nemen stoffen op die met het bloed vanuit de darmen naar de lever zijn gevoerd. Nadat deze 
stoffen zijn opgenomen in de cellen worden ze afgebroken en aan T cellen gepresenteerd, net 
als gebeurt in DCs. Normaal gesproken als een cel een stukje materiaal, een antigen, aan 
deze T cellen presenteert, worden de T cellen geactiveerd en aangezet om een immuunreactie 
uit te voeren. Maar in het geval van deze LSECs blijft deze activatie achterwege en resulteert 
het presenteren van de antigenen in tolerantie voor deze stoffen. Dit is in vele gevallen gunstig 
omdat een heftige immuunreactie tegen antigenen afkomstig van voedsel leidt tot 
voedselallergie. Maar in het geval dat er een ziekteverwekker met het voedsel het lichaam is 
binnengedrongen is een adequate immuunrespons gewenst.  
Op deze LSECs bevindt zich L-SIGN. Deze receptor is familie van DC-SIGN, en herkent, net 
als DC-SIGN, suikerstructuren die zich bevinden op lichaamseigen en lichaamsvreemde 
componenten. L-SIGN en DC-SIGN herkennen veel dezelfde suikers, maar er zijn ook 
verschillen in herkenning. DC-SIGN en L-SIGN kunnen beide hoog mannose bevattende 
suikers, en bepaalde fucose suikers binden. Er is een bepaalde fucose bevattende suiker die 
alleen door DC-SIGN, en niet door L-SIGN wordt herkend; Lewisx (Lex). Dit patroon van 
suikerherkenning bepaalt welke lichaamseigen en -vreemde structuren worden herkend door 
DC-SIGN en L-SIGN. 
 
 
In dit proefschrift is de functie binnen het immuunsysteem van zowel DC-SIGN als L-SIGN 
verder uitgediept. Hiervoor zijn verschillende aspecten onderzocht: de suikerherkenning, 
interacties met lichaamseigen materialen en interacties met virussen. 
 
 
Allereerst is de suikerherkenning van L-SIGN is verder in kaart gebracht. Ondanks de grote 
gelijkenis van de beide receptoren zijn er verschillen in de suikerherkenning. Naast het al 
eerder beschreven verschil, het gebrek aan herkenning van het zogenaamde Lex door L-SIGN, 
wordt in hoofdstuk 2 een ander verschil beschreven. Wij hebben aangetoond dat L-SIGN in 
staat is een siaalzuur bevattende suiker te herkennen, welke niet herkend wordt door DC-
SIGN. Deze siaalzuur bevattende suikers komen veel tot expressie op hepatocyten. Deze 
hepatocyten vormen het grootste deel van de lever en grenzen aan de LSECs die L-SIGN op 
hun oppervlak hebben. L-SIGN is inderdaad in staat om aan deze cellen te binden. De 
specifieke suiker evenals het eiwit waarop deze suiker zit is nog niet gevonden en dit zal 
verder onderzocht gaan worden. Mogelijkerwijze heeft deze binding een rol in het behouden 
van de structuur van de lever. Het L-SIGN bevattende endotheel zit namelijk niet zoals 
conventioneel endotheel vast aan de onderlaag met behulp van een soort matrix maar zit vrij 
los. Door de binding van L-SIGN aan de hepatocyten zouden de endotheel cellen aan de 
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hepatocyten verankerd kunnen zijn en daarmee de structuur van de lever in stand kunnen 
houden. Het is inderdaad bewezen dat het verlies van deze siaalzuur bevattende suikers van 
het oppervlak van de hepatocyten tijdens het proces van tumorvorming een verhoogde kans 
geeft op het vormen van uitzaaiingen.  
 
Naast de interactie met hepatocyten, gaat L-SIGN ook binding aan met monocyten 
(hoofdstuk 8). Monocyten zijn voorlopercellen van macrofagen, een soort alleseters. 
Monocyten zitten in het bloed en als ze naar weefsels verhuizen veranderen zij in macrofagen. 
L-SIGN is in staat met deze voorlopercellen een interactie aan te gaan. Met behulp van een 
muismodel, is deze interactie verder onderzocht. De muis heeft een homologe vorm van L-
SIGN in de lever: mSIGNR1. Deze receptor lijkt zowel met betrekking op suikerherkenning 
alsmede de plekken waar het tot expressie komt in de lever veel op L-SIGN. Dit maakt de muis 
een belangrijk model om de rol van L-SIGN in vivo, dus in een geheel organisme, te kunnen 
onderzoeken. Met behulp van deze muis en een muis waar mSIGNR1 specifiek is 
uitgeschakeld is bepaald dat de aanwezigheid van mSIGNR1 in de lever de hoeveelheid 
macrofagen in de lever verhoogt. Omdat deze macrofagen zijn ontstaan uit monocyten, is het 
aannemelijk dat mSIGNR1, en ook L-SIGN, een rol speelt bij het rekruteren van monocyten uit 
het bloed en de verandering van deze cellen in lever macrofagen.  
 
In hoofdstuk 7 staat de interactie van DC-SIGN en L-SIGN met neutrofielen beschreven. 
Neutrofielen zijn belangrijke cellen binnen het aangeboren immuunsysteem. Neutrofielen 
verzamelen zich snel op de plek van een infectie. Doormiddel van twee eiwitten, Mac-1 en 
CEACAM1, op hun oppervlak sturen zij DCs aan. Na binding van deze eiwitten aan DC-SIGN 
op de DC, zal de DC zodanig veranderen dat deze een specifieke soort T cel reactie op gang 
zal brengen. L-SIGN is in staat één van deze twee eiwitten te binden, namelijk Mac-1. 
CEACAM1 wordt niet herkend door L-SIGN. Tijdens een ontsteking verzamelen neutrofielen 
zich massaal in de lever, zelfs als de ontsteking zich niet in de lever bevindt. Omdat L-SIGN 
zich op een strategische plaats in de lever bevindt, is het waarschijnlijk dat L-SIGN een rol 
speelt bij het vasthouden in de lever van passerende neutrofielen. Neutrofielen kunnen 
namelijk zo sterk aan L-SIGN binden dat ze niet door de stroming van het bloed mee gevoerd 
kunnen worden. Vervolgens kunnen de neutrofielen opgeruimd worden door de LSEC of de 
lever macrofagen. Ook is het mogelijk dat ze het leverweefsel binnendringen nadat ze zijn 
vastgehouden door L-SIGN op het endotheel. 
 
Het was al bekend dat DC-SIGN in staat is verschil te herkennen tussen eiwitten uit gezond 
weefsel en tumorweefsel. Wij hebben in hoofdstuk 2 aangetoond dat L-SIGN ook in staat is 
dit verschil te herkennen. Een bepaald eiwit op darmcellen, CEA, verandert dusdanig tijdens 
het proces van tumorvorming in darmweefsel dat het andere suikers tot expressie gaat 
brengen. Dit leidt tot een betere herkenning door DC-SIGN en dus ook L-SIGN. In het geval 
van L-SIGN kan deze verbeterde herkenning leiden tot het vasthouden van de tumorcellen op 
het moment dat ze uitzaaiingen gaan vormen. Darmtumoren vormen vaak uitzaaiingen in de 
lever. Dit komt doordat de bloedvatstructuur in de lever erg nauw is waardoor de 
verplaatsende tumorcellen daar gemakkelijk vast komen te zitten. Maar ook de binding van de 
tumorcellen aan L-SIGN op het endotheel in de lever sinusoiden kan leiden tot het blijven 
hangen van de tumorcellen die vervolgens een secundaire tumor kunnen gaan vormen. 
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Naast interacties met lichaamseigen eiwitten zijn L-SIGN en DC-SIGN ook belangrijke 
receptoren voor ziekteverwekkers, zoals virussen, bacteriën en parasieten. In de 
hoofdstukken 3 tot en met 6 is de interactie van de twee receptoren met virussen onderzocht. 
In hoofdstuk 3 en 4 is de interactie van L-SIGN en DC-SIGN met het hepatitis C virus (HCV) 
onderzocht. Dit virus wordt omgeven door een envelop bestaande uit eiwitten waarop veel 
hoog-mannose structuren zitten. DC-SIGN en L-SIGN binden aan deze structuren en nemen 
het virus mee de cel in. Eenmaal in de cel kan het virus worden afgebroken en worden 
gepresenteerd aan T cellen. Het virus heeft echter ook een methode ontwikkeld waardoor het 
uit het zicht blijft van het immuunsysteem. Na opname in de cel verstopt het zich in bepaalde 
compartimenten in de cel waarna het, als de cel een geschikte andere cel tegenkomt, naar 
deze andere cel overgegeven kan worden. Hierin lijkt het HCV virus veel op het HIV-1 virus. 
Wij hebben aangetoond dat in de lever L-SIGN het belangrijkste molecuul is dat aan HCV 
envelop eiwitten bindt. Het blokkeren van L-SIGN in leverweefsel heeft tot gevolg dat de HCV 
envelop eiwitten nauwelijks meer aan het leverweefsel binden. Tevens hebben we aangetoond 
dat L-SIGN op cellijnen HCV envelop eiwitten gecombineerd met antilichamen kan opnemen 
en presenteren aan T cellen. Op het moment dat L-SIGN in de lever HCV eiwitten presenteert 
aan T cellen zou dit kunnen leiden tot tolerantie voor het virus, aangezien deze cellen 
verantwoordelijk zijn voor tolerantie inductie. Inderdaad is het aangetoond dat veel T cellen die 
specifiek HCV eiwitten herkennen het virus niet effectief aanvallen. Dit betekent dat het HCV 
virus twee manieren heeft ontwikkeld om via L-SIGN een effectieve immuunrespons te 
omzeilen: ten eerste door zich te verstoppen in de LSEC en ten tweede door via de LSEC 
tolerantie op te wekken.  
Op DCs is DC-SIGN het belangrijkste molecuul dat de HCV eiwitten herkent. Na opname in de 
DC blijft een deel van het virus een lange tijd intact. Maar ook in de DC wordt een deel van het 
virus afgebroken en gepresenteerd aan T cellen. Als de HCV eiwitten op een aluminium drager 
zitten, een methode die veel in vaccinaties gebruikt wordt, worden de eiwitten effectiever aan T 
cellen gepresenteerd door DCs. Dit suggereert dat dit een veel belovende methode is om een 
goed werkend vaccin tegen HCV te ontwikkelen. 
 
In hoofdstuk 5 en 6 is onderzocht hoe de interactie van het HIV-1 virus met DC-SIGN op DCs 
kan worden geblokkeerd. Door middel van antilichamen die specifieke delen van het gp120 
envelop eiwit van HIV-1 binden te gebruiken en te bepalen in welke mate dit een effect heeft 
op de binding van DC-SIGN aan het eiwit hebben wij aangetoond dat bepaalde eiwitten beter 
zijn in het blokkeren van deze interactie dan andere antilichamen. Een verrassend resultaat is 
dat antilichamen die zijn opgewekt tegen suikerloos gp120 goed zijn in het blokkeren van de 
interactie van suiker bevattend gp120 met DC-SIGN. Dit betekent dat de suikers een 
belemmering vormen voor de antilichaam binding die DC-SIGN binding verhindert. Practisch 
gezien houdt dit in dat eventuele vaccinatie met gp120 eiwitten beter kan plaatsvinden met 
suikervrije gp120 dan met suiker bevattend gp120. Tevens hebben we aangetoond dat na 
binding van DC-SIGN aan gp120, gp120 makkelijker aan CD4 bindt. Het HIV-1 virus gebruikt 
de interactie tussen gp120 en CD4 op de T cel om de T cel te infecteren. Dit betekent dat HIV-
1 door het binden aan DC-SIGN niet alleen door de DC naar T cel rijke gebieden kan worden 
getransporteerd maar dat het eenmaal daar aangekomen ook makkelijker de T cel 
binnendringt. 
Een andere methode om DC-SIGN gp120 interacties te voorkomen is het blokkeren van DC-
SIGN. In hoofdstuk 6 staat beschreven dat in moedermelk een eiwit zit dat de overdracht van 
HIV-1 door DCs kan verhinderen. Dit eiwit bevat veel Lex suiker structuren waaraan DC-SIGN 
bindt. Op het moment dat dit eiwit aan DC-SIGN gebonden heeft kan het HIV-1 virus niet meer 
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binden en kan het zich dus niet meer verschuilen in de DC. Dit melk eiwit wordt niet herkend 
door L-SIGN dus de remmende werking van moeder melk heeft geen effect op HIV-1 dat de 
lever heeft kunnen bereiken. 
 
 
In conclusie: DC-SIGN op DCs en L-SIGN op LSECs zijn belangrijk voor de communicatie met 
andere cellen zoals neutrofielen, monocyten en hepatocyten. De virussen HCV en HIV-1 
gebruiken DC-SIGN en L-SIGN in hun eigen voordeel. Maar als de binding van deze virussen 
verhinderd wordt door de functie van DC-SIGN en L-SIGN te remmen zal dit als nadelig effect 
hebben dat ook de interactie met de lichaamseigen componenten geremd worden. Daarom is 
verder onderzoek nodig waar het muismodel een goed hulpmiddel zal zijn. 
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sweet, but because of your input a lot more interesting. Lot, Marien en Jeroen, succes met 
jullie verdere promotie traject. Eiríkur, takk fyrir. Voor alle momenten dat ik bij je kon klagen. 
Grasið er alltaf grænna hinumeginn. Maar ook voor de gezelligheid; ik mis onze vrijdagmiddag 
pannenkoeken.  
Ook alle andere MCBI collega’s, blauw, groen, geel, of wat voor kleur dan ook, bedankt, voor 
de gezelligheid op en ook zeker rond het lab. 
Bill en Marloes, het was leerzaam met jullie samen te werken. Marloes, succes in New York. 
Paula, thank you for your help with the rolling experiments. Alle mensen van Innogenetics, 
bedankt voor de discussies en materialen. 
Kamergenoten van de vrijstaat J296. Het was fijn toefen aan het eind van de gang. Gerben, 
ook al moest er soms rust in de tent, frustraties waren goed kwijt te raken met jou in de buurt. 
Bestek blijft maar bestek buiten J296. Succes met het het worden van doctor en dokter. Raoul, 
ondertussen ben ik toch niet meer zo eng? Ik mis onze, zeldzame treinreizen, maar gelukkig 
hebben we de thee nog, en de cocktails! Succes met je laatste loodjes. Lutz and Brenda, good 
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